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Summary 
Previous studies have identified the 3p14-p22 chromoso al region as a quantitative 
trait locus for bone mineral density (BMD). The overall aim of this thesis is to 
identify the gene or genes from this region that are responsible for the linkage 
observed. The studies described within are centred on the analysis of polymorphisms 
within candidate genes from 3p14-p22 for association with BMD phenotypes in 
Caucasian women. Some functional work has also been performed to provide 
information on the role of these genes in bone cells. It is hoped that by identifying 
the genes that regulate BMD, a better understanding of osteoporosis may be gained, 
more effective treatments can be developed and individuals at increased risk of 
developing the disease can be identified. 
 
Osteoporosis is a systemic bone disease characterised by low bone density and 
micro-architectural deterioration which results in fragile bones that are at increased 
risk of low-trauma fracture. Peak bone mass is attained in early adult life, but 
declines in postmenopausal women, in particular, due to a reduction in oestrogen 
production with effects on bone as well as intestinal and renal calcium handling. 
However, in addition to the effects of oestrogen, calcium and other environmental 
factors on bone structure and fracture, there is a strong genetic effect on peak bone 
mass, bone loss and fracture rates in postmenopausal women. Twin and family 
studies have suggested that 50 – 90 % of the variance in peak bone mass is heritable. 
Multiple genetic linkage studies have identified the 3p14-p22 region of the human 
genome as a quantitative trait locus for BMD. Therefore, it was hypothesised that 
one or more genes in this genomic region are significa tly associated with BMD in 
Caucasian women. 
 
Based on a review of the literature, the ARHGEF3 gene was identified as a positional 
candidate in this chromosomal region. Common genetic variation within this gene 
was analysed by genotyping tagging single nucleotid polymorphisms (SNPs) in two 
populations of Caucasian women using the Illumina GoldenGate assay and matrix-
assisted laser desorption/ionisation time-of-flight (MALDI-ToF) mass spectrometry 
techniques, the latter of which was performed in-house. Multiple associations were 
identified between polymorphism within the ARHGEF3 gene and BMD, with the 
strongest associations observed between the SNP rs7646054 and various BMD 
vi 
phenotypes in both populations (P < 0.001 – 0.038). This SNP was also found to be 
significantly associated with fragility fracture rate (P = 0.026). The SNP rs7646054 
was found to be located within the 5’ untranslated r gion of a recently described 
transcript variant of ARHGEF3 designated NM_001128616. In silico bioinformatics 
analysis suggested that polymorphism at rs7646054 affects the folding and stability 
of NM_001128616. 
 
Based on the associations identified between the ARHGEF3 gene and BMD 
phenotypes and a review of the literature, the RHOA gene was identified as a second 
positional candidate in the 3p14-p22 chromosomal region. Common variation within 
this gene was analysed by genotyping tagging SNPs in the same two populations of 
Caucasian women that were used in the ARHGEF3 study using the same genotyping 
techniques. Multiple associations were identified between polymorphism within the 
RHOA gene and BMD, with the strongest associations observed between the SNP 
rs17595772 and various BMD phenotypes in both populations (P = 0.001 – 0.036). 
The SNP rs17595772 was found to tag a very large linkage disequilibrium block that 
spans across several other genes in the region. 
 
Mutation within another gene from the 3p14-p22 chromosomal region, FLNB (see 
below), has been implicated in a variety of human ge etic disorders characterised by 
skeletal malformation. Disruption of the gene in mice also results in severe skeletal 
abnormalities. A recent publication has identified common sequence variation within 
this gene as significantly associated with various BMD phenotypes and has also 
identified five SNPs from the 5’ region of the gene as associated with FLNB mRNA 
expression. These five SNPs were genotyped in a population of Caucasian women 
using the TaqMan technique. Significant associations were observed between the 
three SNPs rs11720285, rs11130605 and rs9809315 and various BMD phenotypes (P 
= 0.004 – 0.043).  
 
Subsequent to the aforementioned studies, functional studies were performed to 
examine the role of the ARHGEF3 and RHOA genes in bone cells. Expression of the 
ARHGEF3 and RHOA genes was identified in both osteoblast-like and oste clast-
like cells, however expression of the ARHGEF3 transcript variant NM_001128616 
was identified in the osteoclast-like cells only. The effect of ARHGEF3 and RHOA 
vii 
gene knockdown in human osteoblast-like and osteoclast-like cells was then 
investigated to give clues as to the role of these genes in bone cells. Knockdown of 
RHOA in the Saos-2, hFOB 1.19 and MG-63 osteoblast-like cell lines was 
consistently found to significantly reduce the expression of alpha 2 actin, smooth 
muscle (ACTA2) mRNA (P < 0.001), indicating a possible role for RHOA 
signalling in regulation of ACTA2 gene expression. Knockdown of ARHGEF3 in the 
Saos-2 osteoblast-like cell line was found to signif cantly reduce the expression of 
osteoprotegerin mRNA (P < 0.001 – 0.02), an effect that was replicated in the hFOB 
1.19 osteoblast-like cell line (P = 0.003). Knockdown of RHOA in the Saos-2 
osteoblast-like cell line was found to significantly increase the expression of 
parathyroid hormone 1 receptor mRNA (P = 0.002). The protein products of these 
mRNA transcripts are both involved with the mechanism by which parathyroid 
hormone stimulates the osteoblast to promote osteoclast genesis, suggesting a role 
for the ARHGEF3 and RHOA genes in this process. Knockdown of the ARHGEF3 
and RHOA genes in the osteoclast-like cells proved more difficult. However, there 
was some evidence to suggest that knockdown of RHOA significantly reduces the 
expression of Rho GDP dissociation inhibitor alpha (P < 0.001 – 0.004) and ACTA2 
mRNA (P < 0.001 – 0.003). The effect of ARHGEF3 and RHOA gene knockdown 
on the bone resorbing capabilities of osteoclast-like cells was then examined. Gene 
knockdown was performed on osteoclast-like cells cultured on bovine bone slices, 
with the mean resorption pit volume subsequently calcul ted for each treatment 
group. No significant differences were observed betwe n either of the ARHGEF3 or 
RHOA knockdown groups and the negative control group (P = 0.47 and 0.33 
respectively). 
 
These studies have identified common variation within e ARHGEF3 and RHOA 
genes as significantly associated with BMD in Caucasian women. Variation within 
these genes has not been previously implicated in BMD regulation or osteoporosis. 
These studies have also provided supporting evidence for association between 
variation in the FLNB gene and BMD in Caucasian women. All three of these genes 
are involved with cytoskeletal reorganisation and actin polymerisation, mechanisms 
that have been shown to have a role in osteoblast differentiation and osteoclast 
function. This suggests a role for genetic regulation of the cell cytoskeleton as a key 
pathway in osteoporosis susceptibility. In addition t  this, the functional studies 
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performed have highlighted some potential roles for the ARHGEF3 and RHOA genes 
in bone cells and have provided some leads for future study. Knockdown of these 
genes in osteoclast-like cells was not found to influence their bone resorptive 
capabilities, however this could be due to insufficient gene knockdown. 
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Chapter 1 – General introduction and literature review 
1.1 General introduction 
Osteoporosis is a common and debilitating bone disease that is characterised by a 
low bone mineral density (BMD), which leads to an increased risk of fracture (Kanis 
et al., 1994). The disease is particularly prevalent in postmenopausal women due to a 
reduction in oestrogen production, with subsequent effects on bone as well as 
intestinal and renal calcium handling (Prince and Dick, 1997). In addition to the 
effects of oestrogen, calcium and other environmental factors on bone structure, there 
is a strong genetic effect on peak bone mass (attained in early adult life), bone loss 
and fracture rates (Flicker et al., 1995, Michaelsson et al., 2005). Twin and family 
studies suggest that 50 – 90 % of the variation in peak bone mass is heritable (Evans 
et al., 1988, Pocock et al., 1987, Seeman et al., 1996). The genome-wide linkage 
scanning approach has identified at least 11 replicated quantitative trait loci (QTL) 
for BMD (Ioannidis et al., 2007, Lee et al., 2006, Xiao et al., 2006), suggesting that 
the genetic effect for common variation in BMD is under polygenic control. The 
3p14-p22 region of the human genome has been identified as a QTL for BMD in 
multiple studies (Lee et al., 2006, Wilson et al., 2003, Wynne et al., 2003, Xiao et al., 
2006). It is hoped that by identifying the genes that ave a role in BMD regulation, a 
better understanding of the mechanisms and biological signalling pathways 
underlying osteoporosis will be attained. This could lead to better treatments for the 
disease and the development of a panel of genetic marker tests that could identify 
individuals at increased risk of developing osteopor sis. Once these individuals have 
been identified, early intervention strategies can be applied to reduce their risk of 
developing the disease. 
 
This chapter focuses on reviewing the literature rel vant to bone. The basic elements 
of bone structure and remodelling are initially discu sed before an overview of 
osteoporosis and a detailed description of the major cell types involved with 
maintaining the bone structure is given. Environmental and genetic factors thought to 
influence bone are then covered with particular attention given to studies aimed at 
identifying genes that influence bone density. Finally, the aims and unifying 
hypothesis of the thesis are presented. 
 
1.2 Bone structure 
2 
The skeleton is comprised of both bone and cartilage nd serves three main 
functions: to provide mechanical support, protect the internal organs and to act as a 
storage vessel in mineral homeostasis (particularly relevant for calcium and 
phosphate) (Ng et al., 1997). Bone is made up of tw main constituents: cells and the 
extracellular matrix. There are three main cell types that are involved in maintaining 
the bone matrix: osteoblasts, which are responsible for the production of new bone; 
osteoclasts, which are responsible for the resorption of bone; and osteocytes, which 
have a role in maintaining the bone structure in response to mechanical forces and 
damage (Clarke, 2008). The extracellular matrix, which is the most abundant 
constituent, is comprised of collagen fibres and non-c llagenous proteins and is 
hardened by mineralisation with calcium phosphate in the form hydroxyapatite (Lian 
et al., 1999).  
 
The bones of the skeleton can be divided into two main groups: long bones, such as 
the humerus and femur, and flat bones, such as the capula and ilium (pelvis). Long 
bones can be divided into 3 main segments: the two wider sections at each end of the 
bone (the epiphyses), a cylindrical section in the middle (the midshaft or diaphysis) 
and an intermediate section between them (metaphysis) (Figure 1.1). The epiphysis 
and the metaphysis are separated in growing bones by a layer of cartilage known as 
the epiphyseal cartilage or growth plate. This layer contains proliferative cells that 
are responsible for the longitudinal growth of the long bones (Baron, 1999). Long 
bones and flat bones are primarily derived by two different processes: endochondral  
and intramembranous ossification, respectively (Baron, 1999). There are two main 
types of mature bone: cortical (or compact) bone and cancellous (or 
trabecular/spongy) bone. These two types of bone are made up of the same 
constituent cells and matrix elements but display structural and functional 
differences, particularly relevant with regards to porosity and micro-architecture. 
 
Cortical bone has a dense ordered structure, is found in the shaft of long bones 
(Figure 1.1) and the surfaces of flat bones and accounts for approximately 85 % of 
the total bone in the human body (Mundy, 1999). Cortical bone is laid down 
concentrically around central canals (known as Haversian canals), forming structural 
units that are known as Haversian systems. Haversian ystems contain nerves, 
connective tissue, blood vessels and lymphatics, with each Haversian canal 
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Figure 1.1. A section through a growing long bone with the location of the main 
anatomical features indicated. Figure adapted from Arthur’s Medical Clipart 
(Arthur, 2008). 
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surrounded by a concentric layer of rings or lamellae of bone matrix. Each lamella 
contains tiny spaces called lacunae that contain osteocytes. 80 – 90 % of cortical 
bone volume is calcified (Baron, 1999); it has great tensile strength and a high 
resistance to bending and torsion. Cortical bone also cts as a major reservoir for 
various chemical elements such as calcium, phosphate and magnesium (Broadus, 
1999). 
 
Cancellous bone is less dense than cortical bone, is lighter, more elastic and has an 
irregular structure. It is less common than cortical bone, making up approximately 15 
% of the total bone in the human body (Mundy, 1999). Cancellous bone is typically 
found proximal to joints, in the expanded ends of long bones (Figure 1.1) and in the 
interior of flat bones. The structure of cancellous bone is comprised of 
interconnecting beams, rods and bars called trabecula , which act as a supporting 
structure for the bone, with intervening marrow. The trabeculae are aligned along 
lines of stress, which adds considerably to the strngth of the bone by providing 
additional mechanical support (Mosekilde et al., 2000). 15 – 25 % of cancellous bone 
volume is calcified and the bone is very resistant to compressive stress (Baron, 
1999). Cancellous bone is highly vascular, usually contains red bone marrow and is 
the site of haematopoiesis (Arai et al., 2005). 
 
Each bone generally has an outer layer of cortical bone overlying cancellous bone 
and the medullary cavity. Cortical bone has an outer m mbrane called the periosteum 
(Figure 1.1) which is divided into two layers: an outer fibrous layer and an inner 
layer which has osteogenic, or bone forming, potential. New bone is formed within 
this inner layer allowing the bone to enlarge, part of a process known as periosteal 
apposition (Rauch, 2005). An additional layer present on the inner surface of the 
cortex of cortical bone is called the endosteum (Figure 1.1).  
 
In bone tissue, a network of collagen fibres is present in the extracellular matrix and 
is an important element of the bone structure, with the pattern of these fibres having 
an influence on the mechanical properties of the bone. At the microscopic level, two 
types of bone can be identified: lamellar bone and woven bone. Lamellar bone has a 
highly organised structure and contains collagen fibres that are arranged in a parallel 
fashion into concentric sheets, whereas woven bone c tains collagen fibres that are 
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arranged randomly (Baron, 1999). Lamellar bone has a lower proportion of 
osteocytes than woven bone and has greater mechanical strength. Woven bone is 
formed quickly and is primarily found in the growing skeleton, at the site of healing 
injuries and in various pathological conditions. At the site of a fracture, woven bone 
is formed initially and is slowly replaced by lamellar bone in a process known as 
“bony substitution”. 
 
1.3 Bone remodelling 
Bone is a dynamic organ that undergoes significant remodelling and is constantly 
being broken down and reformed through the coordinated actions of osteoblasts, 
osteoclasts and osteocytes. This process is tightly regulated and is essential for 
repairing damage to the bone tissue as well as for maintaining bone strength and 
controlling plasma calcium homeostasis (Ng et al., 1997). Bone remodelling activity 
is regulated by a variety of systemic hormones, local hormones/cytokines and 
mechanical stimuli. The remodelling activity varies in different types of bone, with 
cancellous bone having a higher turnover rate than cortical bone (Hadjidakis and 
Androulakis, 2006). Approximately 20 % of the cancellous bone surface is 
undergoing remodelling at any one time (Hill, 1998). Bone remodelling takes place 
in geographically and chronologically separated regions throughout the skeleton, 
suggesting that activation of the sequence of cellular events that leads to the process 
is primarily controlled by local mechanisms in the bone microenvironment (Mundy, 
1999).  
 
The bone remodelling cycle consists of three consecutive stages: the resorptive 
phase, when bone is actively resorbed by osteoclasts; the reversal phase, when 
macrophage-like cells and subsequently osteoblasts replace the osteoclasts within the 
resorption lacuna; and the formative phase, when th osteoblasts produce new bone 
(see Figure 1.2 for full cycle) (Hadjidakis and Androulakis, 2006). The remodelling 
cycle starts with the retraction of the cells lining the endosteal surface, leading to 
exposure of the endosteal membrane which is subsequently digested by matrix 
metalloproteinases and collagenases (Meikle et al., 1992). Osteoclast precursors 
(from the myeloid lineage) are then activated, which fuse to become large 
multinucleated osteoclasts that resorb the exposed mineralised bone creating a 




Figure 1.2. The bone remodelling cycle.  
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osteoclasts are replaced by macrophage-like cells that prepare the bone surface for 
the arrival of osteoblasts and stimulate osteoblast differentiation and migration 
(Hadjidakis and Androulakis, 2006). Osteoblasts are then recruited to the bottom of 
the resorption pit and lay down fresh osteoid which is subsequently mineralised. This 
is continued until the resorption pit is completely fi led. The complete remodelling 
cycle typically takes from 3 to 6 months (Baron, 1999). Defects in the turnover, 
structure and density of bone can lead to diseases such as osteoporosis, characterised 
by reduced bone density with an increased risk of fracture (Sipos et al., 2009), or 
osteopetrosis, characterised by increased bone density which often results in scoliosis 
and brittle bones (Stark and Savarirayan, 2009). 
 
1.4 Osteoporosis and fracture risk 
1.4.1 Osteoporosis 
Osteoporosis is a systemic bone disease characterised by low bone mass and 
disturbed micro-architecture of bone tissue (Figure 1.3), resulting in increased 
fragility with a corresponding increase in fracture risk (Kanis et al., 1994). There are 
four clinical forms of osteoporosis: postmenopausal, idiopathic, steroid-induced and 
senile (Wingate, 1984). The studies contained within this thesis are primarily 
concerned with postmenopausal osteoporosis, hence this form will be discussed here. 
Peak bone mass is usually attained during the thirddecade of life, after which the 
bone mass of an individual steadily declines with advancing age (Eastell, 1999). This 
decline is particularly pronounced in postmenopausal women due to a reduction in 
oestrogen production with subsequent effects on bone (Prince and Dick, 1997). The 
World Health Organisation (WHO) has proposed that women with bone density 
values greater than 2.5 standard deviations (SD) below the young adult mean value 
are considered osteoporotic (Kanis et al., 1994). According to this definition, based 
on the use of x-ray densitometry as a non-invasive measurement of bone mass and 
size, as many as 30 % of postmenopausal women are afflicted with osteoporosis 
(Melton, 1995). Since postmenopausal osteoporosis is a disease that predominantly 
affects individuals beyond the reproductive years, it has not been strongly selected 
against through the process of natural selection. 
 
Bone loss in postmenopausal women occurs primarily because of an increase in the 




Figure 1.3. An image comparing the micro-architectural differences between normal bone (left) and osteoporotic bone (right). Note the 
thinning and loss of trabeculae in the osteoporotic bone. Figure adapted from the International Osteoporosis Foundation (IOF, 2010). 
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osteoclasts (Eastell, 1999). If the process of bone remodelling were perfect, all 
resorbed bone would be replaced and there would be no overall loss or gain of bone 
mass. However, miniscule reductions in the amount of bone replaced during each 
bone remodelling cycle create a remodelling imbalance and accumulate to produce 
significant reductions in bone mass over time. This bone loss is magnified in 
postmenopausal women by the increased rate of bone remodelling (Eastell, 1999).  
 
Bone loss in postmenopausal women occurs in two phases: the first is a period of 
rapid bone loss that lasts for approximately 5 years after menopause and the second 
is a period of slower bone loss that also affects men (Riggs et al., 1998). The main 
reason for the first rapid phase of bone loss is oetr gen deficiency, since the 
circulating quantity of oestradiol decreases by 90 % after menopause (Eastell, 1999). 
Oestrogen is an inhibitor of bone remodelling (Kanis, 1996), with studies in 
ovariectomised primates revealing an increase in metabolic activity on bone surfaces 
(Thompson et al., 1992) and increased circulating levels of bone turnover markers 
(Hotchkiss et al., 2001). Oestrogen has been shown t  directly inhibit osteoclastic 
bone resorption by inducing osteoclast apoptosis (Kameda et al., 1997). There is also 
evidence to suggest that oestrogen deficiency stimulates the production of interleukin 
6 (IL6) (Manolagas and Jilka, 1992) and interleukin 7 (IL7) (Sato et al., 2007) in 
bone, both of which have been shown to promote osteoclastogenesis (Lowik et al., 
1989, Weitzmann et al., 2000). Oestrogen supplementatio  in postmenopausal 
women via hormone therapy has been shown to reduce the loss of bone mass as well 
as the incidence of vertebral and hip fractures (Cauley et al., 2003, Genant et al., 
1997, Lindsay et al., 1976). 
 
1.4.2 Osteoporotic fracture 
Osteoporotic fractures predominantly occur at the hip, wrist, forearm and in the 
vertebral column. It has been estimated that 9 million fractures occurred worldwide 
in the year 2000, of which 1.6 million were at the hip, 1.7 million at the forearm and 
1.4 million were clinical vertebral fractures (Johnell and Kanis, 2006). The 
prevalence of vertebral fracture is thought to be largely underestimated since the 
majority of these fractures are clinically silent (Cummings and Melton, 2002). It has 
been estimated that irrespective of the site of bone density measurement, for every 
decrease in bone density of one SD, the risk of new v rtebral fracture increases by a 
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factor of 2.0 – 2.4 (Wasnich, 1993). As the population ages and the proportion of 
people aged 80 years and over increases, the incidence of osteoporotic fracture is 
also expected to increase, particularly in the developed world (Johnell and Kanis, 
2006, Reginster and Burlet, 2006, Riggs and Melton, 1995).  
 
Hip fractures are regarded as being the most severe of the osteoporotic fractures 
(Johnell and Kanis, 2005), with almost all hip fracture patients requiring 
hospitalisation (Pasco et al., 2005). Sernbo and Johnell found that only 50 % of hip 
fracture patients managed to regain their pre-fractu e status regarding ability to walk 
and the need for aids at home to increase mobility (Sernbo and Johnell, 1993). Pasco 
et al. published similar findings, observing that almost 50 % of women who had 
suffered a hip fracture had not regained their pre-fracture mobility after 1 year (Pasco 
et al., 2005). Hip fracture patients also have a high mortality rate, with the age-
adjusted relative risk of dying following a hip fracture estimated at 6.7 (Cauley et al., 
2000). Vertebral fractures are slightly less common, with estimates suggesting that 1 
% of women at the age of 65 years and 2.9 % between the ages of 75 and 79 suffer 
from a new vertebral fracture each year (2002). However, the reduction in quality of 
life is almost as severe as for hip fractures (Johnell and Kanis, 2005), with 
suggestions that approximately 34 % of women who have suffered a vertebral 
fracture have impaired mobility 1 year later (Pasco et al., 2005). Mortality is also 
high in patients who have suffered a vertebral fracture, with the age-adjusted relative 
risk of dying following a clinical vertebral fracture estimated at 8.6 (Cauley et al., 
2000). 
 
The economic burden associated with osteoporotic fractu e is substantial, with much 
of the burden attributed to hip fractures (Reginster and Burlet, 2006, Riggs and 
Melton, 1995). More than 2 million osteoporotic fractures are suspected to have 
occurred in the US in 2005, and the costs associated with these are predicted to be in 
the region of US $16.9 billion (Burge et al., 2007). Of this, hip fractures were found 
to account for 14 % of all fractures and 72 % of the total cost (Burge et al., 2007).  
 
1.5 The osteoblast 
1.5.1 Background and function of the osteoblast 
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Osteoblasts differentiate from mesenchymal stem cells (also known as marrow 
stromal cells or MSCs), a multipotent stem cell that can differentiate into a variety of 
cell types including chondroblasts/chondrocytes (cartilage producing cells) and 
adipocytes (fat storage cells). Osteoblasts are capable of producing a variety of 
growth factors under a range of stimuli, some of which include: transforming growth 
factor beta (Canalis et al., 1993b), the bone morphogenic proteins (Chen et al., 2004) 
and the insulin-like growth factors (Canalis et al., 1993a). They are characterised by 
a well-developed rough endoplasmic reticulum and the presence of a large circular 
Golgi complex. The plasma membrane of the cell is typically rich in alkaline 
phosphatase, the concentration of which, in serum, is often used as a marker of 
osteoblastic activity or bone formation (Rodan, 1992). The osteoblast is responsible 
for the formation of new bone, a process that involves, initially, the secretion of 
osteoid (the organic portion of the bone matrix), which is primarily composed of 
fibres and ground substance. The primary fibre-type present in the osteoid is type 1 
collagen and the ground substance is composed mostly f osteocalcin and 
chondroitin sulphate (Netter, 1987). The secreting side of the cell is characterised by 
cytoplasmic processes that extend deep into the osteoid matrix. Approximately 10 
days after secretion of the osteoid (a period of time known as the osteoid maturation 
period), osteoblasts mineralise the matrix through the ordered deposition of 
hydroxyapatite onto the collagen and matrix lattice (Aubin, 1998).  
 
The functions of osteoblasts and osteoclasts are closely linked. Osteoblasts have been 
shown to mediate the effects of PTH on osteoclasts (McSheehy and Chambers, 1986) 
and secrete factors that control osteoclastogenesis, a process that has been well 
established in vivo (Teitelbaum, 2000) and in vitro (Kobayashi et al., 2009). This will 
be discussed later. 
 
1.5.1.i Intramembranous ossification 
There are two types of processes involved in the formation of new bones during 
foetal development: intramembranous ossification and e dochondral ossification. 
During intramembranous ossification, MSCs located within a vascularised region of 
the embryonic connective tissue differentiate into osteoblasts. These osteoblasts then 
synthesise woven bone, without the use of a cartilaginous template, which contains 
many large osteocytes that have differentiated from osteoblasts that have become 
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buried in the matrix (Franz-Odendaal et al., 2006). MSCs at the periphery of the 
woven bone continue to differentiate into osteoblasts, while blood vessels that are 
incorporated between the woven bone trabeculae form the hematopoietic bone 
marrow. The woven bone is then remodelled and gradually replaced with mature 
lamellar bone (Baron, 1999). Bones that are formed through the process of 
intramembranous ossification are known as membrane bo s (Franz-Odendaal et al., 
2006). 
 
1.5.1.ii Endochondral ossification 
Endochondral ossification involves the production of a cartilage template of the bone 
prior to synthesis of the bone matrix (Olsen, 1999). MSCs first condense at the sites 
of future bone formation, where they differentiate into chondroblasts and begin 
secreting cartilaginous matrix. Some of these cells then become embedded in the 
cartilage matrix that they have produced, where they continue to proliferate and 
become large (hypertrophic) chondrocytes (Teixeira t al., 2008). MSCs at the 
periphery of the newly produced cartilage continue to differentiate and proliferate 
resulting in appositional growth of the cartilage template. A bone collar is produced 
around the shaft of the developing bone through intramembranous ossification. 
Vascular invasion of the cartilage subsequently occurs, triggering apoptosis of the 
chondrocytes. Osteoblasts then migrate from the bone collar into the cartilage and 
produce woven bone that is subsequently remodelled and gradually replaced with 
lamellar bone (Baron, 1999). 
 
1.5.2 Influence of parathyroid hormone (PTH) on the osteoblast 
PTH is a systemic hormone that is secreted by the parathyroid glands in response to 
reduced circulating levels of ionised calcium (Ca+2) and is the principal regulator of 
calcium homeostasis along with calcitonin and 1,25-dihydroxyvitamin D3 
(1,25(OH)2D3) (Locker, 1996), the biologically active form of vitamin D. In its intact 
form, PTH is an 84 amino acid peptide, although it also exists in circulation as 
smaller fragments (D'Amour, 2006). PTH has been shown t  regulate blood calcium 
levels through effects on bone (Parfitt, 1976), thekidney (Friedman, 2000) and 
indirectly on the intestine through increased synthesis of vitamin D in the kidney 
(Brenza et al., 1998, Poole and Reeve, 2005). PTH can exert anabolic or catabolic 
effects on bone depending on the length of exposure, with short exposures to high 
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levels of the hormone stimulating anabolic responses and sustained exposure to high 
levels, such as resulting from prolonged hypocalcaemi , resulting in a catabolic 
response (Poole and Reeve, 2005). PTH binds to the parathyroid hormone receptors 
1 and 2, known as PTH1R and PTH2R respectively, with PTH1R the primary 
receptor expressed in bone (Mannstadt et al., 1999). The effects of PTH on bone 
appear to be primarily mediated through the osteoblast, although osteocytes and bone 
lining cells may also have a role in the process (Divieti et al., 2001, Dobnig and 
Turner, 1995). 
 
The anabolic effects of PTH on bone appear to be a combined result of increased 
osteoblast precursor proliferation, increased osteoblast differentiation and decreased 
osteoblast apoptosis. Jilka et al. found that administration of daily PTH injections in 
mice with either normal bone mass or osteopenia (reduc d bone density) stimulated 
an increase in bone formation through prevention of osteoblast apoptosis (Jilka et al., 
1999). This effect was subsequently confirmed in vitro using rodent and human 
osteoblasts (Jilka et al., 1999). A later study by Wang et al. found that continuous 
exposure to PTH blocked the differentiation of murine calvarial osteoblast cultures 
whereas transient exposure to PTH ultimately resultd in enhanced osteoblast 
differentiation (Wang et al., 2005b). Pettway et al. subsequently published evidence 
suggesting that PTH also promotes osteoblast precursor p oliferation (Pettway et al., 
2008). In this study, mesenchymal stem cells were implanted into 
immunocompromised mice before subjecting the mice to 3 weeks of PTH or vehicle 
treatment initiated at different time-points post-implantation (Pettway et al., 2008). 
An anabolic response in PTH-treated implants was oberved, as assessed by 
histomorphometry and MicroCT analysis (Pettway et al., 2008). 
 
In addition its anabolic effects on bone, the catabolic effects of PTH on bone are also 
mediated through the osteoblast and result in increased osteoclastic bone resorption 
through increased osteoclastogenesis (McSheehy and Chambers, 1986), leading to 
mobilisation of calcium from the bone (Poole and Reeve, 2005). PTH stimulates 
production of receptor activator of nuclear factor-κB ligand (RANKL) and inhibits 
the production of osteoprotegerin (OPG) by osteoblasts (Huang et al., 2004, Lee and 
Lorenzo, 1999). This increase in RANKL and decrease in OPG production results in 
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increased osteoclastogenesis. The role of these two molecules in regulating 
osteoclastogenesis is discussed later.  
 
1.5.3 Transcription factors and signalling molecules involved in osteoblast 
differentiation and function 
Transcription factors are proteins that bind to specific DNA sequences and can 
stimulate or inhibit the transcription or expression of certain genes, often playing a 
major role in cellular differentiation (Mitchell and Tjian, 1989). There are a wide 
variety of interacting transcription factors and relat d signalling molecules involved 
in the differentiation, bone production and osteoclast-regulatory functions of the 
osteoblast. Of these, the RUNX2, SP7 and ATF4 transcription factors are considered 
to be the major players (Marie, 2008) and are discus ed here. The established 
(canonical) wingless int (Wnt) signalling pathway has also been shown to play an 
important role in osteoblast differentiation and function (Piters et al., 2008) and is 
discussed here along with the Indian hedgehog homolog (IHH), an integral 
component of the Indian hedgehog signalling pathway that has been shown to 
promote osteoblast differentiation (Day and Yang, 2008). Figure 1.4 presents an 
overview of the potential interactions and relationships between the regulatory 
elements and signalling pathways discussed in this section. 
 
1.5.3.i Runt-related transcription factor 2 (RUNX2) 
Osteoblastic differentiation is controlled by a variety of transcription factors that are 
expressed in a specific sequence (Figure 1.5) (Marie, 2008). One of these 
transcription factors is RUNX2, which appears to have  central role in osteoblast 
differentiation and function (Komori, 2008). Ducy et al. identified the murine Runx2 
protein as a possible osteoblast-specific transcription factor and regulator of 
osteoblast differentiation (Ducy et al., 1997). They observed that its expression in 
primary mouse osteoblasts was down-regulated by 1,25(OH)2D3 (Ducy et al., 1997), 
which supports clinical evidence suggesting that excess 1,25(OH)2D3 may prevent 
osteoblast terminal differentiation and cause aplastic bone disease (Goodman et al., 
1994), a disorder characterised by low bone formation (Andress et al., 1987). 
Expression of the murine Runx2 gene is evident during embryonic development and 
precedes osteoblast differentiation; expression of the gene at this point is restricted to 




Figure 1.4. Schematic diagram presenting an overview of potential interactions between signalling pathways in the osteoblast. This 
diagram helps to illustrate the major role that theRUNX2 transcription factor has in osteoblasts. The influence of PTH in stimulating 




Figure 1.5. Osteoblast and chondrocyte differentiation pathways with associated transcription factors. Note that the RUNX2 gene is 
expressed in both differentiation pathways, whereas expression of SP7 and ATF4 are more specifically related to osteoblast differentiation. 
17 
 
It was initially suggested that later in development xpression is restricted to 
osteoblasts (Ducy et al., 1997), however various stdies have confirmed that RUNX2 
also has a role in the differentiation of chondrocytes (Enomoto et al., 2000, Komori, 
2002, Kim et al., 1999) (Figure 1.5) and odontoblasts (dentin synthesising tooth 
homologs of osteoblasts) (D'Souza et al., 1999). Runx2-deficient mice are born with 
a deficiency of osteoblasts and osteoclasts and possess a skeleton composed 
completely of cartilage (Komori et al., 1997, Otto et al., 1997). Functional studies 
have found that the murine Runx2 protein binds to the osteoblast-specific cis-acting 
element 2 (OSE2) (Ducy and Karsenty, 1995). OSE2 is found in the promoter region 
of many genes essential to osteoblast function, including those encoding: type 1 
collagen, bone gamma-carboxyglutamate (gla) protein (osteocalcin or BGLAP), 
osteopontin, bone sialoprotein, alkaline phosphatase, nd collagenase-3, as well as 
the Runx2 gene itself (Ducy et al., 1997, Harada et al., 1999, Jimenez et al., 1999). 
 
In addition to its proposed role in osteoblast differentiation, RUNX2 also appears to 
have a role in bone formation by differentiated oste blasts. Ducy et al. generated 
transgenic mice that over-expressed the DNA binding domain of Runx2 in 
differentiated osteoblasts postnatally (Ducy et al., 1999). This DNA binding domain 
has a higher affinity for DNA than wild-type Runx2, has no transcriptional activity 
and acts in a dominant-negative manner (Ducy et al., 1999). Mice over-expressing 
this domain were born with a normal skeleton but developed osteopenia thereafter, 
caused by a decrease in bone formation despite a normal steoblast count (Ducy et 
al., 1999). Expression analysis revealed that many osteoblast-related transcripts, 
including several encoding bone extracellular matrix proteins, were virtually absent 
and that the osteoblasts expressing the modified Runx2 protein were less active 
(Ducy et al., 1999). In addition to this, Ziros et al. found that low level mechanical 
deformation, or stretching, of human osteoblasts directly up-regulated the expression 
of RUNX2 and its binding to OSE2 (Ziros et al., 200). This suggests that 
mechanical stimulation may promote osteoblastogenesis and/or osteoblast function 
through effects on RUNX2. 
 
Mutation in the human RUNX2 gene has been implicated in multiple cases of 
Cleidocranial Dysplasia (Bergwitz et al., 2001, Lee et al., 1997, Machuca-Tzili et al., 
2002, Mundlos et al., 1997, Zhou et al., 1999). This is an autosomal dominant 
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condition characterised by a variety of skeletal phenotypes including underdeveloped 
or absent collarbones, delayed closing of spaces between the bones of the skull, 
shortened fingers and forearms, scoliosis of the spine, dental abnormalities and 
reduced BMD (Chitayat et al., 1992, Dore et al., 1987, Jensen, 1990, Morava et al., 
2002, Vaughan et al., 2002).  
 
1.5.3.ii Osterix (SP7) 
SP7 is another transcription factor that is thought to have a role in osteoblast 
differentiation. Nakashima et al. detected expression of the Sp7 gene specifically in 
the developing bones of mouse embryos and subsequently g erated Sp7-null mice 
(Nakashima et al., 2002). The mice died within 1 hour f birth and a complete 
absence of endochondral ossification in the skeletal elements was observed, that is, 
calcification/mineralisation of the cartilaginous skeleton, resulting in a lack of bone 
formation (Nakashima et al., 2002). Intramembranous ossification was also affected, 
with cells in the skeletal elements unable to differentiate into osteoblasts (Nakashima 
et al., 2002).  Kaback et al. analysed the expression of Sp7 during endochondral 
ossification in mice, finding that it is expressed in osteochondroprogenitor cells and 
mature osteoblasts but not in hypertrophic chondrocytes (Figure 1.5) (Kaback et al., 
2008). Over-expression of Sp7 in mouse embryonic limb derived clonal cells was 
found to promote osteoblast differentiation, whereas inhibition of Sp7 expression in 
these cells using small interfering RNA (siRNA) was found to promote chondrocyte 
differentiation (Kaback et al., 2008). Baek et al. subsequently examined the effect of 
Sp7 in the bones of adult mice by inactivation of the Sp7 gene in osteoblasts after 
bone collar formation at embryonic day 14.5 (Baek et al., 2009). Newborn mice 
showed no significant abnormalities, however by adulthood the mice exhibited an 
osteopenic phenotype including delayed osteoblast maturation (Baek et al., 2009). 
Overall, these results point to a role for SP7 in oste blast differentiation and bone 
formation in both developing and adult bone. 
 
In terms of hierarchical relationships, there is evid nce in the literature to suggest 
that SP7 acts downstream of RUNX2 in the pathway of osteoblast differentiation and 
that RUNX2 is required for expression of SP7. Nishio et al. performed an analysis of 
the murine Sp7 gene promoter and identified a putative Runx2 binding site (Nishio et 
al., 2006). They subsequently found that over-expression of Runx2 caused up-
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regulation of this region of the Sp7 promoter 2-fold (Nishio et al., 2006). This 
supports previous evidence published by Nakashima et al., who found that 
osteoblasts obtained from Sp7-null mice continued to express Runx2 at levels 
comparable to the wild-type but that Runx2-null mice failed to express Sp7 
(Nakashima et al., 2002).  
 
1.5.3.iii Activating transcription factor 4 (ATF4) 
Yang et al. identified the transcription factor ATF4 as a critical regulator of 
osteoblast terminal differentiation (Figure 1.5) and osteoblast-specific gene 
expression (Yang et al., 2004). They demonstrated that ATF4 regulates the synthesis 
of type 1 collagen and that deficiency of Atf4 in mice causes delayed bone formation 
during embryonic development and reduced bone mass throughout adult life (Yang 
et al., 2004). They also presented evidence suggestin  that the protein may have a 
role in the pathophysiology of Coffin-Lowry syndrome (MIM 303600) (Yang et al., 
2004), a rare genetic disease characterised by intellectual disability and skeletal 
abnormalities (Coffin et al., 1966, Lowry et al., 1971). In a subsequent study, Yang 
and Karsentry demonstrated that ATF4 is regulated post-translationally and has the 
ability to induce the expression of the osteoblast-specific gene Bglap (which encodes 
osteocalcin) in mouse non-osteoblastic cells (Yang d Karsenty, 2004). Zhang et al. 
found that deficiency of Atf4 in murine osteoblasts and mouse primary MSCs 
resulted in severe proliferative defects including delay of cell cycle progression and 
an increased rate of apoptosis (Zhang et al., 2008).  
 
There is evidence in the literature to suggest that ATF4 has a role in mediating the 
effects of PTH on osteoblasts. Yu et al. found thatreatment of murine osteoblasts 
and mouse primary MSCs with PTH increased Atf4 gene expression and that Atf4 
protein was required for PTH-stimulated Bglap gene expression in these cells, 
suggesting that ATF4 is a downstream target of PTH action in osteoblasts (Yu et al., 
2008). A more recent study by Yu et al. produced supporting evidence for this when 
they found that the anabolic effects of PTH on bone are severely impaired in Atf4-
null mice (Yu et al., 2009). They also found that PTH-induced stimulation of Sp7 
gene expression in murine osteoblasts was completely abolished by Atf4 protein 




1.5.3.iv Wingless int (Wnt) signalling  
Many studies have indicated a role for Wnt signallig and in particular the canonical 
Wnt signalling pathway in the processes of bone formation, osteoblast differentiation 
and skeletal development. The canonical Wnt signalling pathway is activated when 
secreted Wnt glycolipoproteins bind to transmembrane receptors of the Frizzled 
family and their co-receptors, low density lipoprotein receptor-related proteins 5 and 
6 (LRP5 and LRP6), ultimately resulting in regulation of the transcriptional co-
activator beta-catenin (MacDonald et al., 2009). Gong et al. identified mutation 
within the LRP5 gene as responsible for osteoporosis-pseudoglioma syndrome (MIM 
259770) (Gong et al., 2001), a genetic disorder characterised by severe juvenile-
onset osteoporosis and blindness (Gong et al., 1996). They also found that the LRP5 
protein is able to mediate Wnt signalling via the canonical pathway in vitro and that 
dominant-negative mutants of LRP5 can interfere with this signalling pathway and 
cause a reduction in bone thickness in murine calvari l explant cultures (Gong et al., 
2001). The authors also demonstrated that the Lrp5 gene is expressed by murine 
osteoblasts and that expression of the gene was found to increase upon osteoblastic 
differentiation of a pluripotent mesenchymal cell line (Gong et al., 2001). Ellies et al. 
subsequently found that the product of the sclerostin (SOST) gene physically 
interacts with LRP5 and LRP6 to inhibit the canonical Wnt signalling pathway 
(Ellies et al., 2006). Mutation in the SOST gene has been identified as responsible for 
the rare bone disease sclerosteosis (MIM 269500) (Balemans et al., 2001, Brunkow 
et al., 2001), which is an autosomal-recessive disor er characterised by hyperactive 
osteoblasts and progressive bone overgrowth (Hamersma et al., 2003). 
 
Additional evidence for a role of the canonical Wnt signalling pathway in the 
osteoblast was published by Day et al., who demonstrated that expression of beta-
catenin promotes the differentiation of osteoblasts in preference to chondrocytes 
from mesenchymal progenitors (Day et al., 2005). This finding led the authors to 
suggest that the canonical Wnt signalling pathway m act as a molecular switch in 
mesenchymal cells, determining whether they differentiate towards an osteoblast or 
chondrocyte fate (Day et al., 2005). In addition to this, Glass et al. found that beta-
catenin promotes the ability of differentiated osteblasts to inhibit osteoclast 





1.5.3.v Indian hedgehog homolog (IHH) 
The IHH is an integral component of the Indian hedgehog signalling pathway that 
has been shown to control various aspects of skeletal d velopment (Day and Yang, 
2008). A study published by St-Jacques et al. examined mice deficient in Ihh (St-
Jacques et al., 1999), a gene that had previously been implicated in chondrocyte 
differentiation (Vortkamp et al., 1996). The authors found that in addition to reduced 
chondrocyte proliferation and maturation, the I h-null mice were born with severely 
impaired skeletal development as a result of an absence of osteoblast development in 
the endochondral bones (St-Jacques et al., 1999). Long et al. produced supporting 
evidence for this when they found that mouse embryos with defective Ihh signalling 
presented with impaired osteoblast differentiation which led to formation of a 
defective bone collar during endochondral ossification (Long et al., 2004). To 
examine the role of IHH postnatally, Maeda et al. generated tamoxifen-inducible 
conditional Ihh-knockout mice (Maeda et al., 2007). They observed a continued loss 
of trabecular bone over time in the knockout mice with reduced Wnt signalling in the 
osteoblastic cells (Maeda et al., 2007). In addition o this, dwarfism was observed in 
the knockout mice (Figure 1.6) that appeared to be caused by premature fusion of the 
growth plates of various endochondral bones (Maeda t l., 2007). These results 
would suggest that in addition to its role in endochondral ossification, IHH also has a 
role in osteoblast function and maintenance of the skeleton postnatally. 
 
Additional evidence for a role of IHH in skeletal development has come from studies 
implicating mutation within the human IHH gene in two genetic diseases with 
skeletal phenotypes. Gao et al. identified 3 heterozyg us missense mutations within 
the IHH gene in 3 unrelated large Chinese families with a istory of type A1 
brachydactyly (MIM 112500) (Gao et al., 2001), a condition characterised by the 
shortening or absence of the middle fingers (Bell, 1951). Mutations within this gene 
were subsequently identified in many other instances of the disease (Kirkpatrick et 
al., 2003, Liu et al., 2006, McCready et al., 2002). Hellemans et al. identified 2 
missense mutations within the IHH gene in two consanguineous families with 
multiple instances of the genetic disease acrocapitofemoral dysplasia (MIM 607778) 
(Hellemans et al., 2003). This disease is characterised by cone shaped epiphyses in 




Figure 1.6. Wild-type and Ihh-null mice. 8-week old littermates: the mouse on the 
right has had induced knockout of the I h gene at postnatal day 0 while the mouse on 
the left is wild-type. Note the smaller size of the knockout mouse thought to be 
caused by premature fusion of the growth plates of various endochondral bones. 
Figure adapted from Maeda et al. (Maeda et al., 2007).  
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1.5.4 Osteoblast-produced bone gamma-carboxyglutamate (gla) protein (osteocalcin 
or BGLAP) 
BGLAP is a small highly-conserved non-collagenous protein (Carr et al., 1981) that 
is exclusively produced by osteoblasts and binds strongly to hydroxyapatite (Boivin 
et al., 1990). It is associated with the mineralised matrix of bone, is the most 
abundant non-collagenous protein in the bone extracellular matrix (Boivin et al., 
1990, Weinreb et al., 1990) and is secreted into the general circulation where it can 
be used as a clinical indicator of bone formation (Pagani et al., 2005). To investigate 
the role of BGLAP in bone, Ducy et al. generated Bglap-null mice and observed 
increased bone mass relative to wild type mice as a result of an increase in bone 
formation without impairment of bone resorption (Ducy et al., 1996). They also 
found that bone mineralisation was unaffected in Bglap-null mice, prompting the 
authors to suggest that BGLAP works to limit bone formation without impairing 
bone resorption or mineralisation (Ducy et al., 1996). Boskey et al. also generated 
Bglap-null mice and observed differences in bone mineral ratios relative to wild type 
mice (Boskey et al., 1998), indicating a role for BGLAP in stimulating bone mineral 
maturation. However, despite these early findings the exact role of BGLAP in bone 
remains to be determined.  
 
Interestingly, in addition to its apparent role in bone, osteoblast-produced BGLAP 
appears to have a systemic role in glucose metabolism. Ducy et al. noted that mice 
null for Bglap appeared mildly hypoglycaemic and had increased visceral fat (Ducy 
et al., 1996). Lee et al. observed similar effects in that mice null for Bglap displayed 
decreased pancreatic β-cell proliferation, glucose intolerance and insulin resistance 
(Lee et al., 2007). They also demonstrated that BGLAP stimulates insulin expression 
in pancreatic β-cells and adiponectin in adipocytes (Lee et al., 2007). Supporting 
evidence for this was published by Ferron et al., who found that the Bglap protein is 
involved in the regulation of glucose metabolism and fat mass in mice (Ferron et al., 
2008). Several recent clinical studies have reported links between BGLAP levels and 
plasma glucose as well as various measures of adiposity (Im et al., 2008, Kindblom 
et al., 2009, Pittas et al., 2009). It therefore appears that in addition its role in bone 
turnover, the osteoblast may have a role in energy homeostasis. 
 
1.6 The osteoclast 
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1.6.1 Background and function of the osteoclast 
The mature osteoclast is a large cell that can contain from four to twenty nuclei 
(Baron, 1999). It is responsible for the resorption of bone and is usually found in 
contact with a calcified bone surface or within a resorption lacuna. The cytoplasm of 
the osteoclast typically contains many vacuoles, Golgi complexes and transport 
vesicles that contain lysosomal enzymes which are ess ntial to the bone resorptive 
capabilities of the cell. Walker was the first to demonstrate that the osteoclast is of 
hematopoietic origin (Walker, 1975a, Walker, 1975b, Walker, 1975c). Udagawa et 
al. published evidence to suggest that the osteoclast is derived from the 
monocyte/macrophage family and that the principal precursor is located in the bone 
marrow (Udagawa et al., 1990). Subsequent studies have determined that the 
osteoclast is derived from mononuclear precursors in the myeloid lineage of 
hematopoietic cells (Boyce and Xing, 2008). 
 
When an osteoclast comes into contact with bone matrix, the plasma membrane 
forms deep foldings in the area facing the bone (Baron, 1999). A ruffled border in the 
centre of this is surrounded by a ring of contractile proteins that is known as the 
sealing zone. The sealing zone is responsible for the attachment of the cell to the 
bone surface (Marchisio et al., 1984) and for the creation of an isolated compartment 
between the cell and the bone surface. Integrin receptors bind to specific sequences 
within the matrix proteins which results in attachment of the cell to the matrix. The 
lysosomal enzymes synthesised in the osteoclast, includi g cathepsin K (CTSK) and 
tartrate resistant acid phosphatase (TRAP), are secreted through the ruffled border 
into the isolated extracellular compartment (Figure 1.7) (Baron, 1999). The 
osteoclast then acidifies this compartment by pumping protons, present at a high 
concentration in the cytosol as a result of the action of carbonic anhydrase, across the 
ruffled border membrane via an electrogenic H+ ATPase (proton pump) (Figure 1.7) 
(Blair et al., 1989). Mutations in the genes encoding the protein subunits of this 
pump have been identified as a common cause of autosomal recessive osteopetrosis 
(Frattini et al., 2000). The cell avoids alkalinisat on of the cytosol by exchanging 
bicarbonate (HCO3
-) for chloride (Cl-) at the basolateral membrane (Figure 1.7) 
(Baron, 1989). These Cl- ions are then transported to the isolated extracellular 
compartment through a chloride channel known as chloride channel 7 (CLCN7) 




Figure 1.7. The processes of osteoclastogenesis and subsequent bone resorption 
induced by stimulation of monocytes/macrophages with the osteoblast-produced 
cytokines M-CSF and RANKL. 
26 
 
lowering the pH of the compartment to around 4.5 (Schlesinger et al., 1997). 
Mutations to the CLCN7 gene have been known to cause decreased bone resorption 
leading to osteopetrosis (Blair et al., 1986). The bone matrix is exposed when the low 
pH in the isolated extracellular compartment first degrades the hydroxyapatite-
collagen links, then subsequently dissolves the hydroxyapatite crystals. The 
lysosomal enzymes, which are now at optimal pH, proceed in degrading the 
proteinaceous bone matrix (Blair et al., 1986). The elements released during bone 
resorption are either internalised, transported through the osteoclast for release at the 
basolateral membrane, or released directly from the resorption pit during periods of 
relapse of the sealing zone (Baron, 1999).  
 
1.6.2 Cytokines and signalling molecules involved in osteoclast differentiation and 
function 
There are many different cytokines and interacting signalling molecules involved in 
osteoclast differentiation and function. As mentioned previously, PTH has a major 
role in promoting osteoclastogenesis through regulation of RANKL and OPG 
production by the osteoblast (Huang et al., 2004, Lee and Lorenzo, 1999). The role 
of these and other cytokines in regulating osteoclastogenesis will be discussed here, 
including the pro-osteoclastogenic cytokines macrophage colony stimulating factor 
(M-CSF or CSF1) (Asagiri and Takayanagi, 2007), tumo r necrosis factor alpha 
(TNF) (Teitelbaum, 2007) and the intracellular signal transducer TNF receptor-
associated factor 6 (TRAF6) (Blair et al., 2005). Figure 1.8 presents an overview of 
the potential interactions and relationships between the regulatory elements and 
signalling pathways discussed in this section. 
 
1.6.2.i Receptor activator of nuclear factor-κB ligand (RANKL) 
RANKL is encoded for by the TNFSF11 gene (Anderson et al., 1997), is a member 
of the tumour necrosis factor superfamily and is considered to be the primary 
osteoclastogenic cytokine. It had been suggested as early as 1981 that osteoblastic 
cells may have a role in osteoclast recruitment andctivity (Rodan and Martin, 
1981). A study by Udagawa et al. found that osteoclastogenesis was dependent upon 
physical contact between osteoclast precursor cellsand certain mesenchymal cells 
such as osteoblasts or their precursors (Udagawa et al., 1990). This finding led to the 




Figure 1.8. Schematic diagram presenting an overview of potential interactions between signalling pathways in the osteoclast. The 
cytokines RANKL and M-CSF both have prominent roles in timulating osteoclastogenesis. Also of note are the different influences of the TNF 
cytokine on osteoclastogenesis depending on the receptor that has been activated. 
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the surface of cells of the osteoblast lineage and is also produced in both membrane-
bound and soluble forms by T lymphocytes during state  of skeletal inflammation 
such as rheumatoid arthritis or osteomyelitis (infection of the bone) (Kong et al., 
1999). Kong et al. generated Tnfsf11-null mice and observed severe osteopetrosis 
with shortening of the long bones resulting from a bone-remodelling defect (Kong et 
al., 1999). The mice also suffered from failure of tooth eruption, a typical finding in 
osteopetrosis since bone resorption is required to open a pathway through the bone of 
the jaw through which the teeth can erupt. Hematopoietic precursor cells obtained 
from the spleens of the Tnfsf11-null mice were found to be capable of undergoing 
osteoclastogenesis when cultured with M-CSF and RANKL in vitro (Kong et al., 
1999). Subsequent studies have identified soluble RANKL as capable of inducing 
severe skeletal catabolism in rats (Yuan et al., 2008) and loss of function mutations 
in the human TNFRSF11 gene have been implicated in osteoclast-poor autosomal 
recessive osteopetrosis (Sobacchi et al., 2007). 
 
RANKL stimulates osteoclastogenesis in hematopoietic cells by binding to receptor 
activator of nuclear factor-κB (RANK) (Nakagawa et al., 1998), which is encoded 
for by the TNFRSF11A gene (Anderson et al., 1997). Dougall et al. generated 
Tnfrsf11a-null mice and observed pronounced osteopetrosis with shortened limbs 
and failure of tooth eruption which appeared to result from a complete absence of 
osteoclasts (Dougall et al., 1999). Hematopoietic cells from the Tnfrsf11a-null mice 
cultured with M-CSF and RANKL failed to differentiate into osteoclasts (Dougall et 
al., 1999). Li et al. also generated Tnfrsf11a-null mice, again observing osteopetrosis 
along with a complete absence of osteoclasts (Li et al., 2000). Transfection of 
hematopoietic cells from these mice with a functional Tnfrsf11a gene was found to 
rescue the osteoclastogenic capabilities of the cells (Li et al., 2000).  
 
The intracellular signalling mechanism by which RANKL stimulates 
osteoclastogenesis is thought to occur as follows: activation of RANK by RANKL 
results in the recruitment of an adaptor protein know  as TRAF6 (discussed later). 
TRAF6 acts as a second messenger to activate various mitogen-activated protein 
kinase pathways and the nuclear factor-κB (NFκB) family of transcription factors 
(Ross, 2000). Once activated, NFκB transcription factors translocate to the nucleus 
where they bind to DNA target sites (Lee and Kim, 2003). Mice lacking NFκB 
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signalling present with osteopetrosis as a result of impaired osteoclast differentiation 
(Iotsova et al., 1997). See Figure 1.8 for an overview of this pathway. 
 
1.6.2.ii Osteoprotegerin (OPG) 
OPG, which is encoded for by the TNFRSF11B gene (Morinaga et al., 1998), is a 
soluble member of the TNF receptor family that acts s a decoy receptor for RANKL 
that competes with RANK (Hofbauer and Schoppet, 2004). Simonet et al. identified 
OPG as a secreted glycoprotein, over-expression of which causes osteopetrosis in 
mice (Simonet et al., 1997). The authors also observed that OPG inhibits 
osteoclastogenesis of hematopoietic cells in vitro (Simonet et al., 1997). Bucay et al. 
subsequently generated Tnfrsf11b-null mice and observed decreased bone density 
characterised by porosity of the trabecular and cortical bones with a high incidence 
of fracture (Bucay et al., 1998). Mizuno et al. also generated Tnfrsf11b-null mice, 
which presented with severe osteoporosis and reduced bone strength as a result of 
increased osteoclastogenesis (Mizuno et al., 1998). In addition to its role in inhibiting 
osteoclastogenesis, various studies have identified a role for OPG in suppressing 
osteoclast survival (Akatsu et al., 1998), activity (Hakeda et al., 1998) and 
attachment to bone surfaces (O'Brien et al., 2000). OPG has been shown to exist in 
monomeric and homodimeric forms, with evidence suggesting that the homodimeric 
arrangement has a greater affinity for RANKL (Schneew is et al., 2005). 
 
Mutation within the TNFRSF11B gene has been identified as responsible for juvenile 
Paget’s disease (also known as idiopathic or hereditary hyperphosphatasia) (MIM 
239000), a disorder characterised by increased bone turnover, loss of bone 
mineralisation, broadened bone shafts, osteopenia, increased susceptibility to fracture 
and increased levels of alkaline phosphatase in the blood, the latter of which possibly 
reflects increased osteoblast activity (Caffey, 1972, Golob et al., 1996). Whyte et al. 
discovered that homozygous deletion of TNFRSF11B was responsible for juvenile 
Paget’s disease in two unrelated patients of Navajo Indian ancestry (Whyte et al., 
2002). Cundy et al. subsequently identified a homozyg us inactivating deletion 
within the TNFRSF11B gene as responsible for juvenile Paget’s disease in a 
consanguineous family of Iraqi origin (Cundy et al., 2002). A study by Chong et al. 
analysed the TNFRSF11B gene in 8 patients suffering from juvenile Paget’s disease, 
identifying mutations in 5 of the subjects (Chong et al., 2003).  
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1.6.2.iii Macrophage colony stimulating factor (M-CSF or CSF1) 
M-CSF, which is encoded for by the CSF1 gene (Morris et al., 1991) and is produced 
by osteoblasts and their precursors (Takahashi et al., 1991), has been shown to be 
essential for macrophage survival and proliferation as well as regulation of 
osteoclastogenesis (Yoshida et al., 1990). M-CSF exists in both membrane-bound 
and secreted forms (Cosman et al., 1988) and promotes the proliferation of osteoclast 
precursors and survival of the differentiated osteoclast through effects on the colony 
stimulating factor 1 receptor (also known as c-FMS or CSF1R) (Faccio et al., 
2003b), expression of which has been found to be up-regulated by TNF (Yao et al., 
2006). 
 
Yoshida et al. identified a nonsense (protein-truncati g) mutation within the murine 
Csf1 gene as responsible for a form of recessive osteope rosis in mice (Yoshida et al., 
1990). These mice present with a restricted bone remod lling ability and are deficient 
in mature osteoclasts and macrophages (Marks and Lae, 1976). Administration of 
recombinant human M-CSF to the mice was found to corre t their impaired bone 
resorption (Felix et al., 1990). Dobbins et al. identified a similar mutation in the Csf1 
gene as responsible for a form of osteopetrosis in rats (Dobbins et al., 2002). 
Subsequent studies have also implicated M-CSF in pathological bone loss during 
inflammatory osteolysis, a disorder characterised by excessive bone resorption by 
osteoclasts and can result in joint collapse, with blockade of M-CSF signalling found 
to arrest the condition (Kitaura et al., 2005). 
 
1.6.2.iv Tumour necrosis factor alpha (TNF) 
The inflammatory cytokine TNF, which exists in both membrane-bound and soluble 
forms, appears to have a synergistic relationship with RANKL and has been shown 
to promote osteoclastogenesis in both postmenopausal osteoporosis (Weitzmann and 
Pacifici, 2005) and inflammatory osteolysis (Teitelbaum, 2006). Lam et al. published 
evidence suggesting that TNF could not induce osteoclastogenesis of murine 
osteoclast precursors in the absence of RANKL, althoug  the cytokine was found to 
augment RANKL-stimulated osteoclastogenesis in a dose-dependent manner in vitro 
(Lam et al., 2000). Kim et al. subsequently found that TNF can stimulate 
osteoclastogenesis of murine hematopoietic precursor cells of myeloid lineage in the 
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absence of RANKL, although this could only occur in cells treated with M-CSF and 
transforming growth factor beta 1 (TGFB1) (Kim et al., 2005). Other groups have 
presented evidence suggesting that TNF can activate fully differentiated osteoclasts 
in a mechanism that is independent of RANK signallig (Fuller et al., 2006, Fuller et 
al., 2002).  
 
The TNF cytokine binds to two different membrane receptors, the type 1 receptor 
p55 (TNFRSF1A) and the type 2 receptor p75 (TNFRSF1B), with the 
osteoclastogenic effects of the cytokine differing depending on the receptor that has 
been activated. Abu-Amer et al. found that bone marrow from mice expressing only 
the Tnfrsf1a receptor produced substantially more osteoclasts than the wild type, 
whereas marrow from mice only expressing the Tnfrsf1b receptor produced 
substantially fewer than the wild type (Abu-Amer et al., 2000). They also found that 
the soluble form of the cytokine preferentially bound to the Tnfrsf1a receptor, 
whereas the membrane-bound form preferentially bound to Tnfrsf1b (Abu-Amer et 
al., 2000). 
 
1.6.2.v TNF receptor-associated factor 6 (TRAF6) 
TRAF6 is an intracellular signalling molecule that is activated upon binding of 
RANKL to RANK (Asagiri and Takayanagi, 2007) and appears to be involved in 
both osteoclastogenesis (Naito et al., 1999, Ye et al., 2002) and osteoclast function 
(Lomaga et al., 1999). Naito et al. generated Traf6-deficient mice and observed an 
osteopetrotic phenotype that appeared to be a result of impaired osteoclast 
differentiation (Naito et al., 1999). Without Traf6, the murine osteoclast precursor 
cells were unable to differentiate into osteoclasts after stimulation with RANKL 
(Naito et al., 1999). Ye et al. published supporting evidence for this after 
demonstrating that cell-permeable peptides containing the TRAF6-binding motif 
inhibit TRAF6 signalling and prevent osteoclastogenesis in vitro (Ye et al., 2002). 
Lomaga et al. published evidence suggesting that TRAF6 may also be involved with 
osteoclast function when they generated mice deficient n Traf6 and observed an 
osteopetrotic phenotype with defects in bone remodelling that appeared to be due to 
impaired osteoclastic bone resorptive capabilities (Lomaga et al., 1999).  
 
1.6.3 Role of integrins and cytoskeletal dynamics in the osteoclast 
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Communication between the integrin receptors (also kn wn as integrins) and the 
cytoskeleton is an important mechanism in osteoclasts  it is essential for the 
successful attachment of the cell to the bone surface and subsequent resorption of the 
bone. Integrins located on the surface of an osteoclast an recognise specific bone 
matrix proteins and transmit signals to the interior of the cell that bring about 
cytoskeletal responses (Zou and Teitelbaum, 2010). These processes are relevant to 




Integrins, which aid in the attachment of the osteoclast to bone matrix as well as the 
transmission of matrix-derived signals to the interior of the cell (outside-in 
signalling) (Miyauchi et al., 1991), are made up of alpha and beta heterodimers. The 
heterodimer usually consists of a long extracellular domain and a relatively short 
intracellular domain. Outside-in signalling by integrins can mediate numerous 
intracellular events, one of the most prominent being reorganisation of the actin 
cytoskeleton. Various integrins have been implicated in osteoclast function. McHugh 
et al. demonstrated that the αvβ3 integrin complex, made up of the alpha V and beta 
3 integrins, is essential for normal osteoclast functio  in mice (McHugh et al., 2000). 
They found that osteoclasts lacking in the complex w re characterised by abnormal 
formation of the ruffled membrane and actin rings in vivo in addition to failure of the 
cells to spread in vitro (McHugh et al., 2000). This supported previous findings that 
the expression of the αvβ3 integrin replaces that of αvβ5 during osteoclastogenesis 
(Inoue et al., 1998) and that the integrin is essential to the resorptive process (Crippes 
et al., 1996, Horton et al., 1991, Ross et al., 1993). Zhao et al. published evidence 
suggesting that unoccupied αvβ3 integrins transmit a positive death signal resulting 
in osteoclast apoptosis (Zhao et al., 2005). Other int grins that have been implicated 
in osteoclast function include the alpha L and alph 3 integrins, both of which have 
been found to be significantly up-regulated during osteoclastogenesis of peripheral 
blood mononuclear cells (Day et al., 2004). 
 
1.6.3.ii Cytoskeletal dynamics 
To achieve the various tasks required of an osteoclast during bone resorption, 
substantial and rapid cytoskeletal reorganisation is ecessary. Actin is one of the 
33 
most abundant proteins found in eukaryotic cells, is the major component of the 
cytoskeleton and has a role in a variety of cellular events including: determination of 
cell shape, cell division, motility and DNA transcription (Oda and Maeda, 2010). 
Actin in monomeric form is known as globular or G-actin, which can be assembled 
into a polymeric form known as filamentous or F-actin (Pollard, 2007). When an 
osteoclast comes into contact with bone, it forms a large circular ring of actin which 
becomes the sealing zone, enabling the secure attachment of the cell to the bone 
surface (Luxenburg et al., 2007, Vaananen et al., 2000). This actin ring surrounds the 
ruffled membrane and is responsible for the isolatin of the acidified extracellular 
compartment in which bone resorption occurs (Faccio et al., 2003a).  
 
Cytoskeletal reorganisation in the osteoclast can be triggered through outside-in 
integrin signalling, occurring when the extracellular region of the integrin complex 
comes into contact with Arg-Gly-Asp (RGD)-containing proteins in the bone matrix 
such as bone sialoprotein 1 and 2, vitronectin and fibronectin (Helfrich et al., 1992, 
Horton et al., 1995). The intracellular regions of integrin complexes often reside 
within podosomes, which are located within the actin ring (Faccio et al., 2003a). 
Podosomes were first described by Marchisio et al. and are dynamic dot-like 
structures composed of an F-actin core surrounded by the integrin and a ring of 
scaffolding proteins which can include vinculin, paxillin and talin (Marchisio et al., 
1984). Osteoclasts possess unique podosomal arrangeme ts and can reorganise their 
podosomes into superstructures. Binding of the extracellular portion of the integrin to 
a ligand causes the intracellular portion of the int grin complex to dissociate from the 
podosome and move to the lamellipodia, which is a cytoskeletal actin projection 
located on the mobile edge of the cell and is respon ible for mediating osteoclast 
motility (Small et al., 2002). The integrin then becomes localised in the ruffled 
membrane during bone resorption.  
 
It has been suggested that Rho family GTPases, which are regulators of intracellular 
actin dynamics, may also mediate integrin activation. Faccio et al. published 
evidence suggesting that the vav 3 guanine nucleotid  exchange factor (VAV3), 
which activates the RhoGTPases RHOA, RHOG and RAC1, is essential for 
stimulated osteoclast activation (Faccio et al., 2005). They found that mice deficient 
in Vav3 presented with increased bone mass and were protected from bone loss 
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mediated by systemic bone resorption stimuli such as treatment with PTH or 
RANKL (Faccio et al., 2005). Osteoclasts deficient in Vav3 demonstrated impaired 
actin cytoskeletal organisation, polarisation, spreading and resorptive capabilities 
resulting from impaired signalling downstream of the M-CSF receptor and αvβ3 
integrin (Faccio et al., 2005).  
 
1.7 The osteocyte 
1.7.1 Background and function of the osteocyte 
Osteocytes are terminally differentiated osteoblasts that reside within microscopic 
spaces in the bone matrix called lacunae. They form when an osteoblast becomes 
trapped in the mineralised matrix that it has produced; various estimates suggest that 
10 – 20 % of osteoblasts differentiate into osteocytes (Aubin and Turksen, 1996) and 
that osteocytes make up over 90 % of bone cells in the adult (Knothe Tate et al., 
2004). Osteocytes have much longer lifespans than active osteoblasts, are non-
proliferative and have a significantly lower bone forming activity than osteoblasts 
(Manolagas, 2000). A large number of changes occur to the cell during the 
osteoblast-osteocyte differentiation process including reduction in susceptibility to 
apoptosis, permanent cell cycle arrest and production of dendritic processes (Noble, 
2008).  
 
Osteocytes play an important role in the determinatio  and maintenance of bone 
structure (Bonewald, 2007, Heino et al., 2002, Knothe Tate et al., 2004). Despite 
being isolated from each other by the bone matrix, osteocytes are able to 
communicate with each other as well as bone-lining cells at the periosteal and 
endosteal surfaces of the bone through an elaborate network of linked dentritic 
processes that reside within canaliculi. It has been suggested that this network of 
processes can be reorganised (Bonewald, 2007) and hs the potential to stimulate 
bone resorption (Tatsumi et al., 2007, Zhao et al., 2002). Altered osteocyte numbers 
have been noted in many disease states, with an increase in osteocyte density 
observed in osteoporosis (Mullender et al., 1996), osteogenesis imperfecta 
(Sarathchandra et al., 1996) and 1,25(OH)2D3 deficiency (Malluche et al., 1980).  
 
Osteocytes are thought to play a role in bone remodelling in response to mechanical 
stimuli. Evidence has been published suggesting that osteocytes respond to 
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mechanical stimuli by increasing production of various molecules including: nitric 
oxide (Pitsillides et al., 1995), prostaglandin E2 (Ajubi et al., 1996, Cherian et al., 
2005), insulin-like growth factor 1 (Lean et al., 1995, Reijnders et al., 2007) and 
collagen type I (Sun et al., 1995). Some of these molecules have been reported to 
have a role in regulating osteoclastogenesis (MacIntyre et al., 1991, Mochizuki et al., 
1992, Take et al., 2005). While being the predominant cell type found in bone, it has 
been observed that the number of empty osteocyte lacunae increases with age (Frost, 
1960) and that fewer osteocyte lacunae are associated wi h a reduced ability to repair 
accumulated microdamage (Burr, 1993).  
 
Interestingly, the availability of oxygen may have a role in osteocyte differentiation. 
It is likely that oxygen supply to the osteocyte in vivo is relatively low, particularly 
considering that the cells do not directly receive blood flow and instead rely on the 
extracellular fluid contained within the lacuna-canalicular system as a sole provider 
of oxygen and nutrients (Knothe Tate, 2003). It hasbeen demonstrated that growing 
murine MC3T3-E1 osteoblast-like cells in hypoxic conditions (5 % O2) stimulates 
osteocytogenesis (Hirao et al., 2007). This is supported by the fact that expression of 
the protein hypoxia up-regulated 1 (HYOU1) is higher in osteocyte-like cells than in 
osteoblast-like cells (Guo et al., 2005). This protein has been detected in several 
different cell types subjected to oxygen deprivation (Kuwabara et al., 1996) and may 
play a role in the cytoprotective mechanisms necessary for survival in hypoxic 
conditions, having been shown to suppress apoptosis (Ozawa et al., 1999). 
 
1.7.2 Proteins thought to be involved in osteocyte function 
The osteocyte produces a variety of enzymes that are essential to the role of the cell 
in determining and maintaining bone structure (Klein-Nulend et al., 2003). The 
matrix metallopeptidases 14 and 2 (MMP14 and MMP2) and the dentin matrix acidic 
phosphoprotein 1 (DMP1) are produced by the osteocy and appear to have a role in 
modifying the extracellular matrix (Holmbeck et al., 2005, Inoue et al., 2006, 
Narayanan et al., 2003). These are discussed here, along with the matrix extracellular 
phosphoglycoprotein (MEPE) and klotho (KL), which are both thought to play an 
important role in the osteocyte (Igarashi et al., 2002, Suzuki et al., 2005) although 
their exact function in this cell type remains to be determined. Figure 1.9 presents an 
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overview of the potential interactions and relationships between the regulatory 
elements and signalling pathways discussed in this section. 
 
1.7.2.i Matrix metallopeptidases 14 and 2 (MMP14 and MMP2) 
Many genes have been suggested to have a role in osteocyte function, including 
several encoding matrix metallopeptidases. Holmbeck t al. published evidence 
suggesting that deficiency of MMP14 leads to disruption of collagen cleavage in 
osteocytes, resulting in a loss of formation of oste cyte processes with no effects on 
osteocyte number or viability (Holmbeck et al., 2005). The MMP14 protein has been 
shown to activate MMP2 (Sato et al., 1994) and can act as a collagenase. It appears 
that this collagen-cleaving activity is essential for osteocyte function and that a 
degree of bone matrix destruction is necessary for maintenance of the canalicular 
network. This theory is supported by the observation hat in the absence of live 
osteocytes the canalicular network gradually fills with mineralised matrix, a process 
known as micropetrosis (Frost, 1960). In addition t this, it has been demonstrated 
that osteocyte viability is reduced and canaliculae number decreased in animals 
containing a targeted mutation which results in theproduction of collagenase-
resistant type 1 collagen (Inoue et al., 2006, Zhao et al., 2000).  
 
Inoue et al. produced evidence to suggest that MMP2 also plays a crucial role in the 
formation and maintenance of the osteocytic canalicul r network, when they found 
that mice deficient in Mmp2 displayed opposing bone phenotypes with reduced BMD 
in the long bones and increased calvarial BMD (Inoue et al., 2006). These effects 
appeared to be caused by disruptions to the canalicular network with associated 
osteocyte death (Inoue et al., 2006). The authors suggested that the opposing bone 
phenotypes were a result of differences in the extent of canalicular network 
impairment in each bone type: the long bones presenting with reduced canaliculi and 
the calvariae presenting with a completely disrupted canalicular network (Inoue et 
al., 2006). In addition to this, Martignetti et al.identified mutations within the MMP2 
gene as responsible for an autosomal recessive disorder called nodulosis, arthropathy 
and osteolysis (NAO) syndrome (also known as Torg-Winchester syndrome) (MIM 
259600) (Martignetti et al., 2001), which is characterised by joint erosion, osteolysis, 
facial abnormalities and generalised osteoporosis (Al-Mayouf et al., 2000, Al-Otaibi 





Figure 1.9. Schematic diagram presenting an overview of potential interactions between signalling pathways in the osteocyte. Light 
mechanical loading tends to stimulate the osteocyte into promoting bone formation by osteoblasts and inhibiting bone resorption by osteoclasts. 
Heavy mechanical loading can lead to osteocyte apoptosis, which stimulates osteoclastic bone resorption and thus the bone remodelling cycle. 
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1.7.2.ii Dentin matrix acidic phosphoprotein 1 (DMP1) 
Another protein thought to have a role in osteocyte function is DMP1. Toyosawa et 
al. identified the DMP1 protein as highly expressed in chicken and rat osteocytes and 
preosteocytes (Toyosawa et al., 2001). Gluhak-Heinrich et al. subsequently found 
that expression of Dmp1 is up-regulated in mouse osteocytes obtained from b ne that 
has been subjected to mechanical loading (Gluhak-Heinrich et al., 2003), suggesting 
that osteocytes modify their matrix microenvironment in response to mechanical 
stimuli. The Dmp1 protein has also been shown to be produced in undifferentiated 
mouse osteoblasts, where it functions as a nuclear protein involved in the expression 
of osteoblastic genes (Narayanan et al., 2003). However, as the cell matures and 
reaches the later stages of osteoblast differentiation, he murine Dmp1 protein is 
phosphorylated after production and exported to the extracellular matrix where it 
regulates the nucleation of hydroxyapetite (Narayann et al., 2003). Lorenz-
Depiereux et al. and Feng et al. identified loss-of-function mutations within the 
DMP1 gene in five families demonstrating autosomal recessiv  hypophosphatemic 
rickets (MIM 241520) (Feng et al., 2006, Lorenz-Depiereux et al., 2006). Feng et al. 
also found that Dmp1-null mice presented with defective osteocyte maturation, 
which resulted in pathological changes in bone mineralisation and the development 
of osteomalacia (softening of the bones) (Feng et al., 2006). The authors concluded 
that lack of functional DMP1 leads to altered skeletal mineralisation and disturbed 
phosphate homeostasis as a result of defective osteocyte function (Feng et al., 2006).  
 
1.7.2.iii Matrix extracellular phosphoglycoprotein (MEPE) 
There is evidence to suggest that the glycoprotein MEPE may also have a role in the 
osteocyte, although its exact function is yet to be determined. Igarashi et al. found 
that the Mepe gene is first expressed in mice at day 17 of embryogenesis in a small 
number of mature osteoblasts (Igarashi et al., 2002). Expression of the gene was 
subsequently seen in osteocytes during ossification of the skeleton and production of 
the protein seemed to correlate with increased cell differentiation to osteocytes 
(Igarashi et al., 2002). The authors concluded thatMepe represents an important 
marker of the osteocyte phenotype in mice and probably has a role in regulating 
osteocyte function (Igarashi et al., 2002). Gowen et al. studied mice deficient in 
Mepe and observed a phenotype characterised by increased bone mass, suggesting 
that the protein plays an inhibitory role in bone formation (Gowen et al., 2003). 
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Particularly high expression of the MEPE gene was subsequently found in osteocytes 
residing within mineralised bone (Nampei et al., 2004). Gluhak-Heinrich et al. found 
that the expression of Mepe in mice was stimulated by mechanical loading in a 
delayed manner (Gluhak-Heinrich et al., 2007).  
 
1.7.2.iv Klotho (KL) 
The KL gene encodes a type-I membrane protein related to beta-glucosidases and has 
been of much interest to the scientific and medical community over the last few years 
due to its suspected role in a variety of age-related diseases in mice (Kuro-o et al., 
1997, Suga et al., 2000, Utsugi et al., 2000). Kuro-o et al. generated transgenic mice 
with an insertional mutation of the Kl gene (Kuro-o et al., 1997). Mice homozygous 
for this mutated gene presented with various age-related diseases such as 
arteriosclerosis, skin atrophy, ectopic calcification, emphysema and osteoporosis, as 
well as growth retardation, shortened lifespan and infertility (Kuro-o et al., 1997). 
Impairment of osteoblast and osteoclast differentiation resulting in low-turnover 
osteopenia was subsequently identified in Kl-deficient mice (Kawaguchi et al., 
1999). Suzuki et al. conducted a study of the histological and ultrastructural features 
of bone matrix obtained from Kl-deficient mice, observing an abundance of empty 
osteocytic lacunae as well as evidence of increased osteoblastic and osteocytic 
apoptosis (Suzuki et al., 2005). This suggests a possible role for Kl in the osteocyte 
as well as raising the possibility that the osteopor sis seen in Kl-deficient mice is 
partly due to effects in osteocytes. 
 
1.7.3 Regulatory effects of the osteocyte on osteoblasts and osteoclasts 
There is evidence to suggest that the osteocyte has a role in regulating osteoblast 
function. Multiple studies have demonstrated that os e cytes produce sclerostin 
(SOST) (van Bezooijen et al., 2005, Poole et al., 2005, Winkler et al., 2003), which 
is a Wnt signalling pathway antagonist and negative regulator of bone formation 
through inhibiting the production of bone by osteoblasts (Moester et al., 2010). As 
mentioned previously, various mutations within the SOST gene have been implicated 
in Sclerosteosis, an autosomal-recessive bone disease that is characterised by 
hyperactive osteoblasts (Balemans et al., 2001, Brunkow et al., 2001). This would 
suggest that osteocytes are capable of negatively regulating osteoblast function 
through the production of SOST. 
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In addition to its apparent influence on osteoblast function, there is a significant 
amount of evidence in the literature to suggest thalive osteocytes negatively 
regulate osteoclast function whereas osteocyte apoptosis stimulates osteoclastic bone 
resorption. Verborgt et al. found that osteocyte apoptosis induced by bone fatigue 
triggers osteoclastic bone resorption (Verborgt et al., 2000). Heino et al. 
subsequently demonstrated that osteocyte-like cellshave an active inhibitory role on 
osteoclastic bone resorption (Heino et al., 2002). This effect was particularly strong 
after treatment of the osteocytes with oestrogen and appeared to be mediated through 
production of transforming growth factor beta 3 (Heino et al., 2002). Noble et al. 
subsequently studied the effects on osteocyte viability of short periods of mechanical 
loading applied to the ulnae of rats, observing a decrease in osteocyte apoptosis with 
light loading and an eightfold increase in osteocyte apoptosis with heavy loading 
(Noble et al., 2003). The authors speculated that te lighter loading stimulated 
adaptive bone remodelling characterised by decreased o t ocyte apoptosis, decreased 
bone resorption and increased bone formation (Noble et al., 2003). However, the 
heavier loading caused micro-damage to the bone resulting in increased osteocyte 
apoptosis, which in turn stimulated osteoclastic bone resorption and thus the 
remodelling cycle in an effort to repair the damage (Noble et al., 2003). Tatsumi et 
al. published supporting evidence for this after observing large-scale bone resorption 
in a transgenic mouse model subjected to targeted osteocyte death (Tatsumi et al., 
2007). Ikeda  subsequently developed a transgenic mouse model in which osteocytes 
can be specifically ablated in vivo (Ikeda, 2008). This was found to trigger osteoclast 
invasion of cortical bone with subsequent osteoclasti  bone resorption (Ikeda, 2008).  
 
1.8 Major dietary and environmental influences on bone 
Maintenance of healthy bone requires a good supply of a number of nutrients from 
the diet. In addition to this, a number of environmental factors have an influence on 
bone health. Vitamin D (which can be obtained from both the diet and exposure to 
sunlight) and calcium and are perhaps the most well known dietary/environmentally 
acquired factors involved in bone maintenance, and deficiency of either can result in 
detrimental effects on BMD. Other factors such as body mass index (BMI), regular 
resistance/weight bearing exercise and the avoidance of various negative influences 
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on bone such as high alcohol intake and tobacco use also play a role in the regulation 
of BMD.  
 
1.8.1 Calcium 
Dietary calcium intake has a major influence on bone metabolism. Calcium is a 
major component of bone mass and without sufficient calcium intake it is not 
possible to build and maintain an adequate skeleton. In addition to its structural role, 
bone also serves as a calcium store for the body. If the calcium requirements of the 
body are not fulfilled through dietary absorption, it will be resorbed from the bone 
through the actions of PTH (Juppner et al., 1999) to the detriment of the structure and 
strength of the bone (Heaney, 2002). Therefore, sufficient calcium must be obtained 
from the diet to maintain bone strength. However, it is but one of a number of factors 
which can influence BMD and studies into dietary calcium supplementation have had 
mixed results. A meta-analysis of 19 studies into calcium supplementation in 
children found that it increased total body BMD, however the effects were small and 
were not observed at the spine or hip sites (Winzenberg et al., 2006). Studies into the 
effect of calcium supplementation on fracture rates have also had mixed results. A 
meta-analysis published by Reid et al. found that although total fracture numbers are 
diminished in women supplemented with calcium, the probability of sustaining a hip 
fracture is in fact increased (Reid et al., 2008). The authors hypothesised that this is 
due to reduced periosteal expansion in the women using calcium supplementation 
(Reid et al., 2008).  
 
It is plausible that the inconsistent results observed in these studies are merely due to 
the fact that calcium supplementation is only of benefit to individuals that have low 
calcium levels. Lambert et al. published the results of a study into calcium 
supplementation over an 18-month period in 96 adolescent girls from the UK that 
were judged to have low habitual calcium intake (Lambert et al., 2008). They 
observed a significant increase in BMD at all sites studied in girls supplemented with 
calcium. However, they also noted that the positive eff cts disappeared within two 
years of withdrawal of the supplement (Lambert et al., 2008). A recent study into 
calcium supplementation in pregnant Chinese women with habitual low calcium 
intake also found a dose-dependent relationship between calcium intake and BMD 
(Liu et al., 2010). BMD values at the whole body and spine were found to be 
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significantly higher in the calcium supplemented group relative to the control group, 
although these results should be treated with caution due to the small sample sizes 
used in the study (Liu et al., 2010). 
 
1.8.2 Vitamin D 
Vitamin D can be obtained from the diet through consumption of such foods as oily 
fish and eggs, however the main source for the body is obtained through its 
production in the skin stimulated by exposure to sunlight (Holick, 1999). Vitamin D3 
produced by the skin does not have significant biological activity and is first 
converted to 25-hydroxyvitamin D3 in the liver. The 25-hydroxyvitamin D3 is then 
transported to the kidney where it is converted to 1,25(OH)2D3, the biologically 
active form of vitamin D. This compound has a major r le in maintaining serum 
calcium levels by  increasing the efficiency of intestinal calcium absorption (Holick, 
1999). Elderly individuals tend to suffer from diminished calcium absorption from 
the intestine which, when coupled with decreased serum 1,25(OH)2D3 resulting from 
an age-related reduction in the ability of the skin to produce vitamin D3 when 
exposed to sunlight (Holick et al., 1989), results in high PTH levels leading to 
mobilisation of calcium from the bone in an effort to maintain plasma calcium levels 
(Duque and Troen, 2008). In addition to the effects on plasma calcium regulation, 
Duque et al. found that treatment with 1,25(OH)2D3 decreased osteoclast number 
while stimulating osteoblastogenesis and osteoblast activity resulting in enhanced 
formation of new bone in a mouse model of senile ost oporosis (Duque et al., 2005). 
It has also been reported that 1,25(OH)2D3 reduces bone marrow adipogenesis and 
stimulates osteogenic gene expression in the same mouse model (Duque et al., 
2004b) as well as reducing apoptosis in human osteoblasts (Duque et al., 2004a).  
 
A meta-analysis published by Bischoff-Ferrari et al. suggested that oral vitamin D 
supplementation between 700-800 IU per day reduces th  risk of hip and non-
vertebral fractures in ambulatory or institutionalised elderly persons (Bischoff-
Ferrari et al., 2005). However, the effect was not seen with a lower dose of 400 IU 
per day (Bischoff-Ferrari et al., 2005). Interestingly, it has also been observed that 
supplementation with 700-1000 IU per day vitamin D reduces the risk of falling 
among elderly individuals by 19 %, although doses lower than this may not have any 
effect (Bischoff-Ferrari et al., 2009). This reduced risk of falling could partially 
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explain the reduction in fracture rate seen by Bischoff-Ferrari et al. in individuals 
supplemented with vitamin D (Bischoff-Ferrari et al., 2005).  
 
Studies have suggested that supplementation with both calcium and vitamin D has a 
positive effect on bone health. Zhu et al. published the results of a 5-year randomised 
controlled trial into the effects of calcium alone and calcium with vitamin D 
supplementation in elderly ambulatory Australian women (Zhu et al., 2008). They 
found that hip BMD was preserved in both the calcium alone and calcium with 
vitamin D supplementation groups at year 1, however at the year 3 and year 5 time 
points hip BMD was preserved only in the calcium with vitamin D group (Zhu et al., 
2008). A recent meta-analysis of 29 randomised trials found that supplementation 
with either calcium alone or calcium and vitamin D in people aged 50 years or older 
can reduce fracture risk by 24 % and significantly reduce the rate of bone loss at the 
spine and hip, as long as the compliance rate is high (Tang et al., 2007). 
 
1.8.3 BMI and lean body mass 
There is a significant amount of evidence in the lit rature to suggest that BMI and 
lean body mass are involved in the regulation of BMD as well as being major factors 
in fracture risk. Heavier individuals subject their weight-bearing bones to greater 
loads than lighter individuals, which can result in the development of greater bone 
density through the action of osteocytes (Lozupone et al., 1996). In addition to this, 
increased fat mass can result in a greater production of oestrogens since adipose 
tissue serves as the site of conversion of androstenedione to the oestrogenic hormone, 
oestrone (Schindler et al., 1972). Since adipose tisue is the major source of 
oestrogen production in postmenopausal women (Cleland et al., 1985), it could 
explain why obese women do not lose bone as quickly as non-obese women after the 
menopause (Dawson-Hughes et al., 1987, Ribot et al., 1987, Ribot et al., 1994).  
 
Felson et al. published the results of a study to examine the effects of body weight 
and BMI on BMD in elderly males and females (Felson et al., 1993). They found that 
BMI accounted for a substantial proportion of the variance in BMD at all sites in 
women, but only at weight-bearing sites such as the femur and spine in men (Felson 
et al., 1993). An Australian study published in 1996 found that BMD was associated 
with lean mass independently of fat mass and height in 112 female twin pairs with a 
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mean age of 45 (Seeman et al., 1996). The authors observed a 5 – 10 % increment of 
BMD to be associated with a 10 – 20 % increment in lean mass (Seeman et al., 
1996). Joakimsen et al. published data from a study into height, weight and BMI in 
relation to non-vertebral fracture risk in middle-aged Norwegians (Joakimsen et al., 
1998). They observed an increased risk of low-energy f acture in persons with a 
lower BMI (Joakimsen et al., 1998). These findings were supported by data from De 
Laet et al., who conducted a meta-analysis incorporating almost 60,000 subjects 
examining BMI as a predictor of BMD and fracture risk (De Laet et al., 2005). They 
found that a low BMI is associated with a substantial increase in fracture risk, 
particularly with hip fracture, in both men and women that was largely dependent 
upon BMD (De Laet et al., 2005). However, BMI was still found to be a significant 
risk factor for hip fracture even after adjustment of fracture risk for BMD (De Laet et 
al., 2005). This could be due to the thickness of padding over the greater trochanter 
(Nilsson, 1970), nutritional deficiencies resulting in muscle weakness (Bischoff et 
al., 2003) or a greater risk of falling (Willig et al., 2003). A recent study by Morin et 
al. incorporating over 8,000 women aged 40 – 59 again found that low BMI 
predicted an increased fracture risk that was largey d pendent on BMD (Morin et 
al., 2009). 
 
1.8.4 Resistance exercise 
Regular resistance training has been shown to increase BMD. Hind et al. published a 
review of clinical trials examining the effects of exercise and bone mineral accrual in 
children and adolescents (Hind and Burrows, 2007). They found that exercise did 
appear to enhance bone mineral accrual in children, particularly those in early 
puberty, however it was unclear as to the optimal exercise program (Hind and 
Burrows, 2007). Winters-Stone et al. examined the response of bone to exercise at 
specific skeletal sites in premenopausal women (Winters-Stone and Snow, 2006). 
They observed a site-specific positive response of hip and spine BMD to lower and 
upper body exercise respectively (Winters-Stone and S ow, 2006). Martyn-St James 
et al. published the results of a meta-analysis into high-intensity resistance training 
and postmenopausal bone loss, finding a general trend towards an increase in BMD 
following resistance training which reached statistical significance at the lumbar 
spine site (Martyn-St James and Carroll, 2006). These findings were supported by a 
recent study in Brazilian postmenopausal women which found that strength training 
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over 24 weeks preserved BMD at the lumbar spine and femoral neck sites when 
compared to untrained controls (Bocalini et al., 2009). Maddalozzo et al. found that 
resistance training was more effective than hormone replacement therapy in 
attenuating bone loss at the spine in early postmenopausal women (Maddalozzo et 
al., 2007). 
 
1.8.5 Negative influences on bone 
Several negative lifestyle influences on bone healt have been identified. An 
Australian twin study published in 1995 found that lifetime tobacco use was 
independently associated with a reduced BMD at the lumbar spine, total hip and 
forearm sites in postmenopausal women (Flicker et al., 1995). A meta-analysis of the 
effects of cigarette smoking on BMD was published by Ward et al., who found that 
smokers had a significantly reduced BMD at all sites examined when compared to 
non-smokers (Ward and Klesges, 2001). These effects were particularly pronounced 
at the hip where smokers had on average one-third of an SD less bone mass than 
non-smokers (Ward and Klesges, 2001). A recent study in premenopausal Japanese 
women also found a negative effect of smoking on BMD at the lumbar spine 
(Tamaki et al., 2009). Similar results have been found in studies investigating 
smoking and fracture risk. A meta-analysis published by Kanis et al. looking at over 
59,000 men and women found that current smokers have a significantly higher risk 
of fracture than non-smokers (Kanis et al., 2005b). The highest increase in fracture 
risk was observed at the hip and persisted even aftr t king BMD into account (Kanis 
et al., 2005b). Taes et al. found that smoking from a young age in men has a negative 
effect on bone geometry, density and fracture rate (Taes et al., 2009). The authors 
speculated that this could be caused by interactions with the action of sex steroids 
(Taes et al., 2009). 
 
High alcohol intake has also been reported to have a n gative effect on bone health 
(Kanis et al., 2005, Lalor et al., 1986, Santori et al., 2008, Saville, 1965). Kanis et al. 
examined BMD and fracture risk relative to alcohol intake in a cohort comprised of 
almost 17,000 men and women (Kanis et al., 2005). They observed significant 
associations between alcohol intake and the risk of osteoporotic and hip fracture, 
although this was not caused by effects on BMD (Kanis et al., 2005). A recent study 
in male alcoholics found that the skeletal damage caused by alcohol abuse seems to 
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occur through negative effects on bone formation (Santori et al., 2008). It has also 
been found that various factors thought to negatively influence bone health, such as 
impaired vitamin D metabolism and malnutrition, are common among alcoholics 
(Pitts and Van Thiel, 1986, Stransky and Rysava, 2009). 
 
1.9 Heritability of BMD 
In addition to dietary and environmental influences on bone structure and fracture, 
there is a strong genetic effect on peak bone mass, bone loss and fracture rates 
(Flicker et al., 1995, Krall and Dawson-Hughes, 1993, Michaelsson et al., 2005, 
Pocock et al., 1987). Studies using both monozygotic and dizygotic twin pairs have 
proven very useful for examining the heritability of bone mass. Smith et al. analysed 
bone mass and width in 71 juvenile and 80 adult twin pairs, observing greater 
phenotype discordance between dizygotic twins when compared to monozygotic 
twins which increased with age (Smith et al., 1973). Supporting evidence for this was 
published by Pocock et al., who also observed greate  correlation between BMD in 
monozygotic twins than in dizygotic twins (Pocock et al., 1987). They found that the 
genetic effect seemed to be strongest at the spine and slightly weaker at the proximal 
femur and forearm (Pocock et al., 1987). Evans et al. conducted a case-control study 
using 24 patients that had suffered an osteoporotic fracture and 35 asymptomatic 
relatives (Evans et al., 1988). They concluded thatbone mass is lower in healthy 
young and middle-aged relatives of osteoporotic patients than in individuals with no 
family history of osteoporosis (Evans et al., 1988). 
 
Krall et al. analysed familial resemblance in BMD at 5 skeletal sites among 160 adult 
members of 40 families (Krall and Dawson-Hughes, 1993). After adjustment of the 
BMD data for age, height, weight and significant lifestyle or environmental factors, 
they concluded that 46 – 62 % of the variance in BMD is heritable (Krall and 
Dawson-Hughes, 1993). Flicker et al. ran a cross-sectional twin study aimed at 
determining the influence of lifestyle and genetic fa tors on BMD in elderly women 
(Flicker et al., 1995). In 69 female twin pairs aged 60 – 89 years examined it was 
found that 20 – 33 % of the variation in BMD was accounted for by age, lifestyle and 
body composition factors, with 75 % of the residual v riation in BMD at the non-
forearm sites accounted for by genetic factors (Flicker et al., 1995). Seeman et al. 
published the results of a study in 56 monozygotic and 56 dizygotic female twins 
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with a mean age of 45 and concluded that 60 – 80 % of the individual variance in 
femoral neck BMD can be attributed to genetic factors (Seeman et al., 1996). A later 
study published by Hunter et al. examined BMD and heel ultrasound variables in 360 
pairs of female monozygotic twins and 885 pairs of female dizygotic twins (Hunter 
et al., 2001). The authors found that their heritabil y estimates for BMD at most 
body sites was lower in the postmenopausal women, although they produced 
evidence to suggest that the same genes are involved either side of the menopause 
(Hunter et al., 2001). 
 
Michaëlsson et al. ran a large study in over 33,000 Swedish twins to examine the 
genetic contribution to fracture risk in the elderly (Michaelsson et al., 2005). They 
found that the genetic influence on fracture risk differed considerably depending on 
the type of fracture and age of the patient (Michaelsson et al., 2005). The proportion 
of age-adjusted fracture variance explained by genetic variation for the entire cohort 
was 0.16 for any fracture, 0.27 for osteoporotic fracture and 0.48 for hip fracture 
(Michaelsson et al., 2005). These figures increased slightly when looking specifically 
at the female subset of the cohort (Michaelsson et al., 2005). The proportion of age-
adjusted hip fracture variance explained by genetic variation was 0.68 for those 
individuals younger than 69 years of age, 0.47 for th se between 69 – 79 years of age 
and 0.03 for those older than 79 years of age (Michaelsson et al., 2005). The authors 
concluded that the genetic influence on fracture is greater in females than in males 
and decreases with advancing age (Michaelsson et al., 2005).  
 
A recent study by Zhai et al. looked at the heritability of bone loss in 712 
postmenopausal Caucasian women (Zhai et al., 2009). Monozygotic and dizygotic 
twin pairs were measured at baseline and followed-up for an average of 8 years (Zhai 
et al., 2009). After adjustment of the data for aget baseline and weight change at 
follow-up, the heritability estimates for bone loss at the femoral neck, lumbar spine 
and forearm were 0.47, 0.44 and 0.56 respectively (Zhai et al., 2009).  
 
1.10 Additional heritable factors that contribute to fracture risk 
It is important to keep in mind that BMD is not the only heritable phenotype that 
contributes to fracture risk (Albagha and Ralston, 2003). Studies have demonstrated 
that some of the heritable component of fracture risk is independent of BMD (Deng 
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et al., 2002, Kanis et al., 2007), which is supported by the identification of 
polymorphic variants that contribute to variation in BMD but have no impact on 
fracture risk (Andrew et al., 2005). Hip bone geometry phenotypes such as hip axis 
length, which are critical components of bone strength and have been shown to be 
under strong genetic control (Demissie et al., 2007, Shen et al., 2005, Xiong et al., 
2006a), have been demonstrated as important risk factors for hip fracture (Brownbill 
and Ilich, 2003). Differences in femoral neck geometry have in fact been suggested 
as partially responsible for the differences in therate of hip fracture between 
Caucasians and other ethnic groups (Cummings et al., 1994). Biochemical markers 
of bone turnover, including the bone formation marker undercarboxylated 
osteocalcin and the bone resorption markers urinary C-telopeptide cross-links of 
collagen type I and free urinary deoxypyridinoline, have also been shown to predict 
fracture risk independently of BMD (Garnero et al.,1996b, Szulc et al., 1993). In 
addition, a recent study has highlighted impaired balance as a heritable phenotype 
that contributes to fracture risk (Wagner et al., 2009). 
 
1.11 Efforts at identifying the genes involved in BMD regulation and fracture 
risk 
Identifying the specific genes that influence BMD and fracture risk has proven a 
daunting task. Bone mass is a polygenic trait in that it appears to be influenced by 
many different genes, each contributing a small amount to the heritable portion of the 
phenotype. To complicate things further, there is evidence to suggest that the genes 
that regulate BMD and influence fracture risk do so in an age-specific (Kammerer et 
al., 2003, Karasik et al., 2003) and gender-specific (Peacock et al., 2005, Ralston et 
al., 2005) manner. It has also been suggested that different genetic variants are 
responsible for osteoporosis susceptibility in different ethnic groups (Dvornyk et al., 
2003, Lei et al., 2006). These are all factors thatmust be taken into consideration 
when examining the genetics of osteoporosis. 
 
1.11.1 Candidate gene studies 
Early efforts to identify the genes that influence bone mass centred around candidate 
genes, which are selected for study based solely on the function of the gene product 
and its role in bone. Candidate gene studies have the advantage of higher statistical 
power and easier sample recruitment when compared to linkage and genome-wide 
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association studies (Xu et al., 2010). The gene encodi g the vitamin D receptor 
(VDR), which mediates the action of 1,25(OH)2D3 on cells, was the first candidate 
gene to be studied in relation to osteoporosis (Ralston, 2003). Four early publications 
reported significant associations between polymorphism in the VDR gene and BMD 
(Fleet et al., 1995, Krall et al., 1995, Morrison et al., 1994, Riggs et al., 1995), 
although subsequent publications produced conflicting results (Alahari et al., 1997, 
Garnero et al., 1996a, Gross et al., 1996, Houston e  al., 1996, Lim et al., 1995, 
Tokita et al., 1996, Tsai et al., 1996, Viitanen et al., 1996). More recent studies 
examining the relationship between variation in the VDR gene and BMD have been 
conducted using large cohorts. Macdonald et al. genotyped five common 
polymorphisms in the VDR gene in a population of 3,100 women from the UK but 
found no significant associations with bone mass, bone loss or fracture rates 
(Macdonald et al., 2006). Uitterlinden et al. subsequently analysed the same five 
VDR gene polymorphisms in a meta-analysis incorporating 26,242 participants from 
European background, of which 18,405 were women (Uitterlinden et al., 2006). No 
significant associations were observed between any of the five polymorphisms and 
BMD, although one of the polymorphisms was found to be marginally associated 
with risk of vertebral fracture (Uitterlinden et al., 2006).  
 
Another early candidate gene to be studied in relation to osteoporosis was the gene 
encoding the oestrogen receptor 1 (ESR1) (Ralston and Uitterlinden, 2010). An 
article published in late 1995 reported significant ssociations between a dinucleotide 
repeat polymorphism lying upstream of this gene andBMD as well as various 
markers of bone turnover (BGLAP, urinary pyridinoline and urinary 
deoxypyridinoline) in postmenopausal Japanese women (Sano et al., 1995). 
However, an obvious limitation of this study was the small size of the cohort – only 
144 women were used in the study and only 15 of these carried the allele of interest 
(Sano et al., 1995). A study published the following year by Kobayashi et al. 
produced supporting evidence for a role of the ESR1 gene in BMD regulation in 
postmenopausal Japanese women (Kobayashi et al., 1996), although subsequent 
studies in varying ethnic groups produced mixed results (Bagger et al., 2000, Deng et 
al., 1998, Han et al., 1999, Salmen et al., 2000). Ioannidis et al. conducted a meta-
analysis that examined the role of three common ESR1 polymorphisms in a 
population of 18,917 individuals from European background, of which 14,622 were 
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women (Ioannidis et al., 2004). They found that none of the polymorphisms 
examined were significantly associated with BMD parameters, although one of the 
polymorphisms was significantly associated with verteb al and overall fracture risk 
(Ioannidis et al., 2004). 
 
The gene encoding collagen type I alpha 1 (COL1A1) has been extensively studied as 
a candidate gene for BMD regulation. Grant et al. published data suggesting that a 
polymorphism located in the regulatory region of the COL1A1 gene is associated 
with bone mass and vertebral fracture risk in two populations of British women with 
a combined total of 299 individuals (Grant et al., 1996). This polymorphism was 
reported to lie within a recognition site for the transcription factor Sp1, suggesting 
that variation at this site could affect transcription of the gene (Grant et al., 1996). A 
small study in Swedish postmenopausal women published in 1998 cast doubt over 
these findings (Liden et al., 1998) and subsequent studies again produced conflicting 
results (Heegaard et al., 2000, Nakajima et al., 1999, Weichetova et al., 2000). 
Ralston et al. conducted a meta-analysis that examined the role of the Sp1 
transcription factor site polymorphism in BMD regulation in a population of 20,786 
individuals from European background, of which 14,675 were women (Ralston et al., 
2006). They found that the polymorphism was significantly associated with both 
femoral neck and lumbar spine BMD, in addition to a nominally significant 
association with incident vertebral fracture in females (Ralston et al., 2006).  
 
A large number of additional genes have been reportd as significantly associated 
with BMD in candidate gene studies. Some of the more commonly studied include 
those encoding: low density lipoprotein receptor-related protein 5 (LRP5) 
(Mizuguchi et al., 2004, van Meurs et al., 2008), transforming growth factor beta 1 
(TGFB1) (Yamada et al., 1998), bone morphogenic protein 2 (BMP2) (Xiong et al., 
2006b), sclerostin (SOST) (Uitterlinden et al., 2004), runt-related transcription factor 
2 (RUNX2) (Doecke et al., 2006, Vaughan et al., 2002), RANK (TNFSF11A) (Koh et 
al., 2007), RANKL (TNFSF11) (Hsu et al., 2006), osteoprotegerin (TNFRSF11B) 
(Arko et al., 2002, Zhao et al., 2005b) and interleukin 6 (IL6) (Moffett et al., 2004, 
Murray et al., 1997, Tsukamoto et al., 1999).  
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A recent study by Richards et al. analysed more than 36,000 common single 
nucleotide polymorphisms (SNPs) selected from the Int rnational HapMap Project 
(Phase 2 dataset) (Frazer et al., 2007) from the CEU population (Utah residents with 
Northern and Western European ancestry) in 150 genes pr viously proposed as 
candidates for osteoporosis predisposition (Richards et al., 2009). These SNPs were 
analysed in relation to BMD in over 19,000 European individuals and fracture risk in 
almost 6,000 people from the Netherlands (Richards et al., 2009). They found that 
SNPs from only 9 of the 150 gene loci were significantly associated with BMD at the 
femoral neck and lumbar spine (Richards et al., 2009). These 9 genes were: ESR1, 
LRP4 (encoding low density lipoprotein receptor-related protein 4), ITGA1 
(encoding alpha 1 integrin), LRP5, SOST, SPP1 (encoding secreted phosphoprotein 
1), TNFRSF11A, TNFRSF11B and TNFSF11 (Richards et al., 2009). 
 
1.11.2 Genome-wide linkage (GWL) studies 
GWL studies use genetic markers (often microsatellites) to identify chromosomal 
segments that are shared between family members carrying a trait of interest (Dawn 
Teare and Barrett, 2005). This information can be us d to identify regions of the 
genome potentially containing one or more genes influe cing a particular trait. 
Candidate genes can then be selected from the region for analysis. As opposed to 
candidate gene studies, GWL studies are robust with regards to population 
admixture/stratification (Xu et al., 2010) and can be used to study both monogenic 
gene disorders (parametric linkage) and complex gene disorders (non-parametric 
linkage). Evidence for linkage of a particular trait to a region of the genome is 
usually expressed as a logarithm of the odds (LOD) score. Despite the recent 
popularity of genome-wide association (GWA) studies (discussed below), 
information obtained from GWL studies remains important, as GWL studies are 
capable of capturing information from rare polymorphisms/haplotypes and copy 
number variations unlike many GWA studies that only genotype common, low-effect 
variants (Karasik et al., 2010). A large number of disease-associated genes have been 
identified through information provided by GWL studies. Some of these are thought 
to have a role in various polygenic diseases, including: Crohn's disease (Beckly et al., 
2008, Ogura et al., 2001), schizophrenia (Macintyre et al., 2010, Pimm et al., 2005), 
chronic obstructive pulmonary disease (Hersh et al., 2009), attention deficit 
hyperactivity disorder (Wigg et al., 2008) and asthma (Van Eerdewegh et al., 2002). 
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A number of GWL studies aimed at identifying quantitative trait loci (QTL) for 
BMD phenotypes have been performed. One of the first wa  published by Johnson et 
al. who identified the chromosomal locus 11q12-13 as linked to a very high spinal 
bone density phenotype in a single extended pedigree comprised of 22 individuals 
(Johnson et al., 1997). They observed a LOD score of 5.74 with a marker in 11q12-
13, a genomic region that had also been linked with osteoporosis-pseudoglioma 
syndrome (MIM 259770) (Gong et al., 1996). Subsequent g notyping of additional 
markers and a systematic search for mutations that segregated with the phenotype 
revealed that an amino acid change within the LRP5 gene, which is located within 
the 11q12-13 chromosomal region, was responsible for the high spinal bone density 
phenotype in this family (Little et al., 2002). 
 
Devoto et al. published the results of a GWL study aimed at identifying regions of 
the genome likely to contain genes predisposing to low BMD (Devoto et al., 1998). 
330 DNA markers spread across the autosomal genome were analysed in relation to 
spine and hip BMD in 149 members of 7 large pedigrees with recurrence of low 
BMD (Devoto et al., 1998). They found evidence of linkage to the following 
chromosomal regions: 1p36 for hip BMD (LOD score 3.51), 2p23-24 for spine BMD 
(LOD score 2.07) and 4qter for both hip and spine BMD (LOD scores > 2.5) (Devoto 
et al., 1998). Devoto et al. published a follow-up study confirming and extending the 
finding of linkage with 1p36 in an expanded sample of 42 families, observing 
linkage of the region with femoral neck BMD (LOD score 3.53) (Devoto et al., 
2001). 
 
Subsequent GWL studies have identified many different QTL for BMD phenotypes, 
some of which include: 1q21, 2p21, 3p14-p22, 5q33, 6p21, 10q21, 20p12, 20q13 and 
21q22 (Williams and Spector, 2007). Of these, the 3p14-p22 chromosomal region 
has proven to be one of the most replicated (see Table 1.1 for a summary). Duncan et 
al. published the first evidence suggesting linkage between 3p14-p22 and BMD 
(Duncan et al., 1999). They analysed 64 genetic markers around 23 candidate genes 
for BMD regulation in a cohort of 614 individuals from 115 families (Duncan et al., 
1999). These markers were analysed in relation to lumbar spine and femoral neck 
BMD (Duncan et al., 1999). They observed the strongest evidence of linkage with 
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Table 1.1. Summary of linkage findings between the 3p14-p22 chromosomal region and BMD. 
Study Population Phenotype Markers LOD score 
Duncan et al. (1999) 258 males and 356 females from115 families Lumbar spine BMD D3S3559 1.3 – 1.6 
  Femoral neck BMD D3S3559, D3S1289 2.7 – 3.5 
Wilson et al. (2003) 2,775 females from 1,348 families Lumbar spine BMD D3S1298 to D3S1285 2.1 – 2.7 
Wynne et al. (2003) 26 males and 402 females from 175 families Lumbar spine BMD D3S3559, D3S1289 1.1 – 1.6 
Xiao et al. (2006) 1816 males and 2682 females from451 families Total hip BMD D3S2384 / D3S2409 2.3 
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two markers in the 3p14-p22 genomic region, which were linked with both lumbar 
spine (LOD scores 1.3 – 1.6) and femoral neck BMD (LOD scores 2.7 – 3.5) 
(Duncan et al., 1999). 
 
Wilson et al. compared the results between two independent GWL screens: one in 
unselected female dizygotic twin pairs aged 18 – 80 years (1,094 pedigrees) and one 
in extremely discordant or concordant (EDAC) sibling pairs aged 25 – 83 years (254 
pedigrees) (Wilson et al., 2003). Lumbar spine and total hip BMD were analysed in 
both cohorts and whole-body BMD was analysed in the unselected twin pairs 
(Wilson et al., 2003). Maximum evidence of linkage for both the unselected twins 
and EDAC siblings was observed for lumbar spine BMD at 3p14-p22 (LOD scores 
of 2.7 and 2.1 respectively) (Figure 1.10) (Wilson et al., 2003). Evidence of linkage 
in the unselected twin cohort was also observed with hole-body BMD at 1p36 
(LOD score 2.4) (Wilson et al., 2003). 
 
Two later studies and a meta-analysis also found likage between the 3p14-p22 
region of the human genome and BMD phenotypes. Wynne et al. analysed 24 genetic 
markers across 7 chromosomal loci in 175 Irish families containing probands with 
low BMD (Wynne et al., 2003). They found that 2 markers within the 3p14-p22 
genomic region were linked with lumbar spine BMD (LOD scores > 1.0) (Wynne et 
al., 2003). These are the same two markers from this genomic region identified by 
Duncan et al. as linked with BMD (Duncan et al., 1999). Xiao et al. genotyped 4,126 
European individuals from 451 families for a large-scale GWL scan (Xiao et al., 
2006). They observed linkage between the 3p14-p22 chromosomal region and total 
hip BMD (LOD score 2.29) (Xiao et al., 2006). A meta-analysis of 11 GWL scans 
performed by Lee et al. provided convincing support f r linkage between this region 
and BMD (Lee et al., 2006). The study incorporated 12,685 individuals from 3,097 
families and divided the autosomal genome into 120 bins that were ranked according 
to maximum evidence for linkage within each bin (Lee et al., 2006). The 3p14-p22 
chromosomal region was part of one of 7 bins that were found to lie above the 95 % 
confidence level (Lee et al., 2006).  
 
Mouse genetic studies can provide data relevant to human disease gene studies since 




Figure 1.10. Genome-wide linkage scans for quantitative trait loci that regulate lumbar spine BMD in: A) 1,094 twin pairs, and B) 254 
EDAC sibling pairs. Note the strong linkage peaks on chromosome 3 in each population. Figure adapted from Wilson et al. (Wilson et al., 
2003).
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human genome and these can provide supporting evidence for the importance of a 
region. Mouse models help to eliminate many of the complicating environmental 
influences on a trait so that a more refined QTL can be identified. The region 3p14-
p22 in the human genome shares homology with mouse chromosome 14 
(approximately 2 – 10 cM). Klein et al. performed a GWL study for whole-body 
BMD in two genetically distinct strains of laboratory mice that were raised under 
strict environmental control (Klein et al., 1998). They observed a strong genetic 
influence on the trait, indicating an estimated heritability of 0.35 – 0.6 and observed 
linkage of the phenotype with 10 chromosomal sites (Klein et al., 1998). One of 
these sites was on mouse chromosome 14 (approximately 2 – 10 cM) (Klein et al., 
1998), a region that is syntenic with the human chromosomal region 3p14-p22. 
 
Collectively, the literature reviewed here provides compelling evidence for linkage 
between the 3p14-p22 chromosomal region and BMD. This linkage has been 
observed in multiple studies in both humans and in syntenic chromosomal regions of 
the mouse genome. Previous studies have attempted to identify the genes within the 
3p14-p22 region that are responsible for the linkage observed. The PTH1R gene, 
which is located within this chromosomal region and encodes the parathyroid 
hormone 1 receptor, represents an attractive candidte. However, previous studies on 
the gene have reported mixed results (Lei et al., 2005, Scillitani et al., 2006, Tenne et 
al., 2008, Vilarino-Guell et al., 2007, Zhang et al., 2006), suggesting that the main 
gene or genes responsible for the linkage between the 3p14-p22 chromosomal region 
and BMD remain to be identified. 
 
1.11.3 Genome-wide association (GWA) studies 
GWA studies utilise a non-hypothesis-driven approach whereby a large number of 
study subjects are genotyped for dense genetic markers (usually in the form of SNPs) 
covering the genome in an unbiased fashion. These markers are often selected for 
their tagging properties, allowing for capture of maximal genetic variation with a 
minimal marker set which results in cost benefits (Magi et al., 2007). GWA studies 
are well-suited to identifying novel genes with modest influences on complex 
diseases/traits (Hirschhorn and Daly, 2005). However, there are many issues that 
must be carefully considered when interpreting the results from GWA studies, 
including: use of appropriate sample sizes, correction for multiple testing (which is 
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of course very stringent in GWA studies due to the large number of genetic markers 
analysed), use of appropriate marker density, potential population stratification and 
adequate replication of findings (Xu et al., 2010). GWA studies have identified genes 
thought to have a role in a variety of diseases/traits, including: height (Estrada et al., 
2009, Tonjes et al., 2009), hair/skin colour (Han et al., 2008), postmenopausal breast 
cancer (Hunter et al., 2007), prostate cancer (Eeles et al., 2008, Thomas et al., 2008), 
psoriasis (Zhang et al., 2009) and Parkinson’s disease (Satake et al., 2009, Simon-
Sanchez et al., 2009). 
 
The results from the first GWA study aimed at identifying genes associated with 
bone mass phenotypes was published in 2007 (Kiel et al., 2007). The authors 
genotyped more than 70,000 autosomal SNPs in 1,141 individuals (495 men and 646 
women with a total mean age of 62.5 years) for associati n with ten primary 
quantitative traits including various measures of BMD (femoral neck, trochanter and 
lumber spine BMD), calcaneal ultrasound, and geometric indices of the hip (Kiel et 
al., 2007). They found that out of the top 40 SNPs with the greatest number of 
significantly associated BMD traits, one half to two-thirds were in or near genes that 
had not been previously implicated in osteoporosis (Kiel et al., 2007). Using the 
additive generalised estimating equation (GEE) and the family-based association test 
(FBAT) models, the authors identified 12 and 2 associations respectively with the ten 
primary phenotypes using a cut-off of P < 1.0 x 10-6 (Kiel et al., 2007). The 
polymorphisms responsible for these associations were located in the genes 
encoding: ELKS/RAB6-interacting/CAST family member 2 (ERC2), zinc finger 
protein 366 (ZNF366), neuregulin 1 (NRG1) and nuclear receptor subfamily 5, group 
A, member 2 (NR5A2) (Kiel et al., 2007). 
 
Following the initial study published by Kiel et al., there was a flurry of publications 
reporting the results from GWA studies investigating the genetics of bone mass 
regulation. Strykarsdottir et al. genotyped over 300,0 0 SNPs and tested these for 
association with hip and lumbar spine BMD in a discovery population comprised of 
5,861 Icelandic men and women, subsequently genotyping a subset of 74 SNPs in 3 
replication cohorts comprised of 4,165, 2,269 and 1,49  individuals from Iceland, 
Denmark and Australia respectively (Styrkarsdottir et al., 2008). The authors 
identified and replicated significant associations between variation in 5 genomic 
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regions and BMD (Styrkarsdottir et al., 2008). The variants within these 5 regions 
lay within or around the genes: TNFSF11, TNFRSF11B, ESR1, ZBTB40 (encoding 
zinc finger and BTB domain containing 40) and the major histocompatibility 
complex region (6p21) (Styrkarsdottir et al., 2008). Collectively, these variants were 
found to account for approximately 3 % of the total v riation in hip and spine BMD 
(calculated from the replication cohorts) (Styrkarsdottir et al., 2008). The loci at the 
genes TNFRSF11B, ZBTB40 and the major histocompatibility complex region were 
also significantly associated with osteoporotic fracture (Styrkarsdottir et al., 2008). 
By enlarging the discovery and replication cohorts to 6,865 and 8,510 (total) 
individuals respectively, four additional loci signficant at the genome-wide level 
were identified near the genes SOST, MARK3 (encoding MAP/microtubule affinity-
regulating kinase 3), SP7 (encoding osterix) and TNFRSF11A (Styrkarsdottir et al., 
2009).  
 
Richards et al. analysed over 300,000 SNPs for association with lumbar spine and 
femoral neck BMD in a population of 2,094 women from the UK (mean age of 49.7 
years), with replication of significant findings attempted in 6,463 individuals from 3 
other cohorts in Western Europe (Richards et al., 2008). Associations with BMD 
significant at a genome-wide level (P < 5 x 10-8) were identified for two SNPs 
located near to the TNFRSF11B and LRP5 genes (Richards et al., 2008). 
Polymorphism at the SNP near TNFRSF11B was also found to be associated with an 
increased risk of osteoporosis and expression levels of the TNFRSF11B gene in 
lymphoblast cell lines (Richards et al., 2008). Polymorphism at the SNP in LRP5 
causes a non-synonymous coding change (Ala > Val) and this SNP was also found to 
be significantly associated with osteoporotic fracture at the lumbar spine and femoral 
neck sites (Richards et al., 2008). Collectively, the variance in BMD accounted for 
by polymorphism at these two SNP sites was 1 % at the lumbar spine and 0.6 % at 
the femoral neck (Richards et al., 2008). The presence of both risk alleles at these 
two SNPs was found to increase the risk of osteoporotic fracture independently of 
BMD (Richards et al., 2008).  
 
Xiong et al. genotyped over 370,000 SNPs to test for association with BMD at the 
spine and hip in a discovery cohort of 1,000 unrelated Caucasian men and women 
(Xiong et al., 2009). This GWA study was somewhat uniq e as the authors decided 
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to attempt replication of the most significant findi gs in four populations of varying 
ethnic background, including: a cohort comprised of 593 Caucasian families (n = 
1,972), a Chinese hip fracture population (n = 700), a Chinese BMD population (n = 
2,955) and a population from Tobago of African ancestry (n = 908) (Xiong et al., 
2009). In the discovery cohort the authors identified significant associations between 
BMD and polymorphism in two genes, ADAMTS18 (encoding ADAM 
metallopeptidase with thrombospondin type 1 motif, 18) and TGFBR3 (encoding 
transforming growth factor, beta receptor III) (Xiong et al., 2009). These associations 
were subsequently replicated and polymorphism in ADAMTS18 was found to be 
associated with hip fracture in the Chinese sample (Xiong et al., 2009). The results 
from this study indicate a role for the ADAMTS18 and TGFBR3 genes in BMD 
regulation in multiple ethnic groups (Xiong et al., 2009). 
 
Yang et al. performed a slightly different GWA study that involved genome-wide 
copy-number variation (CNV) analysis in 700 elderly Chinese individuals, 350 of 
whom had suffered from osteoporotic hip fracture (man age of 69.4 years) and 350 
of whom were controls (mean age of 69.5 years) (Yang et al., 2008). A genomic map 
was completed containing 727 CNV regions in Chinese individuals and association 
with osteoporotic fracture was identified for a deletion variant of the UGT2B17 gene 
(encoding UDP glucuronosyltransferase 2 family, poly eptide B17) on 4q13.2, the 
product of which is an enzyme that catabolises steroid hormones (Yang et al., 2008). 
This association was subsequently replicated in an independent Chinese cohort 
comprised of 399 individuals that had suffered from hip osteoporotic fracture and 
400 negative controls (Yang et al., 2008). Associations were also identified with hip 
BMD and femoral-neck bone geometry in additional Chinese (n = 689) and 
Caucasian populations (n = 1000), with the UGT2B17 CNV accounting for 1.4 % 
and 0.7 % of the variation in BMD in each of these populations respectively (Yang et 
al., 2008). Deletion of the UGT2B17 gene was also found to be associated with 
higher serum testosterone and oestrogen in a population of 236 young Chinese males 
(Yang et al., 2008). 
 
Meta-analysis of GWA data can greatly enlarge study populations and improves the 
power of the study to detect associations. Rivadeneira et al. conducted a large-scale 
collaborative meta-analysis of five GWA studies incorporating 19,195 subjects of 
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Northern European background (age range of 18 – 96 years) for loci associated with 
femoral neck and lumbar spine BMD (Rivadeneira et al., 2009). They identified 20 
loci that achieved genome-wide significance (P < 5 x 10-8), of which 13 were located 
in genomic regions not previously associated with BMD (Table 1.2) (Rivadeneira et 
al., 2009). The remaining 7 were located in genomic regions that have previously 
been identified as significantly associated with BMD and included the regions 
containing the genes LRP5, TNFSF11, TNFRSF11A and TNFRSF11B (Rivadeneira 
et al., 2009). 15 of the 20 loci were significantly associated with lumbar spine BMD 
and 10 were significantly associated with femoral neck BMD (Table 1.2) 
(Rivadeneira et al., 2009). A highly significant linear decrease in the mean lumbar 
spine and femoral neck BMD was seen with increasing number of low BMD risk 
alleles (Rivadeneira et al., 2009). A risk allele analysis was then conducted using the 
top associated SNPs from the 15 lumbar spine and 10 femoral neck BMD loci 
(Rivadeneira et al., 2009). They found that when combined, the 15 lumbar spine 
SNPs accounted for around 2.9 % of the variance in lumbar spine BMD and the 10 
femoral neck SNPs accounted for around 1.9 % of the variance in femoral neck 
BMD (Rivadeneira et al., 2009).  
 
One of the 20 loci identified by Rivadeneira et al. as significantly associated with 
BMD at genome-wide significance is located within the 3p22 chromosomal region 
(Table 1.2) (Rivadeneira et al., 2009). The polymorphism within this region that 
showed maximal association with BMD is situated approximately 103 Kb upstream 
of the nearest gene, CTNNB1, which encodes beta-catenin (Rivadeneira et al., 2009). 
As discussed earlier, beta-catenin is an integral component of the Wnt signalling 
pathway (Wagner et al., 2010) and thus presents as an excellent candidate for 
regulation of BMD. The CTNNB1 gene is located within the support intervals 
defined for the 3p14-p22 chromosomal region by Wilson et al. as linked with BMD 
by GWL (Wilson et al., 2003). It is therefore possible that this gene is responsible for 
the linkage observed between this chromosomal region and BMD. However, the 
CTNNB1 gene is located approximately 10 Mb from the centre of this linkage region, 
which would suggest that one or more additional genes located within this region 
also contribute to the linkage observed between 3p14-p22 and BMD. 
61 
 
Table 1.2. Twenty loci identified by Rivadeneira et al. as significantly associated with femoral neck and/or lumbar spine BMD in 19,195 
subjects of Northern European background. 
Locus Site Candidate genes in region Gene product 
1p31.3 FN and LS WLS Wntless homolog 
1p36 FN and LS ZBTB40 Zinc finger and BTB domain containing 40 
2p21 LS SPTBN1 Spectrin, beta, non-erythrocytic 1 
3p22 FN CTNNB1 Catenin (cadherin-associated protein), beta 1, 88 kD 
4q21.1 LS MEPE Matrix extracellular phosphoglycoprotein 
5q14 FN MEF2C Myocyte enhancer factor 2C 
6q25 FN and LS ESR1 Oestrogen receptor 1 
7p14 LS STARD3NL STARD3 N-terminal like 
7q21.3 FN and LS FLJ42280 Hypothetical LOC401388 
8q24 FN and LS TNFRSF11B Osteoprotegerin 
11p11.2 FN ARHGAP1 Rho GTPase activating protein 1 
  LRP4 Low density lipoprotein receptor-related protein 4 
11p14.1 LS DCDC5 Doublecortin domain containing 5 
  DCDC1 Doublecortin domain containing 1 
11p15 FN SOX6 SRY (sex determining region Y)-box 6 
11q13.4 LS LRP5 Low density lipoprotein receptor-related protein 5 
12q13 LS SP7 Osterix 
13q14 LS TNFSF11 Tumour necrosis factor (ligand) superfamily, member 11 (RANKL) 
16q24 LS FOXC2 Forkhead box C2 (MFH-1, mesenchyme forkhead 1) 
  FOXL1 Forkhead box L1 
17q12 LS CRHR1 Corticotropin releasing hormone receptor 1 
17q21 FN HDAC5 Histone deacetylase 5 
  C17orf53 Chromosome 17 open reading frame 53 
18q21 LS TNFRSF11A Tumour necrosis factor receptor superfamily, member 11a, NFKB activator (RANK) 
62 
The results from these GWA studies have helped to highlight the importance of the 
Wnt signalling and RANK-RANKL-OPG pathways in the gnetic regulation of bone 
mass as well as the complex architecture that underlies variation in BMD. They have 
also proved useful for identifying genes that may hve a role in BMD regulation that 
do not stand out as strong candidate genes, such as ZBTB40. However, the genetic 
variants identified as significantly associated with BMD in these studies account for 
only a small amount of the variance of each phenotype. This would suggest that there 
are still a large number of BMD-influencing genes in the human genome that are yet 
to be identified, a notion supported by the fact that genes strongly associated with 
BMD are yet to be identified for many of the chromosomal regions that have been 
linked with BMD in GWL studies. 
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1.12 Aims and unifying hypothesis of this thesis 
1.12.1 Aims 
The broad aims of this thesis are to identify the gene or genes located within the 
3p14-p22 chromosomal region that are responsible for the linkage observed between 
the region and BMD, and further, to explore the role f these genes in bone 
metabolism. The thesis incorporates a series of genetic and functional studies, a 
number of which are follow-up studies to findings generated during the course of the 
work. 
 
The specific aims are: 
 
1)  Determine whether common polymorphism within a candidate gene from the 
3p14-p22 chromosomal region, ARHGEF3, is associated with bone density in 
Caucasian women. 
 
2)  Determine whether common polymorphism within a second candidate gene from 
the 3p14-p22 chromosomal region, RHOA, is associated with bone density in 
Caucasian women.  
 
3) Analyse variation at five polymorphic sites located in the FLNB gene (also 
situated in the 3p14-p22 chromosomal region), which have been identified as 
significantly associated with FLNB mRNA expression, for associated with bone 
density phenotypes in Caucasian women.  
 
4)  Analyse expression of the NM_001128616 transcript variant of ARHGEF3 in 
human osteoblast-like and osteoclast-like cells. 
 
5) Identify genes, from a list of candidates, whose expression is influenced by 
ARHGEF3 and RHOA gene knockdown in human osteoblast-like and osteoclast-
like cells. 
 
7)  Determine whether knockdown of the ARHGEF3 and RHOA genes influences 
the bone-resorptive capabilities of osteoclast-like cells. 
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1.12.2 Unifying hypothesis of this thesis 
One or more genes in the human genomic region 3p14-p22 are significantly 
associated with bone mineral density in Caucasian women. 
 
Specific hypotheses are contained within each chapter. 
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Chapter 2 – Materials and methods 
2.1 Materials 
2.1.1 Whole-genome amplification 
Item Supplier 
REPLI-g Midi Kit 
 - Buffer D1 
 - Buffer N1 
 - 4X REPLI-g Buffer 
 - REPLI-g DNA Polymerase 
QIAGEN, USA 
96-Well PCR Microplate Axygen, USA 
8-Cap Strips Axygen, USA 
 
2.1.2 PicoGreen DNA quantitation 
Item Supplier 
Quant-iT PicoGreen dsDNA Assay Kit 
 - Quant-iT PicoGreen dsDNA Reagent 
 - Lambda DNA Standard (100 µg/mL) 
Invitrogen, USA 
96-Well OptiPlate PerkinElmer, USA 
 
2.1.3 SNP genotyping by single nucleotide extension using matrix-assisted laser 
desorption/ionisation time-of-flight (MALDI-ToF) mass spectrometry 
Item Supplier 
Multiplex PCR Kit 
 - 2X Multiplex PCR Master Mix 
QIAGEN, USA 
Shrimp Alkaline Phosphatase (1 unit/µL) USB Corporati n, USA 
Shrimp Alkaline Phosphatase Dilution 
Buffer 
USB Corporation, USA 
Dideoxynucleotide Triphosphate 
(ddNTP) Set 5 mM 
Amersham Biosciences, USA 
Oligonucleotide primers 100 µM Sigma-Aldrich, USA 
Thermo Sequenase (32 units/µL) Amersham Biosciences, USA 
Thermo Sequenase Dilution Buffer Amersham Biosciences, USA 
384-Well Hard-Shell PCR Plate MJ Research, USA 
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Microseal ‘A’ Film Bio-Rad, USA 
AG 501-X8(D) 20-50 Mesh Ionic 
Exchange Resin 
Bio-Rad, USA 
3-Hydroxypicolinic Acid (≥ 99 %) Fluka, Switzerland 
Acetonitrile EM Science, USA 
Ammonium Citrate Sigma-Aldrich, USA 
 
2.1.4 Agarose gel electrophoresis 
Item Supplier 
DNA Grade Agarose Progen Biosciences, Australia 
DirectLoad Wide Range DNA Marker Sigma-Aldrich, USA 
Ethidium Bromide Sigma-Aldrich, USA 
1Kb DNA Ladder Promega, USA 
 
2.1.5 TaqMan SNP genotyping 
Item Supplier 
10X PCR Buffer II Applied Biosystems, USA 
25mM MgCl2 Applied Biosystems, USA 
dNTP set 100mM Promega, USA 
AmpliTaq Gold DNA Polymerase (5 
units/µL) 
Applied Biosystems, USA 
384-Well Hard-Shell PCR Plate (Black) Bio-Rad, USA 
Microseal ‘A’ Film Bio-Rad, USA 
TaqMan SNP Genotyping Assay Applied Biosystems, USA 
 
2.1.6 Isolation of peripheral blood mononuclear cells 
Item Supplier 
Vacutainer K2E 10 mL Becton, Dickinson and Company, USA 
Ficoll-Paque Pharmacia, Sweden 
 
2.1.7 RNA extraction 
Item Supplier 
RNeasy Mini Kit QIAGEN, USA 
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 - Buffer RLT 
 - Buffer RW1 
 - Buffer RPE 
 - RNeasy Spin Column 
 
2.1.8 Reverse transcription 
Item Supplier 
QuantiTect Reverse Transcription Kit 
 - gDNA Wipeout Buffer 
 - 5X QuantiScript Reverse Transcription 
Buffer 
 - Reverse Transcription Primers 
 - QuantiScript Reverse Transcriptase 
QIAGEN, USA 
96-Well PCR Microplate Axygen, USA 
8-Cap Strips Axygen, USA 
 
2.1.9 Real-time PCR 
Item Supplier 
QuantiFast SYBR Green PCR Kit 
 - 2X QuantiFast SYBR Green Master 
Mix 
QIAGEN, USA 
96-Well iCycler iQ PCR Plates Bio-Rad, USA 
Microseal ‘B’ Film Bio-Rad, USA 
QuantiTect Primer Assay QIAGEN, USA 
Oligonucleotide primers 100 µM Sigma-Aldrich, USA 
 
2.1.10 Cell culture 
Item Supplier 
Dulbecco’s Modified Eagle’s Medium 
(DMEM) 
Sigma-Aldrich, USA 
α-Modified Eagle’s Medium (α-MEM) Invitrogen, USA 




Foetal Bovine Serum (FBS) Sigma-Aldrich, USA 
Penicillin/Streptomycin 100X (10,000 
units penicillin and 10 mg 
streptomycin/mL) 
Sigma-Aldrich, USA 
Trypsin-EDTA Solution 1X (0.25 % 
trypsin, 0.1% EDTA) 
Sigma-Aldrich, USA 
Small interfering RNA (siRNA) QIAGEN, USA 
HiPerFect Transfection Reagent QIAGEN, USA 
Recombinant Human RANKL Invitrogen, USA 
Recombinant Human M-CSF Invitrogen, USA 
25 cm2 Tissue Culture Flasks DKSH, Switzerland 
75 cm2 Tissue Culture Flasks DKSH, Switzerland 
24-Well Tissue Culture Plates Greiner Bio-One, Germany 
96-Well Tissue Culture Plates Greiner Bio-One, Germany 
Bovine Bone Obtained from butcher  
Cell Dissociation Solution Non-Enzymatic 
1X 
Sigma-Aldrich, USA 
Sodium Bicarbonate (NaHCO3) Ajax Finechem, Australia 




TotalPrep RNA Amplification Kit Applied Biosystems, USA 
HumanHT-12 v3 Kit Illumina Inc., USA 
 
2.1.12 Statistical and other software packages 
Item Supplier 
PASW Statistics 17 SPSS Inc., USA 
Statistica v8.0 StatSoft Inc., USA 
BeadStudio v3.4.0 Illumina Inc., USA 
MetroPro v8.2.0 Zygo Corp., USA 





Ethanol Thermo Fisher Scientific, USA 
Gloves, Non-Sterile, Latex Ansell, USA 




Sodium Hydroxide (NaOH) APS Finechem, Australia 
Glacial Acetic Acid Biolab, New Zealand 
Bromophenol Blue Sigma-Aldrich, USA 
Xylene Cyanol Sigma-Aldrich, USA 
Glycerol Ajax Finechem, Australia 
Sodium Chloride (NaCl) Sigma-Aldrich, USA 
Potassium Chloride (KCl) Merck Pty Ltd., Australia 
Sodium Phosphate Dibasic (Na2HPO4) Sigma-Aldrich, USA 
Potassium Phosphate (KH2PO4) Sigma-Aldrich, USA 
Paraformaldehyde Merck Pty Ltd., Australia 
Sodium Acetate (C2H3NaO2) BDH Chemicals, Australia 
Sodium Tartrate Dihydrate (C4H8Na2O8) Ajax Finechem, Australia 
2-Ethoxyethanol (C4H10O2) Sigma-Aldrich, USA 
Fast Red Violet LB Salt Sigma-Aldrich, USA 
0.8 µm Filter Millipore, USA 






PTC-220 DNA Engine Dyad Peltier 
Thermal Cycler 
MJ Research, USA 
iQ5 Multicolor Real-Time PCR 
Detection System 
Bio-Rad, USA 
2100 Bioanalyzer Agilent Technologies, USA 
ND-1000 Spectrophotometer NanoDrop Technologies, USA
DNA Electrophoresis Cell Tank Bio-Rad, USA 
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CO2 Incubator – Hera Cell 150 Forma Scientific, USA 
MicroCL 21R Centrifuge Thermo Electron Corporation, USA 
Orbital 420 Centrifuge Clements Medical Equipment, Australia 
Vortex, ST19 Sentra, USA 
Victor2 Multilabel Plate Reader Wallac, USA 
PowerPack 3000 Bio-Rad, USA 
Voyager-DE PRO 6066 Mass 
Spectrometer 
Applied Biosystems, USA 
384-Well MALDI-ToF Array Applied Biosystems, USA 
Ultraviolet Transilluminator (UVT) 100 International Biotechnologies Inc., USA 
Pipettes – P1000, P200, P20, P2 Gilson Inc., USA 
Phase Contrast Microscope, IMT-2 Olympus, Japan 
pH and Temperature Meter, 900-P TPS Pty Ltd., Australia 
10 mL Transfer Pipette  Falcon, USA 
3.5 mL Transfer Pipette  Sarstedt, Germany 
Polaroid Camera, Model QSP International Biotechnologies Inc., USA 
Orbital 900 Centrifuge  Clements Medical Equipment, Australia 
Plate Rotator, IKA-VIBRAX-VXR Wiarton, Canada 
Light Microscope, CH-2 Olympus, Japan 
LaborLux II Light Microscope Leitz, Germany 
DXC-390P 3CCD Colour Video Camera Sony, Japan 
XL30 Scanning Electron Microscope Philips, Netherlands 
NewView 6300 3D Optical Profilometer Zygo Corp., USA 
 
2.2 General methods 
2.2.1 Whole-genome amplification 
Whole-genome amplification was performed as a way of increasing the quantity of 
template DNA available for SNP genotyping from a genomic DNA sample. This was 
carried out using the REPLI-g Kit (QIAGEN), which uses exonuclease-resistant 
primers to non-specifically amplify all DNA sequenc within a sample in a highly 
uniform manner (Hosono et al., 2003). Each genomic DNA sample was first diluted 
to a concentration of 20 ng/µL in 1X TE buffer (Tris-EDTA buffer, Appendix I). 2.5 
µL of each template DNA sample was then added to a 96-well PCR plate (Axygen). 
One well on each plate was used for a negative control and received 2.5 µL of 1X TE 
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buffer instead of template DNA and one well received a duplicate sample. Therefore, 
each 96-well PCR plate contained 94 different genomic DNA samples (1 of which 
was present in duplicate) and 1 negative control. 2.5 µL of Buffer D1 (denaturation 
buffer) was then added to each well on the plate and the samples were mixed 
thoroughly by vortexing before being left to stand at room temperature for 3 minutes. 
5 µL of Buffer N1 (neutralisation buffer) was subsequ ntly added to each sample. A 
master mix was then prepared by combining the following components while 
keeping the mixture chilled on ice: 
 
Component Volume per reaction 
4X REPLI-g Buffer (QIAGEN) 
(contains primers) 
12.5 µL 
Distilled-deionised water 27 µL 
REPLI-g DNA Polymerase (QIAGEN) 0.5 µL 
Total volume 40 µL 
 
Each sample was chilled using ice before 40 µL of this master mix was added to 
each. The microplate was then capped, mixed by vortexing and centrifuged before 
being incubated in a thermal cycler using the following temperature programme: 
 
Temperature Duration Cycles 
30 °C 8 h 1 
65 °C 3 min 1 
Lid temperature tracking at 1 °C above block temperature 
 
The mean quantity (± standard deviation) of whole-genome amplified DNA 
produced in each 50 µL reaction was 31 (± 10) µg, as assessed by PicoGreen 
quantitation (described below). An example of whole-genome amplified DNA 
electrophoresed on an agarose gel is shown in Figure 2.1. 
 
2.2.2 PicoGreen DNA quantitation 
Whole-genome amplified DNA samples were quantitated using the Quant-iT 
PicoGreen dsDNA Assay Kit (Invitrogen). PicoGreen is an ultrasensitive nucleic 
acid stain that fluoresces when bound to double-stranded DNA (dsDNA), making it 
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Figure 2.1. Seven whole-genome amplified DNA samples electrophoresed 
alongside a 1 Kb DNA ladder in a 1 % agarose gel. This image illustrates the large 
size of the amplified DNA fragments, the majority of which are over 1 Kb in length. 
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ideal for specific quantitation of dsDNA in the presence of other single-stranded 
nucleic acids (Ahn et al., 1996). Compared to other DNA quantitation techniques, the 
PicoGreen method is more sensitive than the Hoechst (bisbenzimide) dye (Singer et 
al., 1997) and is more specific for dsDNA than spectrophotometric absorbance at 260 
nm (Ahn et al., 1996).  
 
All quantitations were performed in a darkened room t  prevent photodegredation of 
the PicoGreen reagent. 1 µL of each whole-genome amplified DNA sample was first 
diluted in 9 µL of 1X TE buffer. 2 µL of this dilution was then added to a single well 
in a 96-well OptiPlate (PerkinElmer) containing 1 µL of Quant-iT PicoGreen dsDNA 
Reagent diluted in 194 µL 1X TE buffer. The contents of the well were then mixed 
by pipetting and the fluorescence measured using a Victor2 Multilabel Plate Reader 
(Wallac). Each 96-well plate analysed contained two blanks (1X TE buffer instead of 
whole-genome amplified DNA) and duplicate sets of 7 dsDNA standards at the 
following concentrations: 75 ng/µL, 50 ng/µL, 25 ng/µL, 12.5 ng/µL, 6.25 ng/µL, 
3.125 ng/µL, 1.5262 ng/µL. The fluorescence from each standard was then plotted 
against concentration to create a standard curve from which the concentration of each 
sample could be read in a linear model. All samples w re quantitated in duplicate 
with the mean of the two values obtained used for downstream work. 
 
2.2.3 SNP genotyping by single nucleotide extension using matrix-assisted laser 
desorption/ionisation time-of-flight (MALDI-ToF) mass spectrometry 
The MALDI-ToF mass spectrometry method of SNP genotyping involves two PCR 
steps followed by analysis of the reaction products on a MALDI-ToF mass 
spectrometer (Ross et al., 1998). The first of the two PCR steps uses a forward and 
reverse oligonucleotide primer pair to amplify the g nomic region containing the 
SNP site. The second PCR step is a single-base primer extension reaction. This is 
achieved using a sequence specific oligonucleotide sequencing primer that binds to 
the amplified template DNA sequence in such a way th t the 3’ end of the primer is 
bound to the base immediately adjacent to the SNP site. This primer is then extended 
by a single nucleotide, the identity of which is determined by the base present at the 
SNP site on the template sequence (Figure 2.2). Dideoxynucleoside triphosphates 
(ddNTPs) are used in this reaction instead of deoxynucleoside triphosphates (dNTPs) 
because they do not contain an OH group on their 3’ carbon atom. As a result, 
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Figure 2.2. Illustration of how the single nucleotide extension step works in the 
MALDI-ToF mass spectrometry SNP genotyping technique. Note: due to the use 
of dideoxynucleoside triphosphates the reaction will be terminated after the addition 
of the G nucleotide by the Thermo Sequenase enzyme. 
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ddNTPs cannot bind to additional incoming nucleotides and hence the sequencing 
primer is extended by a single base only. The products from the second PCR step are 
de-salted before being analysed on a MALDI-ToF mass spectrometer. By 
determining the mass of the sequencing primer plus single base extension molecule, 
the identity of the ddNTP that was attached to the sequencing primer and hence the 
identity of the SNP allele can be determined.  
 
The two PCR steps were performed in a 384-well PCR plate (MJ Research). 
Reactions were multiplexed so that multiple SNP regions were amplified in a single 
reaction. The Multiplex PCR Kit (QIAGEN) was used to perform the first PCR step 
with sequence specific oligonucleotide primers (refe  to section 2.1.16 for primer 
sequences). A mixture of the following components was made up at room 
temperature: 
 
Component Volume per reaction 
2X Multiplex PCR Master Mix (QIAGEN) 8.25 µL 
2 µM forward and reverse primer solution 1.65 µL 
Distilled-deionised water 5.6 µL 
Total volume 15.5 µL 
 
15.5 µL of this master mix was combined with 2.5 µL genomic DNA (20 ng/µL) in 
each well of the 384-well plate. The plate was then covered with Microseal ‘A’ Film 
(Bio-Rad) before being vortexed and centrifuged. The samples were then incubated 
in a thermal cycler using the following temperature p ogramme: 
 
Temperature Duration Cycles 
95 °C 15 min 1 
98 °C 15 s  
45 60 °C 1.5 min 
72 °C 1.5 min 
72 °C 10 min 1 
Lid temperature constant at 85 °C 
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Randomly selected samples from each 384-well PCR plate were subsequently 
electrophoresed on an agarose gel to confirm specific amplification of correct target 
sequences (example displayed in Figure 2.3). After th  first PCR step each reaction 
mix was dephosphorylated using shrimp alkaline phosatase (USB Corp.) to 
hydrolyse residual oligonucleotide primers and nucleotides. This involves 
preparation of a mixture at room temperature containing the following components: 
 
Component Volume per reaction 
Shrimp Alkaline Phosphatase Dilution 
Buffer (USB Corp.) 
2 µL 
Shrimp Alkaline Phosphatase (1 unit/µL) 
(USB Corp.) 
1 µL 
Total volume 3 µL 
 
3 µL of this mixture was added to each sample in the 384-well PCR plate. The plate 
was then covered with Microseal ‘A’ Film, vortexed and centrifuged. The samples 
were incubated in a thermal cycler using the following temperature programme: 
 
Temperature Duration Cycles 
37 °C 1 h 1 
80 °C 15 min 1 
Lid temperature constant at 100°C 
 
Subsequent to dephosphorylation, the samples were subj cted to a second PCR step 
involving a single-base primer extension reaction (refer to section 2.1.16 for primer 
sequences). A master mix for this step was prepared at room temperature containing: 
 
Component Volume per reaction 
ddNTP mix (1.25 mM of each ddNTP) 0.4 µL 
Sequencing primer (100 µM) 0.1 µL - 0.18 µL 
Thermo Sequenase Dilution Buffer 
(Amersham Biosciences, USA) 
0.28 µL 
Thermo Sequenase (Amersham 0.01 µL 
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Biosciences, USA) 
Distilled-deionised water Variable 
Total volume 4.5 µL 
 
4.5 µL of this master mix was added to each sample before the 384-well PCR plate 
was covered using Microseal ‘A’ Film, vortexed and centrifuged. The samples were 
then incubated in a thermal cycler using the following temperature programme: 
 
Temperature Duration Cycles 
94 °C 2 min 1 
98 °C 7 s  
50 37 °C (ramp to 37 °C at 1.2 °C/s) 30 s 
72 °C (ramp to 72 °C at 1.2 °C/s) 10 s 
16 °C 5 min 1 
Lid temperature constant at 100°C 
 
Following the second PCR step, each sample was de-salted to allow for analysis 
using the MALDI-ToF mass spectrometer. This was carried out by adding 10 mg of 
AG 501-X8(D) 20-50 Mesh Ionic Exchange Resin (Bio-Rad) to each sample and 
incubating for 15 min with rotation. A batch of fresh MALDI-ToF matrix was then 
prepared by combining 6 mg 3-hydroxypicolinic acid (Fluka), 12.5 µL ammonium 
citrate (50 mg/mL) and 100 µL acetonitrile. 1 µL of this matrix was added to each 
well of a 384-well MALDI-ToF sample analysis array nd left to dry before 1 µL of 
sample was added to the dried matrix. The sample array was then analysed on a 
Voyager-DE PRO 6066 mass spectrometer. Each matrix element of the sample array 
was sequentially irradiated with ultraviolet laser pulses leading to ionisation of the 
analyte molecules. The ions were then accelerated through a detection region at a 
velocity that was inversely proportional to their mass-to-charge ratio. Spectra were 
obtained using an accelerating voltage of 25 kV andextraction delay time of 300 
nsec with 20 laser pulses averaged. Spectra were visualised using Data Explorer 
Software v4.0 and were processed using a macro developed to handle accumulated 
spectra and apply noise removal and baseline correction functions (example 
displayed in Figure 2.4).  
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Figure 2.3. Multiplexed PCR products. Reaction products from four DNA samples 
(lanes 1 – 4) and one negative control (lane 5) multiplexed with five primer pairs 
electrophoresed alongside a 1 Kb DNA ladder in a 3 % agarose gel. The five product 
sizes are (in bp): 101, 241, 285, 339 and 435. Note the faint band of unused primer at 




Figure 2.4. An example of a processed MALDI-ToF spectrum showing the genotypes for six SNPs in a single multiplexed reaction. SNP 1 
= TC, SNP 2 = AG, SNP 3 = CC, SNP 4 = AA, SNP 5 = TC, SNP 6 = CC. 
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2.2.4 Agarose gel electrophoresis 
1 – 3 % agarose gels containing 500 ng/mL ethidium bromide were prepared in 1X 
TAE buffer. 2 µL of loading buffer was mixed with 6 µL of sample and loaded onto 
the gel before being electrophoresed at 100 – 120 V for 20 – 50 min, depending on 
DNA fragment size. The gel was then viewed using an ultraviolet transilluminator 
(UVT) and photographed using a Polaroid camera fitted o the UVT housing.  
 
2.2.5 TaqMan SNP genotyping 
TaqMan SNP genotyping reactions were performed in a 384-well PCR plate (Bio-
Rad) using a TaqMan SNP genotyping assay (Applied Bosystems) specific for each 
SNP. Each TaqMan SNP genotyping assay contained four oligonucleotides: two as 
forward and reverse primers to amplify the region ctaining the SNP site and two 
allele specific oligonucleotide TaqMan probes that ybridise to their respective 
targets at the SNP site and which differ in sequence by a single base. Each of these 
probes is labelled with either a FAM or VIC reporter dye at their 5’ end and a 
quencher at their 3’ end. Only one of the two probes will bind to a template DNA 
fragment depending on the identity of the base at the SNP site. Once the forward and 
reverse primers have bound to a DNA fragment, extension will occur through 
incorporation of nucleotides which is catalysed by the polymerase enzyme. Upon 
reaching the probe, the 5’ label is cleaved by the polymerase which separates it from 
the quencher and causes it to fluoresce. This label-specific fluorescence can then be 
used to determine which probe has bound to the template DNA and hence the 
identity of the allele at the SNP site. 
 
To perform SNP genotyping using the TaqMan method, a master mix was first 
prepared at room temperature containing the following components: 
 
Component Volume per reaction 
10X PCR Buffer II (Applied Biosystems) 0.5 µL 
25 mM MgCl2 (Applied Biosystems) 0.7 µL 
dNTP mix (25 mM of each dNTP) 0.04 µL 
TaqMan SNP Genotyping Assay (including 
four oligonucleotides) (Applied Biosystems) 
0.125 µL 
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AmpliTaq Gold DNA Polymerase (5 
units/µL) (Applied Biosystems) 
0.06 µL 
Distilled-deionised water 3.075 µL 
Total volume 4.5 µL 
 
4.5µL of this master mix was added to each well of the 384-well PCR plate prior to 
the addition of 0.5 µL of genomic DNA (20 ng/µL). The 384-well PCR plate was 
then covered using Microseal ‘A’ Film, vortexed and centrifuged before being 
incubated in a thermal cycler using the following temperature programme: 
 
Temperature Duration Cycles 
50 °C 2 min 1 
95 °C 10 min 1 
92 °C 15 s  
35 
60 °C 1 min 
Lid temperature constant at 100°C 
 
Following PCR, fluorescence from the 384-well PCR plate was detected using a 
Victor2 Multilabel Plate Reader (Wallac). A scatter plot was then created using the 
data on fluorescence emitted from each of the two probes (Figure 2.5) and genotypes 
were assigned to each sample. 
 
2.2.6 RNA extraction 
Total RNA was extracted from cells in culture using the RNeasy Mini Kit 
(QIAGEN). The first step involved lysis of the cultured cells by adding 350 µL of 
Buffer RLT (lysis buffer) directly to the cell cultre vessel, with the lysate mixed and 
homogenised by pipetting up and down at least 5 times. 350 µL of 70 % ethanol was 
added to the lysate to precipitate the RNA with the pipetting step repeated to mix. 
The sample was then transferred to an RNeasy Spin Column (QIAGEN) placed in a 
2 mL collection tube. The column was centrifuged at ≥ 10,000 rpm for 15 s and the 
flow-through discarded. 700 µL Buffer RW1 (wash buffer 1) was then added to the 
spin column and the centrifugation step was repeated with the flow-through 
discarded (care was taken at this point not to let th  spin column contact the flow-




Figure 2.5. An example of a TaqMan scatter plot with the GG, AG and AA genotype groups indicated. For each sample, the fluorescence 
emitted from the VIC reporter (G allele) is plotted against the fluorescence emitted from the FAM reporter (A allele). 
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column and the centrifugation step repeated with the flow-through discarded. 
Another 500 µL aliquot of Buffer RPE was added to the spin column with 
centrifugation proceeding at ≥ 10,000 rpm for 2 min. The collection tube was 
discarded with the flow-through after this step and a new collection tube was 
attached to the spin column. The spin column was then centrifuged at ≥ 11,000 rpm 
for 1 min before being placed in a clean 1.5 mL collection tube. 30 – 50 µL of 
RNase-free water was subsequently added directly to he spin column membrane and 
centrifugation at ≥ 10,000 rpm for 1 min followed to elute total RNA. RNA was 
quantitated using an ND-1000 spectrophotometer (NanoDrop Technologies) and was 
kept chilled using ice while being used or at - 80 °C for long term storage. 
 
2.2.7 Reverse transcription 
Reverse transcription of RNA was performed using the QuantiTect Reverse 
Transcription Kit (QIAGEN). This kit removes contaminating genomic DNA from 
the RNA sample before using random hexamer primers to produce cDNA from all 
regions of the template RNA in an unbiased manner. RNA samples and reagents 
were thawed while chilled on ice before ≤ 1 µg of RNA was added to a single well in 
a 96-well PCR plate (Axygen) made up to a total volume of 12 µL with RNase-free 
water. 2 µL of gDNA Wipeout Buffer was then added to each sample while chilled 
on ice before the samples were capped, mixed by vortexing and centrifuged. The 
samples were then incubated at 42 °C for 2 min then chilled on ice. A reverse-
transcription master mix was then made up while chilled on ice containing: 
 
Component Volume per reaction 
5X QuantiScript Reverse Transcription Buffer 
(QIAGEN) 
4 µL 
Reverse Transcription Primers (QIAGEN) 1 µL 
QuantiScript Reverse Transcriptase (QIAGEN) 1 µL 
Total volume 6 µL 
 
6 µL of this master mix was added to each sample while c illed on ice before the 96-
well PCR plate was capped, mixed by vortexing and centrifuged. The samples were 
incubated in a thermal cycler using the following temperature programme: 
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Temperature Duration Cycles 
42 °C 15 min 1 
95 °C 3 min 1 
Lid temperature tracking at 1 °C above block temperature 
 
2.2.8 Real-time PCR 
Real-time PCR was carried out using SYBR green, which is an asymmetrical cyanine 
dye that fluoresces when bound to DNA (Cosa et al., 2001). The dye preferentially 
binds to double-stranded DNA and can be used in non-specific DNA quantitation. 
Real-time PCR incorporating SYBR green technology can be used to quantitate the 
amount of template RNA, DNA or cDNA in a sample by amplifying a region of 
interest within the template sequence using a standard PCR primer pair and thermal 
cycler protocol (Arya et al., 2005). During the extension step of each PCR cycle a 
fluorescence reading is taken, with the cycle number at which the SYBR green 
fluorescence rises above a specific threshold (CT value) used to calculate the 
concentration of the target sequence in the original sample (Figure 2.6a). Relative 
quantitation can be performed by comparing a test sample against a control, or 
absolute quantitation can be performed by comparing a test sample against a standard 
of known concentration. 
 
Real-time PCR was carried out using the QuantiFast SYBR Green Kit (QIAGEN). 
The following master mix was made up at room temperature: 
 
Component Volume per reaction 
2X QuantiFast SYBR Green Master Mix 
(QIAGEN) 
7.5 µL 
10 µM Forward and Reverse Primer Mix 1.5 µL 
Distilled-deionised water 4.5 µL 
Total volume 13.5 µL 
 
13.5 µL of this master mix was combined with 1.5 µL of template cDNA in a single 
well of a 96-well iCycler iQ PCR plate (Bio-Rad). Reactions were then covered 
using Microseal ‘B’ Film (Bio-Rad), mixed by vortexing and centrifuged before 
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Figure 2.6a. An example of a real-time PCR amplification plot with the baseline 
threshold value set at 300.57. The CT values generated by this amplification chart 
range from ~ 12.5 to ~ 33. 
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Figure 2.6b. An example of a melting-curve analysis for a set of samples 
subjected to real-time PCR. The target sequence has been amplified in all samples 
except one, where amplification of a primer-dimer has occurred (indicated). Note 
that the melting temperature of the amplified primer-dimer is significantly lower than 
that of the amplified PCR product (~ 74 °C compared to ~ 87 °C). 
87 
being incubated in an iQ5 Multicolor Real-Time PCR Detection System (Bio-Rad) 
using the following temperature programme:  
 
Temperature Duration Cycles 
95 °C 5 min 1 
95 °C 10 s  
35 
60 °C (fluorescence data collection point) 30 s 
Lid temperature constant at 100°C 
 
Upon completion of the PCR protocol, a melting-curve analysis was performed by 
the real-time PCR thermal cycler (Figure 2.6b). This can indicate whether a single 
sequence was amplified in each sample during the thermal cycling. To achieve this, 
the temperature was slowly increased from 65 °C to 95 °C with a fluorescence 
reading taken at every 0.5 °C interval. This allows the user to identify the melting 
temperature of the amplified sequence within each sample, since there is a large 
decrease in SYBR green fluorescence when the amplified DNA within a sample 
becomes single-stranded. The amplification of prime-dimers can also be easily 
detected using this technique, as they usually have a low melting temperature due to 
their short length. As an additional quality control step, PCR product from randomly 
selected samples was electrophoresed on an agarose gel to confirm specific 
amplification of the correct target sequence. 
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Chapter 3 – Analysis of variation within the ARHGEF3 gene for association 
with bone mineral density phenotypes 
3.1 Introduction 
The ARHGEF3 gene encodes the Rho guanine nucleotide exchange fctor (GEF) 3. 
Thiesen et al. identified the ARHGEF3 transcript as composed of 3,561 nucleotides 
including a large 3’ untranslated region (UTR) of 1,853 nucleotides (Thiesen et al., 
2000). The transcript encodes a protein of 526 amino acids, expression of which was 
detected in wide variety of tissues including the heart, brain, kidney, lung, pancreas, 
spleen and skeletal muscle (Thiesen et al., 2000). The ARHGEF3 gene was mapped 
to the 3p14-p22 chromosomal region (Thiesen et al., 2000) and represents a strong 
candidate gene for BMD regulation. 
 
The function of ARHGEF3 was first discussed by Arthur et al., who stated that it was 
a Rho family GEF containing two domains: a Dbl homology (DH) domain which is 
responsible for catalytic activity and a pleckstrin homology (PH) domain (Arthur et 
al., 2002) which is thought to provide a site for regulation by phospholipids and 
localise the GEFs to the plasma membrane where they can regulate their downstream 
targets (Schmidt and Hall, 2002). The product of the ARHGEF3 gene specifically 
activates two members of the RhoGTPase family: RHOA (Arthur et al., 2002), 
known to play a role in bone (Chellaiah et al., 2000, Meyers et al., 2005), and RHOB 
(Arthur et al., 2002), with a potential role in osteoarthritis (Gebhard et al., 2004, 
Mahr et al., 2006). When expressed in fibroblasts ARHGEF3 has been shown to 
cause the assembly of more robust stress fibres and focal adhesions than in 
fibroblasts not expressing the protein through specific activation of the RHOA and 
RHOB GTPases (Arthur et al., 2002).  
 
Members of the RhoGEF family have been found to have  role in bone cells. A 
study published by Brazier et al. used gene arrays and quantitative real-time PCR to 
identify genes encoding members of the RhoGEF and RhoGTPase families that are 
up-regulated during RANKL-mediated osteoclastogenesis in mouse cells (Brazier et 
al., 2006). They identified the RhoGTPase gene Rhou and the RhoGEF genes Net1 
(also known as Arhgef8) and Dock5 as significantly up-regulated by RANKL 
treatment (Brazier et al., 2006). Silencing of the Rhou and Net1 genes was 
subsequently found to inhibit osteoclastogenesis and silencing of Dock5 was lethal in 
89 
osteoclast precursors (Brazier et al., 2006). The product of the murine Net1 gene has 
been identified as a Rhoa-specific exchange factor (Alberts and Treisman, 1998). 
 
There is evidence in the literature to suggest that members of the RhoGEF family are 
involved in human genetic disease with skeletal phenotypes. The FGD1 gene is 
located in the p11 region of the X chromosome (Glover et al., 1993, Pasteris et al., 
1994) and encodes a RhoGEF protein that specifically activates the Rho family 
GTPase CDC42 (Zheng et al., 1996). Mutation in this gene has been linked with the 
genetic disease faciogenital dysplasia (also known Aarskog-Scott syndrome) (Figure 
3.1) (MIM 305400) (Kaname et al., 2006, Orrico et al., 2005, Orrico et al., 2004, 
Orrico et al., 2000, Orrico et al., 2007, Pasteris t al., 1994, Schwartz et al., 2000, 
Shalev et al., 2006, Bedoyan et al., 2009, Bottani et al., 2007, Orrico et al., 2010). 
This disorder is rare, having first being described by Aarskog with additional 
characterisation by Scott (Aarskog, 1970, Scott, 1971). The disorder is characterised 
by a variety of skeletal abnormalities including short stature, hypertelorism, 
brachydactyly and retarded bone age (Orrico et al., 2007, Schwartz et al., 2000). 
Pasteris et al. was the first to identify a point mutation within the FGD1 gene as 
responsible for the disorder in a small family with two affected male siblings 
(Pasteris et al., 1994). This mutation was identified as a single base insertion within 
exon 7 of the gene, resulting in a frameshift and the formation of a premature stop 
codon causing the production of a truncated FGD1 protein (Pasteris et al., 1994). 
Orrico et al. analysed 13 independent patients suffering from faciogenital dysplasia 
and identified a missense mutation (altering the amino acid sequence of the protein) 
located within exon 10 of the FGD1 gene in one patient (Orrico et al., 2000). This 
mutation was found to reside within one of the two PH domains of the FGD1 gene 
and cause the substitution of a highly conserved residu  (Orrico et al., 2000). Since 
these early studies, many incidences of mutation to the FGD1 gene in patients 
suffering from faciogenital dysplasia have been repo ted (Kaname et al., 2006, 
Orrico et al., 2005, Orrico et al., 2004, Orrico et al., 2007, Shalev et al., 2006, 
Bedoyan et al., 2009, Bottani et al., 2007, Orrico et al., 2010). These mutations seem 
to be randomly distributed across all domains of the FGD1 protein (Orrico et al., 
2010), some of which have been found to affect the intracellular localisation of the 
protein and/or its GEF activity (Bedoyan et al., 2009, Orrico et al., 2004, Orrico et 
al., 2000, Schwartz et al., 2000). 
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Figure 3.1. A case of faciogenital dysplasia caused by mutation to the FGD1 
gene. Note the clinical craniofacial features: palpebral ptosis (drooping of the upper 
eyelid), downslanting palpebral fissures (separation between the upper and lower 




The pattern of Fgd1 expression has been examined in mice and has been found to 
correlate with faciogenital dysplasia skeletal manifestations (Gorski et al., 2000). 
Initial expression of Fgd1 was found during the onset of embryonic ossification in 
regions of active bone formation and up-regulation of the gene was found to cause an 
increase in expression of osteopontin (Gorski et al., 2000), a protein synthesised by 
osteoblasts at the onset of matrix mineralisation (Bianco et al., 1991). This would 
suggest that FGD1 plays a role in ossification and bone formation and not in earlier 
stages of skeletogenesis. Evidence has also been prsented to suggest that FGD1 is 
preferentially associated with the trans-Golgi network (TGN) and that reduced 
expression of FGD1 causes a reduction in post-Golgi transport of various cargoes 
including bone-specific proteins in osteoblasts (Egorov et al., 2009). These effects 
were found to be dependent upon CDC42 activation by FGD1 and appear to be 
caused by impairment of TGN membrane extension along microtubules (Egorov et 
al., 2009). 
 
Due to the apparent role of members of the RhoGEF family in bone and the location 
of the ARHGEF3 gene in the 3p14-p22 chromosomal region, the aim of the work 
described in this chapter was to analyse common variation within the ARHGEF3 
gene for association with BMD parameters in a discovery cohort of Caucasian 
women. Replication of significant findings was subsequently performed in an 
independent replication cohort. 
 
3.1.1 Hypothesis 
Polymorphism within the ARHGEF3 gene is significantly associated with bone 
density in Caucasian women. 
 
3.2 Materials and methods 
3.2.1 Subjects 
3.2.1.i Discovery cohort  
A total of 769 women from 335 families were recruited in Australia and the UK. 
This family-based population included siblings recruited in 1998 for a study of the 
genetics of osteoporosis (Wilson et al., 2003). BMD Z-score values for the proband 
at the spine, total hip and femoral neck sites were Z = - 1.54 (1.03), - 1.00 (0.95) and 
- 1.03 (1.05) respectively (median (interquartile range)). Sibships within the cohort 
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included two-hundred and sixty-four families with 2 siblings, forty-nine with 3, 
seventeen with 4, four with 5 and one with 7 siblings. The median difference in Z 
score between sibs with extreme BMD measurements were: spine Z = 2.2, total hip Z 
= 1.5 and femoral neck Z = 1.6. Exclusion criteria were applied where possible and 
included the presence of bone cancer, hyperparathyroidism, unstable thyroid disease, 
long term steroid use (> 5 mg/day for more than 6 months and presently on therapy), 
chronic immobility, rheumatoid arthritis, anorexia nervosa, osteomalacia, 
amenorrhea for > 6 months, premature cessation of regular menstruation or surgical 
oophorectomy +/- HRT (age < 40 yrs), and epilepsy with use of anticonvulsant 
medication for > 1 year. All subjects from the study provided written informed 
consent, and the ethics committees of participating institutions including the Human 
Research Ethics Committee at Curtin University of Technology approved the 
experimental protocols. 
 
At a clinic visit data including age, height, weight, medical, gynaecological, and 
lifestyle data were recorded and a blood sample collected. Dual energy X-ray 
absorptiometry (DXA) BMD was assessed (Hologic Inc., Bedford, MA, USA) at the 
lumbar spine L1-L4 and the total hip that includes an area from the femoral neck to 
just below the lesser trochanter. Within this area the femoral neck sub-region is 
widely used in clinical practice for prediction of fracture propensity and was the 
phenotype chosen for use in this study. Due to the range of ages in this cohort, BMD 
data were adjusted for age prior to analysis by conversion to BMD Z-scores. The 
correlations between the BMD Z scores obtained from different sites were r = 0.82 
(total hip and femoral neck), r = 0.63 (total hip and spine) and r = 0.52 (femoral neck 
and spine). 
 
3.2.1.ii Replication cohort  
This group of subjects was recruited in 1988 to participate in a longitudinal 
epidemiological study of rheumatic diseases (The Chingford Study). Women 
between the ages of 45 and 64 were recruited from a single large general practice in 
Chingford, North-East London using a population-based method. All women within 
this age range that were on a register of > 11,000 patients were invited to participate 
in the study. No exclusion criteria were applied. This cohort has similar 
demographics and anthropometry to the general UK population regarding height, 
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weight, smoking status and hysterectomy rates (Arden et al., 1996, Hart and Spector, 
1993). Demographic and lifestyle factors data were obtained by questionnaires 
completed in 1988. DNA samples were obtained from 780 individuals. Bone density 
measurements were undertaken using a Hologic QDR-2000 densitometer (Hologic 
Inc., Bedford, MA, USA) in 1998 approximately 10 years after the subjects were 
initially recruited, with hip and spine DXA BMD data obtained from 775 and 779 
individuals respectively. The correlations between the BMD measurements obtained 
from different sites were r = 0.89 (total hip and femoral neck), r = 0.7 (total hip and 
spine) and r = 0.67 (femoral neck and spine). Subjects were categorised as fracture-
free or having had a previous fracture as described pr viously (Keen et al., 1999), 
with fractures sustained at any skeletal site up to 2003 included in the analysis 
excluding those caused by high-impact trauma. All subjects from the study provided 
written informed consent, and the ethics committees of participating institutions 
including the Human Research Ethics Committee at Cur in University of Technology 
approved the experimental protocols. 
 
3.2.2 Genotyping 
3.2.2.i Discovery cohort  
Genomic DNA was extracted and purified from EDTA whole blood obtained from 
each subject (Johns and Paulus-Thomas, 1989). Whole-genome amplification was 
performed on each DNA sample using the REPLI-g Midi Kit (QIAGEN) (see 
Chapter 2 for a full description of the technique). Genotyping was then performed on 
the amplified DNA using the Illumina GoldenGate assay on an Illumina BeadStation 
500 GX, utilising bead array hybridisation (Illumina, 2004). This part of the analysis 
was performed by staff at Illumina Inc. (San Diego, USA). The genotype call rate 
using this technique was 99.8 % with an estimated error rate of < 0.1 %, as assessed 
by comparing genotype calls between 8 samples genotyped in duplicate. 
 
3.2.2.ii Replication cohort  
Genotyping in the replication cohort was performed in-house using the MALDI-ToF 
mass spectrometry technique (Wise et al., 2003) (see Chapter 2 for a full description 
of the technique). Genotyping reactions were performed using sequence specific 
oligonucleotide primers designed using Primer3 software (Rozen and Skaletsky, 
2000) in a multiplex PCR (see Appendix II for primer sequences). The volume of 
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each genotyping primer used was optimised prior to analysis of the test samples. 
Using this technique the genotype call rate was 96.6 % and the estimated error rate 
was < 0.1 %, as assessed by comparing genotype calls between 8 samples genotyped 
in duplicate. 
 
3.2.3 SNP selection 
17 SNPs were selected in the region of the ARHGEF3 gene for genotyping in the 
discovery cohort. Tagging SNPs (tSNPs) were initially selected across the region 
using the Perlegen Genome Browser (European American population) (Hinds et al., 
2005), which at the time was considered to be one of the most comprehensive 
resources available for viewing patterns of linkage disequilibrium (LD) across the 
human genome. The Perlegen Genome Browser identifies tSNPs as being in linkage 
LD of r² > 0.8 with all other SNPs in the LD bin. An effort was made to tag all 13 
LD bins identified within the gene and the 50 Kb region immediately 5’ of the gene 
that contained 2 or more SNPs. Due to assay design issues, 9 of the 13 LD bins were 
able to be tagged. The remaining SNPs genotyped were selected from the Perlegen 
Genome Browser (European American population) (Hinds et al., 2005) as 
independent SNPs not belonging to any LD bin, or wee selected from the dbSNP 
database. 
 
One SNP from the 17 genotyped in the discovery cohort was initially selected for 
genotyping in the replication cohort. In subsequent studies, made possible by the 
release of more detailed LD data for the European American population in the 
Perlegen Genome Browser (Hinds et al., 2005), three additional tSNPs around the 5’ 
end of ARHGEF3 were selected for genotyping in the replication cohort using a 
tagging strength of r² >0.8. Two extra SNPs from the 17 genotyped in the discovery 
cohort were also analysed at this time. 
 
3.2.4 Statistical analysis 
Analysis of the data from the discovery cohort was performed using the FBAT 
(Family Based Association Tests) software to test for association within sib-pairs 
(Laird et al., 2000). The empirical variance estimaor was used to allow for prior 
linkage to the region. Correction for multiple testing was performed by randomly 
permuting phenotypes within sibships and repeating all FBAT tests on the permuted 
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datasets. The minimum P-values were recorded for 10,000 random reassignments of 
the data (using an automated script written in Perl), with an adjusted P-value ≤ 0.05 
considered significant. This approach was used to corre t for tests of multiple SNPs 
within each phenotype, and also for tests of multiple SNPs across multiple 
phenotypes. For the latter, correlation between phenotypes was preserved by 
permuting the whole phenotype vector for each subject. For individual BMD scores, 
adjusting for multiple SNPs, this corresponds to an unadjusted P-value of about 
0.0037. For adjustment for testing BMD scores at three sites, the corresponding 
unadjusted P-value was 0.002. To examine the effect of reducing the number of 
correlated traits, principal component analysis was c rried out. The effect of 
menopausal status on BMD in the discovery cohort was analysed using multiple 
linear regression implemented in Statistica v8.0. 
 
QPDTPHASE v2.404, which is part of the UNPHASED software suite (Dudbridge, 
2003), is a program for association analysis of multilocus haplotypes from unphased 
genotype data and was used to estimate the genetic effe t size in the discovery 
cohort. This program was also used to perform a haplotype analysis. Throughout, 
two-tailed P-values are reported, with P ≤ 0.05 considered significant. LD between 
the different SNPs was evaluated using the JLIN software (Carter et al., 2006) and 
Graphical Overview of Linkage Disequilibrium (GOLD) (Abecasis and Cookson, 
2000). 
 
Statistical analysis of the data from the replication cohort was performed using 
Statistica v8.0. One-way analysis of variance (ANOVA) was used to test for 
differences between genotype groups. BMD data were adjusted for age and weight 
using analysis of co-variance (ANCOVA). QTPHASE v2.404, which is also part of 
the UNPHASED software suite (Dudbridge, 2003), was used to perform an allelic 
association test for the replication cohort. Genotype effects on the prevalent fracture 
rate were examined using a Chi-square test. 
 
3.3 Results 
3.3.1 Discovery cohort 
All SNPs genotyped were in Hardy-Weinberg equilibrium (χ2 test, P < 0.05). The 
demographic and morphometric characteristics of the populations are detailed in 
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Table 3.1. The discovery cohort recorded a lower mean BMD than the replication 
cohort at each site studied despite a younger mean age, which was expected due to 
the high proportion of osteoporotic individuals in this population. The discovery 
cohort also recorded a lower mean weight than the replication cohort. For the total 
hip and femoral neck sites, menopausal status was not a significant predictor of 
BMD. At the spine, menopausal status was found to acc unt for < 1% of the variance 
in BMD. 
 
The chromosomal position and allele distribution of the 17 SNPs genotyped is 
detailed in Table 3.2 with the location of each SNP relative to the various splice 
variants of ARHGEF3 displayed in Figure 3.2. Using FBAT, significant associations 
were seen between the SNPs rs4681928, rs1344142, rs1110866, rs7646054 and 
rs3772219 and various measures of BMD Z score (P < 0.001 – 0.041). The strongest 
associations were observed with rs7646054, which was associated with BMD Z 
score at the total hip (P = 0.006), femoral neck (P < 0.001) and spine (P = 0.006). 
Among the other SNPs, rs4681928 was significantly associated with BMD Z score of 
the femoral neck (P = 0.01) and spine (P = 0.03), rs1344142 with spine (P = 0.04), 
rs1110866 with femoral neck (P = 0.02) and rs3772219 with spine (P = 0.03). The 
significant association between rs7646054 and femoral neck BMD Z score persisted 
after adjustment of the data for testing multiple SNPs (P = 0.007), as did the 
association corrected further for testing multiple anatomical sites (P = 0.024). 
 
Principal component analysis was also applied to the BMD trait group. The first two 
principal components explained 94.5 % of the trait v riance. However, using the 
eigenvalue > 1 criterion, only the first component, which explained 77.3 % of the 
variance in BMD, should be retained. This component showed maximal association 
with rs7646054 (P = 0.002). 
 
The more common G allele at rs7646054 is associated with a lower BMD Z score at 
each site studied (Table 3.3), indicating that thisallele has a negative effect on BMD. 
Note that the mean BMD Z scores reported by QPDTPHASE are loosely interpreted 
as the expected trait value for an individual carrying that particular allele, and are not 
interpretable as additive effects on the mean. 
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Table 3.1. Demographics and bone density parameters of the discovery and replication populations. 
Variable Discovery Replication 
Age (years) 54.2 ± 12.7 (769) 62.5 ± 5.9 (780) 
Weight (Kg) 62.7 ± 11.27 (699) 69.1 ± 12.6 (778) 
Prevalent fractures (%) - 34 (780) 
Total Hip DXA BMD (mg/cm2) 801 ± 136 (760) 869 ± 128 (775) 
Total Hip BMD Z Score - 0.420 ± 0.992 (760) 0.489 ± 0.994 (775) 
Femoral Neck DXA BMD (mg/cm2)  700 ± 133 (749) 747 ± 119 (775) 
Femoral Neck BMD Z Score - 0.355 ± 1.050 (749) 0.276 ± 1.019 (775) 
Spine L1-L4 DXA BMD (mg/cm2) 855 ± 158 (767) 955 ± 155 (779) 
Spine BMD Z Score - 0.669 ± 1.252 (767) 0.745 ± 1.384 (779) 
Results are given as mean ± SD (number of measurements). 
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Genotype Distribution in the 
Discovery Cohort (%) 
rs17288993 56940107 5’ region AA (79.7), AG (18.8), GG (1.4) 
rs4681928 56901206 5’ region AA (63.6) (65.7)†, AG (33.5) (30)†, 
GG (2.9) (4.3)† 
rs1039381 56849769 5’ region AA (61.8), AG (35), GG (3.1) 
rs9311623 56846106 5’ region TT (56.8), TC (38), CC (5.2) 
rs9842692 56844958 5’ region CC (73.1), TC (24.7), TT (2.2) 
rs1344142 56832473 5’ region GG (26.4) (30.1)†, AG (52.6) 
(48.1)†, AA (21) (21.8)† 
rs17288922 56826427 5’ region GG (68.4), AG (29.4), AA (2.2) 
rs1566487 56822871 5’ region TT (36.8)†, TC (49.6)†, CC (13.6)† 
rs4681898 56811780 5’ region CC (44.1), TC (43.6), TT (12.2) 
rs13434307 56809329 Intron 1 AA (75.9), AG (22.8), GG (1.3) 
rs6803697 56806588 Intron 1 GG (49)†, AG (42)†, AA (9)† 
rs4681888 56805127 Intron 1 TT (70.1), TC (26.4), CC (3.5) 
rs12632941 56804703 Intron 1 GG (70.8)†, AG (26.8)†, AA (2.4)† 
rs1110866 56801364 Intron 1 AA (41.2), AC (47.2), CC (11.6) 
rs7646054 56784668 Intron 1 GG (29.1) (33.2)†, AG (52.1) 
(47.4)†, AA (18.8) (19.4)† 
rs2171855 56764783 Intron 2 TT (73.8), TC (23.3), CC (2.9) 
rs3821412 56762491 Intron 4 AA (24.3), AG (53.1), GG (22.6) 
rs3772219 56746291 Exon 8 
Change of aa 
335 (Leu to 
Val) 
TT (45.6), TG (42.5), GG (11.9) 
rs11919130 56732292 3’ region CC (73), TC (25.4), TT (1.7) 
rs2317248 56714619 3’ region TT (33.9), AT (48.6), AA (17.6) 
* From GenBank reference sequence NM_019555, Genome Build 36.2.   
 † Allele distribution in the replication cohort. 




Figure 3.2. 17 SNPs genotyped in the ARHGEF3 gene. Diagram showing the localisation of the 17 SNPs in ARHGEF3 genotyped in the 
discovery cohort relative to the 3 RefSeq splice variants of the gene according to the University of California - Santa Cruz (UCSC) Genome 
Browser (February 2009 assembly). The SNPs highlighted in red are those that are significantly associated with BMD parameters in the 
discovery cohort prior to adjustment for multiple testing. 
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Table 3.3. Association between rs7646054 and BMD Z scores in the discovery 
cohort. 
BMD Z Score Phenotype Mean BMD Z Score P 
 G allele A allele  
Total hip - 0.437 ± 1.235 (837) - 0.399 ± 1.222 (683) 0.013 
Femoral neck - 0.383 ± 1.325 (825) - 0.322 ± 1.264 (673) 0.001 
Spine - 0.686 ± 1.619 (842) - 0.650 ± 1.538 (692) 0.008 
Results are given as mean ± SD (number of alleles contributing to the mean), derived 
from QPDTPHASE v2.404. 
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Pair-wise linkage disequilibrium D’ and r² values for the five SNPs are shown in 
Figure 3.3. A haplotype analysis was undertaken on the femoral neck and spine 
BMD Z score data using UNPHASED to determine whether any haplotypes were 
more strongly associated with either phenotype than individual SNPs. Each 
haplotype analysis incorporated only the 3 SNPs that were most significantly 
associated with the phenotype in the FBAT analysis. For femoral neck BMD Z score 
the SNPs included in the haplotype analysis were rs4681928, rs1110866 and 
rs7646054 whereas the SNPs rs4681928, rs7646054 and rs3772219 were included in 
the spine BMD Z score analysis. Significant associations were observed with both 
phenotypes (Table 3.4), including a stronger overall association with spine BMD Z 
score than in the individual SNP analysis suggesting independent effects of the SNPs 
on BMD. In the femoral neck BMD haplotype analysis the significance of the overall 
association did not surpass that of the individual SNP analysis. However, a very 
strong association was observed between femoral neck BMD Z score and the most 
common AAA haplotype (588 alleles) in a post hoc analysis (P < 0.001). 
 
3.3.2 Replication study  
Because rs7646054 was the strongest predictor of spine and hip bone density, it was 
taken forward to the replication study to determine whether the effect would be 
detectable in a population-based cohort of postmenopausal women. Significant 
associations were observed between rs7646054 and spi e and total hip BMD 
including the femoral neck area, all of which persisted after adjustment of the BMD 
data for the covariates age and weight (Table 3.5).Consistent with the results for the 
discovery cohort, subjects homozygous for the G allele compared to individuals 
homozygous for the A allele had lower BMD at the total hip, femoral neck and spine 
sites (- 3.7 %, - 3.3 %, and - 3.5 % respectively). Compared to heterozygous 
individuals with the AG genotype, GG individuals again had lower BMD at the three 
sites (- 1.8 %, - 2.4 % and - 3.7 % respectively). No significant associations between 
genotype and the covariates age or weight were found. 
 
An allelic association test of the replication cohort using BMD Z score as the 
phenotype was then carried out using QTPHASE to confirm replication with the 
same type of association test and the same phenotype as that used for the discovery 
cohort. Significant associations were observed betwe n rs7646054 and total hip 
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Figure 3.3. Pairwise linkage disequilibrium plot for the five SNPs in the 
ARHGEF3 gene associated with BMD in the discovery population. Different 
colours represent the strength of LD according to the scale shown on the right. 
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Table 3.4. BMD Z-scores for ARHGEF3 3-SNP haplotypes in the discovery cohort. 
BMD Z Score Phenotype Haplotype (rs4681928, rs1110866, rs7646054) 
 AAA allele ACG allele AAG allele GCG allele GAA allele GAG allele P 
Femoral neck - 0.341 ± 
1.188 (588)c 
- 0.376 ± 
1.162 (374) 
- 0.408 ± 
1.129 (239) 
- 0.358 ± 
0.974 (144)a 
- 0.205 ± 
1.072 (81) 
- 0.359 ± 
0.781 (65) 
0.003 
 Haplotype (rs4681928, rs7646054, rs3772219) 
 AGT allele AAT allele AAG allele AGG allele GGT allele GGG allele P 
Spine - 0.677 ± 
1.378 (450)a 
- 0.573 ± 
1.299 (375)a 
- 0.720 ± 
1.187 (228)a 
- 0.665 ± 
1.171 (177) 
- 0.725 ± 
1.161 (151)b 
- 0.722 ± 
0.864 (61) 
0.002 
Results are given as mean ± SD (number of alleles), derived from QPDTPHASE v2.404. 
aP < 0.05, bP < 0.01 and cP < 0.001 for individual haplotypes compared to all others. 
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Table 3.5. Osteodensitometry parameters and fracture rate in relation to the genotype distribution of rs7646054 in the replication 
cohort. 
Phenotype AA Genotype AG genotype GG genotype P 
Total Hip DXA BMD (mg/cm2) 889 ± 128a (150) 872 ± 128a (354) 857 ± 122b (252) 0.013 
Femoral Neck DXA BMD (mg/cm2) 759 ± 115a (150) 753 ± 120a (354) 735 ± 117b (252) 0.038 
Spine DXA BMD (mg/cm2) 967 ± 172a (150) 969 ± 148a (356) 934 ± 152b (253) 0.007 
Prevalent Fracture (%) 36.4 (151) 29.1 (358) 39.1 (253) 0.026 
Results are given as mean ± SD (number of measurements). 
The BMD data are adjusted for age and weight. 
a significantly different from b in post hoc analysis (P < 0.05). 
105 
BMD Z score (P = 0.007), femoral neck BMD Z score (P = 0.02) and spine BMD Z 
score (P = 0.02). 
 
In the replication cohort 265 subjects had suffered a fracture prior to 2004, giving a 
prevalent fracture rate of 34 %. rs7646054 was found to be significantly associated 
with fracture rate, GG individuals having an increased fracture rate (Table 3.5). 
 
As mentioned previously, more comprehensive genome-wid  LD data became 
available for the European American population in the Perlegen Genome Browser 
(Hinds et al., 2005). Subsequently, a more detailed pattern of LD across the 
ARHGEF3 gene in the European American population became apparent. In an effort 
to tag additional variation around the 5’ region of the gene, three additional tSNPs 
around the 5’ end of ARHGEF3 were selected for genotyping in the replication 
cohort. These SNPs are rs1566487, rs6803697 and rs12632941. In addition to this, 
two SNPs from the 17 genotyped in the discovery cohort that were significantly 
associated with BMD phenotypes were also analysed for replication: rs4681928 and 
rs1344142. No significant associations were observed between any of the additional 
5 SNPs genotyped and BMD phenotypes. The chromosomal position and allele 
distribution of these SNPs in this cohort is detaild in Table 3.2. 
 
3.4 Discussion 
The data presented in this chapter provide evidence that variation within the 
ARHGEF3 gene affects BMD in women aged 40 to 70 in the peri and early 
postmenopausal phase of life, at the time that fracu e risk is rising. Strong evidence 
was found for an influence of individual SNPs and haplotypes on spine and femoral 
neck BMD Z score. The SNP rs7646054, located within intron 1 of the ARHGEF3 
gene, was the best predictor of bone density and the results were replicated in a 
second cohort including a statistically significant association with fracture rate. In 
general, fracture risk rises by about two times for a reduction in hip BMD of one 
standard deviation (15 % of the mean) (Marshall et al., 1996). We saw decreases in 
BMD of about 3 % that equate to an increase in fracture risk for the "disease" 




Using the genetic power calculator developed by Purcell and colleagues (Purcell et 
al., 2003), with QTL variance set as 0.05, QTL and marker frequency 0.5 and 0.55 
respectively, D’ = 0.9 and sib correlation of 0.4, the power of the discovery cohort is 
0.91 at a type-1 error rate of 0.05. If the QTL variance is only 0.03, then the power is 
0.72. Similarly for the replication cohort, if the QTL variance is set as 0.05 then the 
power for this study is 0.99, whilst for a QTL variance of 0.03 the power is estimated 
as 0.98. 
 
Since rs7646054 is located within an intron, it is unlikely that polymorphism at this 
site would result in structural changes to the ARHGEF3 protein. According to 
updated LD data provided by the International HapMa Project (Phase 3 dataset) 
(Altshuler et al., 2010), rs7646054 is in strong LD(r2 > 0.8) with the SNPs rs983739 
and rs4681859 in the CEU population (Utah residents wi h Northern and Western 
European ancestry). These two SNPs are both located 5' of rs7646054, with the LD 
between the three SNPs spanning a region of approximately 13.7 Kb located within 
the first intron of the predominantly expressed ARHGEF3 transcript (RefSeq 
accession number NM_019555) (Figure 3.4). The region is adjacent to exon 2 of this 
splice variant, although no polymorphisms within this exon have been identified to 
date. The region is, however, positioned immediately 5’ of a recently described 
transcript variant of ARHGEF3 (RefSeq accession number NM_001128616) (Totoki 
et al., 2007). Indeed, the rs7646054 SNP is located within the 5’ UTR of this 
transcript. Since mRNA UTRs have been identified as an integral component of post-
transcriptional regulation of gene expression (Mignone et al., 2002), the 5’ UTR 
sequence from the NM_001128616 transcript was analysed using the Vienna RNA 
Websuite (Gruber et al., 2008) using both the A and G alleles at the rs7646054 SNP 
site (Figures 3.5a and 3.5b respectively). The minium free energy, which is the 
difference in free energy between the unfolded and fol ed mRNA states (Ringner 
and Krogh, 2005), was 3.5 kcal/mol lower for the 5’ UTR containing the A allele 
than for the 5’ UTR containing the G allele. This would suggest that the mRNA 
transcript containing the A allele has a more stable secondary structure, a feature that 
is associated with lower translation rates and higher transcript turnover in yeast 
(Muhlrad et al., 1995, Ringner and Krogh, 2005). Indeed, this effect has been 
observed with differences in minimum free energy as small as 1 kcal/mol (Ringner 
and Krogh, 2005). Collectively, these data would suggest that polymorphism at 
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Figure 3.4. The location of 3 SNPs that are in strong LD, relative to two splice 
variants of ARHGEF3. The solid boxes represent exons and the empty boxes 












Figure 3.5a. Schematic of the 5’ 
UTR of NM_001128616 containing 
the less common A allele at 










Figure 3.5b. Schematic of the 5’ 
UTR of NM_001128616 containing 
the more common G allele at 




rs7646054 could influence the stability and hence the expression of the 
NM_001128616 mRNA transcript of the ARHGEF3 gene. Future studies could 
investigate whether polymorphism at this SNP site is associated with 
NM_001128616 mRNA levels (discussed in Chapter 7). 
 
A recent study published by Li et al. analysed the rs7646054 SNP from ARHGEF3 
for association with BMD parameters in a case-control population of 1,080 Chinese 
females, 533 of whom were postmenopausal (Li et al., 2010). The authors did not 
observe any associations between the rs7646054 SNP and BMD (Li et al., 2010). 
Comparisons between this study and the results present d in this chapter must be 
done with caution due to differences in study design as well as differences in the 
ethnicity of the study subjects. There are well documented differences in typical bone 
mass and bone turnover phenotypes between different th ic groups (Araujo et al., 
2007, Davis et al., 1994, Finkelstein et al., 2002, Nelson et al., 2000, Tobias et al., 
1994) and it has been suggested that these groups may also have different genetic 
susceptibility loci for osteoporosis (Dvornyk et al., 2003, Lei et al., 2006). There is 
also a substantial difference in the frequency of the A and G alleles at the rs7646054 
SNP site in Caucasian and Chinese populations. According to the International 
HapMap Project (Phase 3 dataset) (Altshuler et al., 2010) the frequency of the A and 
G alleles in the CEU population is 0.46 and 0.54 respectively, which is similar to 
those seen in our study populations (0.45 and 0.55 respectively in our discovery 
cohort; 0.43 and 0.57 respectively in our replication cohort). Li et al. did not publish 
the allele frequencies that they observed for rs764605  in their study population (Li 
et al., 2010), however according to the International HapMap Project (Phase 3 
dataset) (Altshuler et al., 2010) the frequency of the A and G alleles for rs7646054 in 
the CHB population (Han Chinese in Beijing, China) is 0.19 and 0.81 respectively. 
 
The primary role of the RhoGEFs such as ARHGEF3 is to activate the RhoGTPases, 
key regulators of actin dynamics that cycle between an inactive GDP-bound and an 
active GTP-bound state (Figure 3.6). RhoGEFs achieve this by catalysing the 
exchange of GDP for GTP through stabilisation of the nucleotide-free state 
(Rossman et al., 2005). GTP then spontaneously binds a  renders the protein active. 
The RHOA GTPase, which is activated by the product of the ARHGEF3 gene 
(Arthur et al., 2002), has been implicated in osteoblast differentiation and osteoclast 
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Figure 3.6. Mechanism of action of the RhoGEFs. The RhoGEFs work to activate 
the RhoGTPases, which cycle between an inactive GDP-bound and an active GTP-
bound state. The RhoGEFs achieve this by catalysing the exchange of GDP for GTP.
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function (discussed in Chapter 4). The RHOB GTPase, which is also activated by the 
product of the ARHGEF3 gene (Arthur et al., 2002), seems to have a role in cartilage 
biology, having been linked to osteoarthritis in which a chondrocyte disorder plays a 
major role (Gebhard et al., 2004, Mahr et al., 2006). 
 
In conclusion, it has been shown that genetic variation within the ARHGEF3 gene is 
associated with variation in BMD in Caucasian women, possibly through effects on 
mRNA folding and stability. Therefore, the hypothesis has been supported by the 
data. There is evidence in the literature to suggest that the two RhoGTPases that are 
specifically activated by the product of the ARHGEF3 gene, RHOA and RHOB, 
have a role in bone and cartilage cell biology. 
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Chapter 4 – Analysis of variation within the RHOA gene for association with 
bone mineral density phenotypes 
4.1 Introduction 
The Rho genes were first isolated from a cDNA library created from RNA obtained 
from abdominal ganglia of molluscs (Aplysia) (Madaule and Axel, 1985). 
Evolutionarily conserved counterparts encoding proteins of around 21 kDa in size 
were subsequently identified in flies, yeast cells, rats and humans (Madaule and 
Axel, 1985). Indeed, these homologs were so conserved that amino-acid sequence 
analysis revealed 96.8 % homology between the human and Aplysia proteins 
(Madaule and Axel, 1985). The mammalian Rho family of GTPases belongs to the 
Ras superfamily of small GTP-binding proteins. It contains 20 members from eight 
subfamilies (Boureux et al., 2007) that cycle betwen an inactive GDP-bound and an 
active GTP-bound state. The three most commonly studied members of the Rho 
family are RHOA, CDC42 and RAC1, and these three proteins have been shown to 
interact with each other (Nobes and Hall, 1995). The Rho family of proteins can be 
distinguished from other small GTPases by the presence of the Rho insert domain 
which is located between the fifth β strand and the fourth α helix in the small GTPase 
domain (Valencia et al., 1991). There are three typs of regulatory protein that have 
been shown to influence the activation state of the R oGTPases: the GEFs, of which 
ARHGEF3 is a member, which catalyse the exchange of GDP for GTP thus 
activating the RhoGTPases (Hart et al., 1996); the GDIs (GDP dissociation 
inhibitors), which inhibit the release of GDP, thereby keeping the RhoGTPases in an 
inactive state (Fukumoto et al., 1990); and the GAPs (GTPase activating proteins), 
which increase the hydrolysis rate of GTP by the Rho proteins and thus the rate at 
which they become inactivated (Diekmann et al., 1991). The human RHOA gene, 
which encodes the Ras homolog gene family member A, is situated within the 3p14-
p22 chromosomal region (Cannizzaro et al., 1990, Kiss et al., 1997). The human 
RHOA protein is 193 amino acids in length (Avraham and Weinberg, 1989, 
Yeramian et al., 1987) and shares 88 % homology with the RHOB protein (Avraham 
and Weinberg, 1989). It is located primarily in the cytosol with smaller amounts 
bound to the plasma membrane (Adamson et al., 1992). 
 
Paterson et al. injected a constitutively active GTP-bound form of RHOA into Swiss 
3T3 cells, observing contraction of the cell bodies and formation of finger-like 
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processes at the cell periphery within minutes (Paterson et al., 1990). Subsequent 
actin staining with phalloidin revealed strong actin stress fibres extending from these 
finger-like processes across the cell, leading the authors to suggest that the RHOA 
protein has a role in cytoskeletal organisation (Paterson et al., 1990). A later study 
also using Swiss 3T3 cells found that RHOA could be activated by the addition of 
extracellular ligands (for example, lysophosphatidic acid) and that activation of this 
protein lead to the assembly of contractile actin-myosin stress fibres and focal 
adhesion complexes (Ridley and Hall, 1992). There is also evidence to suggest that 
RHOA activity is essential to maintain focal adhesion  in attached cells (Hotchin and 
Hall, 1995). These combined data suggest that the RhoGTPase family members are 
key regulatory molecules that link cell surface receptors with the actin cytoskeleton 
(Hall, 1998). 
 
There is evidence from gene knockout work in mice that he RhoGTPases have a role 
in skeletal development. Wang et al. generated micew th a targeted disruption of the 
Arhgap1 gene (Wang et al., 2005a), the product of which hasbeen shown to 
deactivate the RhoGTPase CDC42 by catalysing GTP hydrolysis of the protein 
(Moon and Zheng, 2003). The authors found that embryonic and neonatal mice 
homozygous for the disruption were approximately 25 – 40 % smaller than those that 
were wild-type and suffered severe growth retardation (Wang et al., 2005a). A 
subsequent study by the same group found that Arhgap1-knockout mice presented 
with shortened lifespan, multiple premature aging-like phenotypes, osteoporosis and 
severe lordokyphosis (Figure 4.1) (Wang et al., 2007). This led the authors to 
speculate that CDC42 has a role in DNA damage repair ability and aging related 
physiology (Wang et al., 2007). 
 
Due to the location of the RHOA gene in the 3p14-p22 chromosomal region, its role 
in bone cells (discussed below), the apparent role of the RhoGTPase CDC42 in bone 
and the associations observed between polymorphism in the ARHGEF3 gene and 
BMD phenotypes, the aim of the work described in this chapter was to analyse 
polymorphism within the RHOA gene for association with BMD parameters in a 
discovery cohort of Caucasian women. Replication of significant findings was 
subsequently performed in an independent replication c hort. These are the same 





Figure 4.1. X-rays of 15-month old male wild type and Arhgap1 knockout mice. 
Note the severe lordokyphosis and reduced bone density i  the knockout mouse. 
Figure adapted from Wang et al. (Wang et al., 2007). 
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4.1.1 Hypothesis 
Polymorphism within the RHOA gene is significantly associated with bone density in 
Caucasian women. 
 
4.2 Materials and methods 
4.2.1 Subjects 
4.2.1.i Discovery cohort  
For a full description of the discovery cohort refe to Chapter 3, section 3.2.1.i. 
Briefly, a total of 769 women from 335 families were recruited in Australia and the 
UK. This family-based population included siblings recruited in 1998 for a study of 
the genetics of osteoporosis (Wilson et al., 2003). All subjects from the study 
provided written informed consent, and the ethics committees of participating 
institutions including the Human Research Ethics Committee at Curtin University of 
Technology approved the experimental protocols. 
 
4.2.1.ii Replication cohort  
For a full description of the replication cohort refer to Chapter 3, section 3.2.1.ii . 
Briefly, women between the ages of 45 and 64 were rcruited using a population-
based method. DNA samples were obtained from 780 individuals, with hip and spine 
DXA BMD data obtained from 775 and 779 individuals respectively. All subjects 
from the study provided written informed consent, and the ethics committees of 
participating institutions including the Human Research Ethics Committee at Curtin 
University of Technology approved the experimental protocols. 
 
4.2.2 Genotyping 
4.2.2.i Discovery cohort 
Genotyping in the discovery cohort was performed as de cribed in Chapter 3, 
sections 3.2.2.i. Briefly, genotyping was performed using the Illumina GoldenGate 
assay (Illumina, 2004) on whole-genome amplified DNA. The genotype call rate 
using this technique was 99.6 % with an estimated error rate of < 0.1 %. 
 
4.2.2.ii Replication cohort 
Genotyping in the discovery cohort was performed as de cribed in Chapter 3, 
sections 3.2.2.i. Briefly, genotyping was performed in-house using the MALDI-ToF 
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mass spectrometry technique (Wise et al., 2003) (see Appendix II for primer 
sequences). Using this technique the genotype call rate was 97.1 % and the estimated 
error rate was < 0.1 %. 
 
4.2.3 SNP selection 
Nine SNPs were selected in the region of the RHOA gene for genotyping in the 
discovery cohort. Tagging SNPs (tSNPs) were initially selected across the region 
using the Perlegen Genome Browser (European American population) (Hinds et al., 
2005) as described in Chapter 3. We were able to tag all 3 LD bins identified within 
the immediate vicinity of the RHOA gene (Perlegen LD bins 1050962, 1046850 and 
1046281). The remaining SNPs genotyped were selected from the dbSNP database 
(Build 132), which does not currently contain any record of exonic polymorphisms 
within the human RHOA gene with a minor allele frequency > 1 % (discussed later).  
 
Two SNPs from the nine genotyped in the discovery cohort were selected for 
genotyping in the replication cohort.  
 
4.2.4 Statistical analysis  
For a full description of the statistical analysis performed in the discovery cohort 
refer to Chapter 3, section 3.2.4. Briefly, the data from the discovery cohort were 
analysed using the FBAT (Family Based Association Tests) software to test for 
association within sib-pairs (Laird et al., 2000). Correction for multiple testing was 
performed to correct for tests of multiple SNPs within each phenotype, and also for 
tests of multiple SNPs across multiple phenotypes.  
 
To estimate the genetic effect size, the genotype-specific adjustment to the trait 
values that leads to an FBAT statistic of zero for the residuals was calculated 
(Vansteelandt et al., 2008). This gives an estimate of he additive effect on the mean 
that is consistent with the testing method used. Haplotype analysis used 
QPDTPHASE v2.404, which is part of the UNPHASED software suite (Dudbridge, 
2003). Throughout, two-tailed P-values are reported, with P ≤ 0.05 considered 
significant. LD between the different SNPs was evaluated using the JLIN software 
(Carter et al., 2006). 
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Statistical analysis of the data from the replication cohort was performed in Statistica 
v8.0 using ANOVA for differences between genotype groups. BMD Z-score data 
were adjusted for weight by ANCOVA. Genotype effects on fracture rate were 
examined using a Chi-square test. 
 
4.3 Results 
4.3.1 Discovery cohort 
All SNPs genotyped were in Hardy-Weinberg equilibrium (χ2 test, P < 0.05). Of the 
9 SNPs genotyped in the discovery cohort, one was found to be monomorphic 
(rs6446270), that is, only one allele was identified in the entire cohort. The 
remaining 8 fell into 3 distinct LD blocks as defined by a tagging strength of r² > 0.8 
(Figure 4.2). The chromosomal position and allele distribution of all 9 SNPs 
genotyped is detailed in Table 4.1. LD block 1 contained the SNPs rs6446272 and 
rs17080528 (Perlegen LD bin 1050962); block 2 contained rs4855877, rs17595772 
and rs17650792 (Perlegen LD bin 1046850); block 3 contained rs940045, 
rs10155014 and rs4955426 (Perlegen LD bin 1046281). Using FBAT, significant 
associations were observed between various measures of BMD Z-score and the SNPs 
in block 1 (rs6446272, rs17080528) and block 2 (rs4855877, rs17595772, 
rs17650792) (P = 0.001 – 0.036). No significant associations were seen between th 
SNPs in block 3 (rs940045, rs10155014, rs4955426) and BMD phenotypes (P = 0.46 
– 0.8). The SNP rs17080528 was selected to represent block 1 and rs17595772 was 
selected to represent block 2, since these two SNPs demonstrated the strongest 
associations with BMD parameters. The SNP rs1708052 was significantly 
associated with BMD Z-scores for the total hip (P = 0.026) and femoral neck (P = 
0.003) whereas rs17595772 was significantly associated with BMD Z-scores for the 
total hip (P = 0.014), femoral neck (P = 0.001) and spine sites (P = 0.036). 
Significant associations for rs17595772 with total hip and femoral neck sites were 
maintained after correction for testing multiple SNPs (P = 0.038 and 0.002 
respectively), and the association with femoral neck was maintained after further 
correction for testing multiple anatomical sites (P = 0.007). Estimates of the additive 
genetic effect suggest that the less common T allele at rs17080528 and the more 
common G allele at rs17595772 are associated with a reduced BMD Z-score (Table 





Figure 4.2. LD analysis of the 5 SNPs significantly associated with BMD 
parameters in the discovery cohort. 
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Genotype Distribution in the 
Discovery Cohort (%) 
rs6446272 49438291 5’ region GG (45.8), AG (45), AA (9.3) 
rs940045 49424642 5’ region TT (54.6), TC (39.1), CC (6.3) 
rs4855877 49423531 Intron 1 AA (32.4), AG (51), GG (16.5) 
rs6446270 49420781 Intron 1 CC (100) 
rs10155014 49407325 Intron 1 TT (54.3), TC (39.3), CC (6.4) 
rs17595772 49384708 Intron 2 GG (32.1) (29.9)†, AG (50.9) 
(50.0)†, AA (17.0) (20.1)† 
rs17650792 49365254 3’ region AA (32.4), AG (50.4), GG (17.2) 
rs17080528 49364846 3’ region CC (45.8) (50.9)†, TC (45.2) 
(41.3)†, TT (9.0) (7.8)† 
rs4955426 49118442 3’ region TT (60.7), TG (33.7), GG (5.6) 
* From GenBank reference sequence NM_001664, Genome Build 36.3. 
† Allele distribution in the replication cohort. 
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Table 4.2a. Additive effect of the T allele at rs17080528 on BMD Z-score 
phenotypes in the discovery cohort. 
BMD Z-score Phenotype Additive effect of T allele 
Total hip - 0.12 
Femoral neck - 0.15 
Spine - 0.13 
Results are given as the effect size that gives a ridual FBAT statistic of zero. 
 
Table 4.2b. Additive effect of the G allele at rs17595772 on BMD Z-score 
phenotypes in the discovery cohort. 
BMD Z-score Phenotype Additive effect of G allele 
Total hip - 0.20 
Femoral neck - 0.25 
Spine - 0.20 
Results are given as the effect size that gives a ridual FBAT statistic of zero. 
121 
A 2-SNP haplotype analysis was undertaken on rs17080528 and rs17595772 to 
determine whether haplotypes of the LD blocks tagged by each SNP would prove to 
be more significantly associated with BMD Z-scores than either block individually. 
The TA haplotype had an estimated frequency of zero, suggesting a lack of historical 
recombination. The association of the CA haplotype was therefore equivalent to that 
of the A allele of rs17595772, and the association of TG equivalent to that of the T
allele of rs17080528. The CG haplotype had no significant association, so it was 
concluded that no additional information was obtained from the haplotype analysis.  
 
4.3.2 Replication cohort 
The SNPs rs17080528 and rs17595772 were genotyped in the replication cohort. The 
allele distribution of these two SNPs in this cohort is detailed in Table 4.1. No 
significant associations between rs17080528 and BMD Z-scores were observed (P = 
0.21 – 0.42). However, rs17595772 demonstrated significant associations with BMD 
Z-scores for the total hip, femoral neck and spine sit s after adjustment of the BMD 
Z-score data for the covariate weight (Table 4.3). Consistent with the results for the 
discovery cohort, subjects homozygous for the G allele at rs17595772 compared to 
individuals homozygous for the A allele had lower BMD at the total hip, femoral 
neck and spine sites (- 3.4 %, - 3.8 %, and - 5.9 % respectively). Compared to 
heterozygous individuals with the AG genotype, GG individuals again had lower 
BMD at the three sites (- 1.1 %, - 1.8 % and - 2.7 % respectively). No significant 
association between rs17595772 genotype and the covariate weight was found. 
 
In the replication cohort 265 subjects had suffered a fracture prior to 2004, giving a 
prevalent fracture rate of 34 %. Neither rs17080528 nor rs17595772 were 
significantly associated with fracture rate.  
 
4.4 Discussion  
The results presented here suggest that genetic varation in the RHOA gene, in 
addition to that in the ARHGEF3 gene, may influence BMD in women. These genes 
are both situated in the 3p14-p22 region of the genome, an area that has been linked 
with BMD in multiple studies (Duncan et al., 1999, Wilson et al., 2003, Wynne et al., 
2003, Klein et al., 1998, Xiao et al., 2006, Lee et al., 2006). This certainly raises the 
possibility that more than one gene from this region is responsible for the linkage 
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Table 4.3. BMD Z-scores in relation to the allele distribution of rs17595772 in the replication cohort. 
Phenotype AA Genotype AG genotype GG genotype P 
Total Hip BMD Z score 0.7 ± 1.1a (149) 0.5 ± 1.0b (371) 0.4 ± 0.9b (225) 0.034 
Femoral Neck BMD Z score 0.4 ± 1.1a ( 49) 0.3 ± 1.0 (371) 0.2 ± 0.9b (225) 0.036 
Spine BMD Z score 1.1 ± 1.5a (150) 0.8 ± 1.5b (374) 0.6 ± 1.2b (225) 0.002 
Results are given as mean ± SD (number of measurements). 
The BMD Z-score data are adjusted for weight. 
a significantly different from b in post hoc analysis (P < 0.05). 
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observed, a phenomenon that has been reported previously with genetic susceptibility 
to tuberculosis (Jamieson et al., 2004) and essential-hypertension (chronically 
elevated blood-pressure with no identifiable cause) (Chang et al., 2007). This is 
discussed further in Chapter 7.  
 
According to updated LD data provided by the International HapMap Project (Phase 
3 dataset) (Altshuler et al., 2010), for the CEU population the two SNPs rs17080528 
and rs17595772 tag two large LD blocks that span a region approximately 219 Kb on 
chromosome 3 (Figure 4.3). Seven genes have been identif ed in this region 
(including RHOA) and it is possible that variation within any one of these is 
responsible for the associations observed. After interrogation of the literature to 
investigate the function of each gene product (Table 4.4), it was found that the TCTA, 
GPX1 and USP4 genes all have potential roles in bone metabolism. It cannot be ruled 
out that polymorphism within these two LD blocks influences BMD through effects 
on these genes. However, RHOA is considered to be the most likely candidate among 
these for a role in BMD regulation especially when considering the associations 
identified in these same populations between the ARHGEF3 gene and BMD 
phenotypes (refer to Chapter 3). 
 
The RHOA GTPase has been implicated in osteoblast differentiation. McBeath et al. 
found that cell shape regulates the commitment of human mesenchymal stem cells 
(hMSCs) to the adipocyte or osteoblast lineages by modulating endogenous RHOA 
activity (McBeath et al., 2004). They also demonstrated that RHOA expression 
committed hMSCs to an osteoblastic fate whereas expression of dominant-negative 
RHOA caused adipogenesis (McBeath et al., 2004). These effects overrode the 
presence of differentiation factors in the media and re thought to occur through 
regulation of cytoskeletal tension (McBeath et al.,2004). Meyers et al. found that 
over-expression of RHOA restored actin cytoskeletal arrangement, enhanced the 
expression of osteoblastic genes and suppressed the xpr ssion of adipocytic genes in 
hMSCs cultured in modelled microgravity (MMG) (Meyers et al., 2005). 
Interestingly, it was found that the quantity of activated RHOA protein dropped by 
88 ± 2% in hMSCs cultured in MMG whereas the total expression of RHOA did not 
change significantly (Meyers et al., 2005), indicating that the RhoGEFs responsible 




Figure 4.3. LD blocks tagged by rs17080528 and rs17595772 according to the International HapMap Project (Phase 3 dataset) (Altshuler 
et al., 2010). 
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Table 4.4. Role of gene products, including any potential role in bone metabolism, for each of the 6 genes (in addition to RHOA) covered 
by the linkage disequilibrium blocks tagged by rs17080528 and rs17595772. 
Gene Role of gene product 
DAG1 Encodes dystroglycan 1, an integral component of the dystrophin-glycoprotein complex. This complex provides a link between the 
subsarcolemmal cytoskeleton and the basement membrane (B rresi and Campbell, 2006). Reduced glycosylation of dystroglycan has 
been implicated in some cases of muscular dystrophy (Mercuri et al., 2009). 
NICN1 Encodes nicolin 1, which is a nuclear protein (Backofen et al., 2002). Not a great deal is known about this protein, however the 
murine Nicn1 gene has been highlighted as a possible candidate gene for alcohol preference (Mulligan et al., 2006). 
AMT Encodes aminomethyltransferase, which is part of a complex involved with glycine cleavage (Nanao et al., 1994). Mutations in this 
gene have been implicated in nonketotic hyperglycinemia, a condition characterised by severe neurological symptoms resulting from 
disturbed glycine metabolism (Toone et al., 2001). 
TCTA Encodes T-cell leukemia translocation altered gene protein, which was originally implicated in T-cell acute lymphoblastic leukemia 
(Aplan et al., 1995). A recent study has suggested that this protein may play an important role in the cellular fusion that takes place 
during osteoclastogenesis (Kotake et al., 2009). 
GPX1 Encodes glutathione peroxidase 1, a selenium-containi g antioxidant enzyme that appears to have a role in metabolising hydrogen 
peroxide (Lei et al., 2007) and has been implicated in various types of cancer (Hu et al., 2005). Overexp ession of Gpx1 in a mouse 
macrophage cell line has been found to impair osteoclastogenesis (Lean et al., 2005) and a recent study has identified associations 
between polymorphism in GPX1 and BMD in humans (Mlakar et al., 2010). 
USP4 Encodes ubiquitin specific peptidase 4, which is a deubiquitinating enzyme that has been implicated in lung cancer (Frederick et al., 
1998, Gray et al., 1995). USP4 has recently been idtified as a member of the Wnt signalling pathway, with suppression of USP4 
having been found to activate beta-catenin dependent transcription (Zhao et al., 2009). 
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Wang and Stern  has also suggested a possible role fo  RHOA in the production of 
RANKL and OPG by osteoblasts in response to PTH stimulation (discussed in 
Chapter 7) (Wang and Stern, 2010). 
 
In addition to its role in osteoblast differentiation, the RHOA GTPase has also been 
implicated in osteoclast function. Osteoclasts are highly motile cells that rely on 
rapid changes to their cytoskeleton to achieve the movement and attachment that is 
required for bone resorption (Kanehisa and Heersche, 1988, Lakkakorpi et al., 1993, 
Lakkakorpi and Vaananen, 1991, Lakkakorpi and Vaanane , 1996). Chellaiah et al. 
identified RHOA as playing a major role in this process (Chellaiah et al., 2000). By 
transducing active and inactive RHOA into avian oste clasts they demonstrated that 
the protein is essential for podosome assembly, stress fibre formation, osteoclast 
motility and bone resorption (Chellaiah et al., 2000). In addition, farnesyl 
pyrophosphate synthase, the specific target of nitrogen-containing bisphosphonates 
widely used in the treatment of osteoporosis, is essential for the prenylation and 
therefore activity of RhoGTPases including RHOA (Reszka and Rodan, 2004). 
Bisphosphonates cause loss of osteoclast activity and induction of apoptosis, possibly 
through the inactivation of RhoGTPases (Denoyelle et al., 2003). Zhang et al. found 
that the actin ring structure that is typical of a resorbing osteoclast is disrupted by 
ADP-ribosyltransferase C3 (C3 exoenzyme) (Zhang et al., 1995). This exoenzyme is 
produced by Clostridium botulinum and is specifically involved in ADP-ribosylation 
of Rho proteins, thereby inactivating them (Sekine et al., 1989, Narumiya and Morii, 
1993, Nemoto et al., 1991). 
 
As mentioned previously, the RHOA protein appears to be very highly conserved 
across multiple species. Indeed, the dbSNP database (Build 132) does not presently 
contain any record of exonic polymorphisms within the human RHOA gene with a 
minor allele frequency > 1 %. There is also no evidnce of polymorphism within the 
gene that could influence splicing. This suggests that he function of the RHOA 
protein is critical for survival, a theory supported by the fact that RHOA is involved 
with a wide range of biological processes in multiple tissue types (Etienne-
Manneville and Hall, 2002). As such, all of the SNPs genotyped in this study are 
either intronic or located 5’ or 3’ of the RHOA gene. When considering this, it seems 
likely that if the SNPs genotyped in this study do influence BMD, they do so through 
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mild regulatory effects on the RHOA gene as opposed to structural changes to the 
RHOA protein, the latter of which could result in profound phenotypic changes. 
Future studies could investigate whether polymorphism at rs17595772 or rs17080528 
is associated with RHOA mRNA levels (discussed in Chapter 7). 
 
In conclusion, the evidence presented here suggests that common genetic variation 
within the RHOA gene region is associated with BMD in Caucasian women. 
Therefore, the hypothesis has been supported by the data. There is a substantial 
amount of evidence to suggest that RHOA has a role in the biology of osteoblasts 
and osteoclasts. These data further support a role for the RhoGTPase-RhoGEF 
pathway in osteoporosis. 
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Chapter 5 – Analysis of variation within the FLNB gene for association with 
bone mineral density phenotypes 
5.1 Introduction 
Mammals carry three filamin genes, encoding: filamin A (FLNA), filamin B (FLNB) 
and filamin C (FLNC). The FLNC gene appears to be predominantly expressed in 
muscle, whereas the FLNA and FLNB genes are widely expressed (Brocker et al., 
1999, Chakarova et al., 2000). A comparison between th  FLNA, FLNB and FLNC 
genes revealed a highly conserved intron-exon structure, with significant differences 
observed in the 32nd exon of each gene encoding the hinge 1 region (Chakarova et 
al., 2000). Filamins exist in vivo as dimers, with around 70 % homology existing 
between the FLNA, FLNB and FLNC protein structures (van der Flier and 
Sonnenberg, 2001). The FLNB monomer is a 278 kDa protein (Xu et al., 1998) 
consisting of an N-terminal actin-binding domain composed of two calponin 
homology domains (CH1 and CH2) (Gorlin et al., 1990), followed by a series of 24 
β-sheet repeats that bind to various cytoplasmic and transmembrane proteins (Gorlin 
et al., 1990, Xu et al., 1998). The C-terminal β-sheet repeat (repeat number 24) is 
known as the dimerisation domain and allows for the formation of FLNB 
homodimers (Weihing, 1988). The FLNB gene is located in the p14-p22 region of 
human chromosome 3 (Brocker et al., 1999) and presents as another strong candidate 
for BMD regulation. The gene is made up of 45 exons a d 44 introns, spanning 
around 80 Kb of genomic DNA (Chakarova et al., 2000).  
 
Mutations to the FLNB gene have been implicated in a variety of genetic disorders 
characterised by skeletal malformation. Steiner et al. performed a linkage study in 
three consanguineous families and one non-consanguineo s family with high 
incidences of spondylocarpotarsal synostosis (SCT) syndrome (MIM 272460) 
(Steiner et al., 2004), a rare autosomal recessive disorder characterised by fusions of 
the vertebrae as well as the carpal and tarsal bones (Langer et al., 1994). They 
observed linkage of the disorder with the 3p14 region of the human genome (LOD 
6.49) (Steiner et al., 2004).  Krakow et al. subsequently examined the FLNB gene for 
mutations in these four families, identifying a unique nonsense mutation (creating a 
premature stop codon) in each (Krakow et al., 2004). The authors concluded that 
SCT syndrome results from the absence or truncation of the FLNB gene product 
(Krakow et al., 2004). This theory was supported by two later studies that identified 
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nonsense FLNB mutations in two individuals suffering from SCT syndrome 
(Brunetti-Pierri et al., 2008, Mitter et al., 2008). 
 
Larsen syndrome (LS) is a genetic disease characterised by craniofacial 
abnormalities in addition to multiple dislocations of the large joints such as the 
knees, elbows and hip joints (Larsen et al., 1950). The condition can be inherited as 
an autosomal dominant (MIM 150250) or recessive (MIM 245600) form, with the 
recessive form arguably the more severe (Bonaventur et al., 1992, Chen et al., 
1982). Vujic et al. published the results of a linkage study in a large Swedish 
pedigree suffering from autosomal dominant LS (Vujic et al., 1995). This study 
highlighted the 3p14-p21 region of the human genome as potentially harbouring the 
gene responsible for the disorder (LOD 13.4) (Vujic et al., 1995). Krakow et al. 
analysed the FLNB gene for mutations in four individuals with sporadically 
occurring LS and one family with a dominantly inherit d form of the condition 
(Krakow et al., 2004). They identified a unique d  novo missense mutation within the 
FLNB gene in each of the five cases (Krakow et al., 2004). Bicknell et al. 
subsequently identified FLNB mutations in 20 unrelated individuals suffering from 
LS, these mutations seemed to cluster in the actin-binding domain of the FLNB 
protein and in the β-sheet repeats 13-17 (Bicknell et al., 2007). 
 
Atelosteogenesis is a heritable lethal chondrodysplasia characterised by insufficient 
ossification of various bones including the humerus, femur, thoracic spine and hand 
bones (Maroteaux et al., 1982). The disease shares many phenotypic features with LS 
(Nishimura et al., 1997, Schultz et al., 1999). Krakow et al. examined the FLNB gene 
in five unrelated individuals suffering from atelosteogenesis: three suffering from 
atelosteogenesis type I (AOI) (MIM 108720) and two suffering from 
atelosteogenesis type III (AOIII) (MIM 108721) (Krakow et al., 2004). They 
observed missense mutations in the FLNB gene in all five individuals, with one 
individual suffering from AOI and another suffering from AOIII carrying the same 
mutation (Krakow et al., 2004). Farrington-Rock et al. subsequently identified 14 
novel FLNB missense mutations in 15 unrelated patients with AOI and AOIII 
(Farrington-Rock et al., 2006). Most of these mutations were found to reside within 
exons 2 and 3 which encode part of the actin-binding region of the protein, with the 
remainder found in exons 28 and 29 which encode the β-sheet repeats 14 and 15 
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(Farrington-Rock et al., 2006). Some of these mutations are thought to act in a gain-
of-function mechanism, resulting in increased actin-binding affinity (Sawyer et al., 
2009). 
 
Boomerang dysplasia (MIM 112310) is a perinatal lethal osteochondrodysplasia 
characterised by insufficient or non-existent ossification of the limb bones and 
vertebrae (Kozlowski et al., 1985). Bicknell et al. identified missense FLNB 
mutations in two individuals suffering from the disorder (Figure 5.1) (Bicknell et al., 
2005). These mutations were found to reside within regions of the gene that are 
evolutionarily well conserved and encode parts of the actin-binding domain of the 
protein (Bicknell et al., 2005).  
 
Wilson et al. published the results of the first study into common variation within the 
FLNB gene and BMD (Wilson et al., 2009). The four SNPs rs7637505, rs9822918, 
rs2177153 and rs2001972, were identified as significantly associated with age-
adjusted femoral neck BMD (BMD Z-score) in a discovery population of 767 
women from 334 families of European background (Wilson et al., 2009). Each of 
these four SNPs is located in either an intron or 5’ of the FLNB gene. Of these four 
SNPs, rs7637505 was significantly associated with femoral neck and lumbar spine 
BMD Z-score in a replication population of 1,085 female twins from the UK, while 
rs9822918 and rs2177153 were significantly associated with femoral neck BMD Z-
score in an additional replication population comprised of 1,315 unrelated 
postmenopausal Australian women (Wilson et al., 2009). Subsequent gene 
expression analysis in 96 human osteoblast cell cultures derived from 96 unrelated 
donors revealed that rs9822918, rs2177153 and rs2001972 did not reveal any 
association with FLNB mRNA expression levels (rs7637505 was not represent d on 
the analysis chip) (Wilson et al., 2009). However, five SNPs located either 5’ or in 
intron 1 of the FLNB gene, all in moderate LD (D’ > 0.5) with either rs7637505 or 
rs2177153, were identified as significantly associated with FLNB mRNA expression: 
rs11130605, rs839230, rs11720285, rs1718481 and rs9809315 (Wilson et al., 2009). 
The aim of the work described in this chapter was to analyse these 5 SNPs for 




Figure 5.1. A male foetus delivered at 22 weeks suffering from boomerang 
dysplasia. This radiograph reveals unossified humeri, absent fmora and a complete 
lack of ossification in the hands and feet. Figure adapted from Bicknell et al. 
(Bicknell et al., 2005). 
132 
5.1.1 Hypothesis 
Variation at one or more of the polymorphic sites r11130605, rs839230, 
rs11720285, rs1718481 and rs9809315 in the FLNB gene is significantly associated 
with bone density in Caucasian women. 
 
5.2 Materials and methods 
5.2.1 Subjects 
For a full description of the cohort used in this study refer to Chapter 3, section 
3.2.1.i. Briefly, a total of 769 women from 335 families were recruited in Australia 
and the UK. This family-based population included siblings recruited in 1998 for a 
study of the genetics of osteoporosis (Wilson et al., 2003) and is the same cohort as 
used in the “Discovery Study” by Wilson et al. (Wilson et al., 2009) with the 
inclusion of one additional sibling pair. All subjects from the study provided written 
informed consent, and the ethics committees of participating institutions including 
the Human Research Ethics Committee at Curtin University of Technology approved 
the experimental protocols. 
 
5.2.2 Genotyping 
Genomic DNA was extracted and purified from EDTA whole blood obtained from 
each subject (Johns and Paulus-Thomas, 1989). Genotypi g was performed on 
genomic DNA using the TaqMan assay, which utilises fluorogenic 5' nuclease 
chemistry, in 384-well PCR plate format (see Chapter 2 for a full description of the 
technique). Using this technique the genotype call rate was 99.3 % and the estimated 
error rate was < 0.1 %, as assessed by comparing genotype calls between 8 samples 
genotyped in duplicate. 
 
5.2.3 SNP selection 
5 SNPs from the 5’ region of the FLNB gene were selected for genotyping. These 
were selected based on previously published data sugge ting that all five SNPs are 
significantly associated with expression of FLNB mRNA in 96 human osteoblast cell 
cultures (Wilson et al., 2009).  
 
5.2.4 Statistical analysis 
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For a full description of the statistical analysis performed in this cohort refer to 
Chapter 3, section 3.2.4 (discovery cohort). Briefly, the data from the cohort were 
analysed using the FBAT (Family Based Association Tests) software to test for 
association within sib-pairs (Laird et al., 2000). Correction for multiple testing was 
performed to correct for tests of multiple SNPs within each phenotype, and also for 
tests of multiple SNPs across multiple phenotypes. 
 
UNPHASED v3.1.3 was used to estimate the genetic effect size in this cohort by 
generating an additive value as an estimate to how each allele influences the trait 
value relative to the most common allele (Dudbridge, 2003). This program was also 
used to perform a haplotype analysis. Throughout, two-tailed P-values are reported, 
with P ≤ 0.05 considered significant. LD between the different SNPs was evaluated 
using the JLIN software (Carter et al., 2006). 
 
5.3 Results 
All 5 SNPs genotyped were in Hardy-Weinberg equilibrium (χ2 test, P < 0.05). LD 
analysis revealed that none of the 5 SNPs genotyped were in LD of r2 > 0.8 with each 
other (Figure 5.2). An additional LD analysis revealed that one of the 5 SNPs 
genotyped in this study, rs839230, is in strong LD (r2 > 0.8) with rs704529 which 
was genotyped by Wilson et al. (Wilson et al., 2009). However, none of the other 4 
SNPs genotyped in this study were in LD of r2 > 0.8 with any of the 13 SNPs 
genotyped by Wilson et al. (Figure 5.2) (Wilson et al., 2009). The chromosomal 
position and allele distribution of the 5 SNPs genotyped is detailed in Table 5.1. 
 
Using FBAT, significant associations were seen for femoral neck BMD Z-score with 
the SNPs rs11720285, rs11130605 and rs9809315 (P = 0.005, 0.043 and 0.004 
respectively). These three SNPs were also found to be significantly associated with 
total hip BMD Z-score (P = 0.014, 0.026 and 0.022 respectively). No significant 
associations were observed between any of the 5 SNPs examined and spine BMD Z-
score. After correction of the data for testing 5 SNPs across 3 anatomical sites, the 
significant association between rs9809315 and femoral neck BMD Z-score was 
maintained (P = 0.028). Estimates of the additive genetic effect suggest that the less 
common C allele at rs11720285, the T allele at rs11130605 and the T allele at 
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Figure 5.2. LD analysis of the 13 SNPs in FLNB genotyped by Wilson et al. 









Location relative to 
transcription start site* 
Genotype Distribution (%) 
rs11720285 57936410 5’ region 32,757 bp upstream AA (54.9), AC (39.8), CC (5.2) 
rs11130605 57964209 5’ region 4,958 bp upstream CC (36.5), TC (48.6), TT (14.9) 
rs1718481 58000943 Intron 1 31,776 bp downstream GG (32.2), AG (50.3), AA (17.5) 
rs839230 58011832 Intron 1 42,665 bp downstream GG (40.1), AG (47.4), AA (12.5) 
rs9809315 58025305 Intron 1 56,138 bp downstream CC (49.5), TC (40.7), TT (9.8) 
* Relative to GenBank reference sequence NM_001457, Genome Build 36.3. 
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rs9809315 are associated with an increased BMD Z-score at both the total hip and 
femoral neck sites (Table 5.2).  
 
A 3-SNP haplotype analysis was carried out using rs11720285, rs11130605 and 
rs9809315 to determine whether haplotypes of the LD blocks tagged by each SNP 
would prove to be more significantly associated with femoral neck or total hip BMD 
Z-score than in the individual SNP analysis. 6 haploty es with a frequency greater 
than 4 % in the population were identified. Significant associations were observed 
with femoral neck BMD Z-score only (Table 5.3), although the level of significance 
did not surpass that observed in the individual SNP analysis for this phenotype. The 




The results presented here suggest that genetic variation within the 5’ region of the 
FLNB gene has a role in determining bone density in Caucasian women. Wilson et 
al. identified 5 SNPs from the 5’ region of the FLNB gene that were strongly 
associated with expression levels of FLNB mRNA, 3 of which have been shown here 
to be significantly associated with age-adjusted total hip and femoral neck BMD in 
Caucasian women (Wilson et al., 2009). The less comm n allele at each of these 3 
SNP sites was associated with an increased BMD Z-score in this study. FLNB is the 
third gene from the 3p14-p22 region of the human geome that has been implicated 
in the regulation of bone density in this population f women. This supports the 
theory raised in Chapter 4 that more than one gene from this chromosomal region is 
responsible for the linkage observed between 3p14-p22 and BMD. 
 
A recent study published by Li et al. analysed seven SNPs from the FLNB gene (Li et 
al., 2010), including the SNPs rs9822918 and rs2177153 genotyped by Wilson et al. 
(Wilson et al., 2009), for association with BMD parameters in a case-control 
population of 1,080 Chinese females, 533 of whom were postmenopausal (Li et al., 
2010). The authors were not able to replicate the findings for rs2177153 (probably 
due to the fact that this SNP had a minor allele frequency of only 0.02 in their 
population), however they did observe significant associations between the 
rs9822918 SNP and BMD at the total hip (Li et al., 2010). Although providing more 
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Table 5.2. Additive value of the less common allele at rs1172085, rs11130605 
and rs9809315 relevant to BMD Z-score. 
SNP BMD Z Score Phenotype Additive value of less common allele 
rs11720285 Femoral neck + 0.306 (366) 
 Total hip + 0.274 (373) 
rs11130605 Femoral neck + 0.241 (575) 
 Total hip + 0.268 (592) 
rs9809315 Femoral neck + 0.304 (435) 
 Total hip + 0.254 (448) 
Results are given as additive effect on the trait of the less common allele relative to 




Table 5.3. Haplotype analysis and additive value of each haplotype relevant to femoral neck BMD Z-score. 
BMD Z score phenotype Haplotype (rs11720285, rs11130605, rs9809315) 
 ACC allele CTT allele ATC allele ACT allele ATT allele CTC allele P 
Femoral neck 0 (769) + 0.72 (260) + 0.184 (148) + 0.044 (83) - 0.442 (82) - 0.164 (76) 0.006 
Results are given as additive effect on the trait of each haplotype relative to the most common haplotype (number of alleles included in the 
analysis), derived from UNPHASED v3.1.3. 
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support of a role for the FLNB gene in osteoporosis, comparisons with this study and 
that performed by Wilson et al. must be done with caution due to differences in study 
design as well as differences in the ethnicity of the study subjects (Wilson et al., 
2009), as discussed in Chapter 3. 
 
Filamins are promiscuous proteins, with over 70 binding partners identified to date 
(Popowicz et al., 2006, Sarkisian et al., 2008).  They are thought to have a role in 
stabilising the actin cytoskeleton, providing a link between the actin network and the 
cellular membranes, and mediating interactions betwe n actin and transmembrane 
receptors (Stossel et al., 2001). Filamins act to maintain the structural integrity of 
cells by crosslinking the actin cytoskeleton into 3D gels (Hartwig and Shevlin, 1986, 
Stossel, 1989, Stossel et al., 2001). The ability of filamin proteins to bind actin at 
their N-terminus and form tail-to-tail homodimers at their C-terminus allows them to 
create the orthogonal actin networks and bundles that result in gelation (Gorlin et al., 
1990). It has also been proposed that filamins are important during foetal 
development, regulating the communication between extracellular signals and the 
cytoskeleton to guide migration of cells into the correct anatomical sites (Stossel et 
al., 2001). 
 
There is a large amount of evidence to suggest that FLNB has a role in bone in 
humans, particularly when considering the various genetic diseases with skeletal 
phenotypes thought to be caused by mutation to the FLNB gene (Bicknell et al., 
2007, Bicknell et al., 2005, Bonaventure et al., 1992, Brunetti-Pierri et al., 2008, 
Krakow et al., 2004, Mitter et al., 2008). In addition to this, there is evidence to 
suggest that the murine Flnb gene has a role in bone. Flnb expression has been 
detected in vertebral bodies obtained from mouse embryos, and it has been suggested 
that the gene plays a role in vertebral segmentatio, j int formation and 
endochondral ossification (Krakow et al., 2004). Zhou et al. generated mice with a 
targeted disruption of the Flnb gene and observed impaired development of the 
microvasculature and skeletal systems in Fl b-deficient embryos, few of which 
reached term (Zhou et al., 2007). Those that were bo n were very small and had 
severe skeletal malformations including scoliotic and kyphotic spines, fusion of 
vertebral bodies, lack of intervertebral discs and re uced hyaline matrix in the 
extremities, thorax and vertebrae (Zhou et al., 2007). Interestingly, the authors also 
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noted that the expression of the Rhoa gene increased > 3-fold in Flnb-deficient 
fibroblasts. 
 
Additional support for the role of FLNB in bone has been generated through studies 
on the highly homologous FLNA protein. Leung et al. recently published evidence 
suggesting a major role for the FLNA gene in osteoclast differentiation (Leung et al., 
2010). Osteoclastogenesis in Flna-null mice was severely impaired as a result of 
decreased migratory ability of monocyte precursors (Leung et al., 2010). Activation 
of the Rho proteins Rac1, Cdc42 and Rhoa were partially or completely abolished in 
these monocytes, with addition of constitutively active Rac1 and Cdc42 found to 
rescue their migratory capabilities (Leung et al., 2010). These results suggest that 
FLNA has a major role in osteoclastogenesis through re ulation of the cytoskeleton 
via RhoGTPases that are required for the migratory capabilities of osteoclast 
precursors. Interestingly, the Flna-null mice generated by Leung et al. presented with
osteoporosis, suggesting that additional bone-related mechanisms are at work (Leung 
et al., 2010). 
 
There are two non-synonymous coding changes within the FLNB gene that have a 
minor allele frequency > 1 % in Caucasians, both of which were genotyped in the 
study by Wilson et al. and neither of which demonstrated significant associations 
with BMD parameters (Wilson et al., 2009). It is hig ly likely that the associations 
observed here between polymorphism at rs11720285, rs11130605 and rs9809315 
and BMD in women are a result of regulatory effects to the gene as opposed to 
structural changes to the FLNB protein. Firstly, these three SNPs are all located in 
either the 5’ region or intron 1 of the FLNB gene. Secondly, all three of these SNPs 
have been reported as significantly associated with FLNB mRNA expression (Wilson 
et al., 2009). Interrogation of this genomic region using the Eponine program (Down 
and Hubbard, 2002), the SwitchGear Transcription Start Site (TSS) prediction 
algorithm (Trinklein et al., 2003) and the Cold Spring Harbor Laboratory 
Transcriptional Regulatory Element Database (TRED) (Zhao et al., 2005a) revealed 
the presence of 4, 1 and 2 predicted regulatory elem nts respectively. However, all 7 
of these predicted regulatory elements are located within a 650 bp region 






Figure 5.3. Diagram of the 5’ end of the FLNB gene with significant SNPs and predicted regulatory elements. The approximate locations 
of the three SNPs significantly associated with BMD phenotypes, the LD blocks that they are a part of (red), and the 650 bp region containing the 
predicted regulatory regions (blue) are indicated. 
142 
An analysis of the LD surrounding the SNPs rs11720285, rs11130605 and rs9809315 
was carried out using data for the CEU population fr m the International HapMap 
Project (Phase 3 dataset) (Altshuler et al., 2010). The SNP rs11720285 was found to 
be in strong LD (r2 ≥ 0.8) with the SNPs rs4681770, rs7637505 and rs6445937; 
rs11130605 was in strong LD with rs7631741 and rs7634 53; and rs9809315 was in 
strong LD with rs13096731 and rs13071918. The locati n of these LD blocks is 
displayed in Figure 5.3. The LD block tagged by rs11720285 stretches to within 24 
Kb of the 650 bp region containing the predicted regulatory elements and the LD 
block tagged by rs11130605 spans across this 650 bp region. The LD block tagged 
by rs9809315 on the other hand is quite small and is located well away from this 
area, near the 3’ end of intron 1. These data would s ggest that polymorphism within 
the LD block tagged by rs11130605 is the most likely candidate of the three as being 
directly responsible for the regulatory effects seen on the gene. This is further 
supported by the fact that rs11130605 was also identified as the SNP most strongly 
associated with FLNB mRNA levels in the study by Wilson et al. (Wilson et al., 
2009). If this were the case, the associations seen b tween rs11720285 and 
rs9809315 and BMD phenotypes would probably be a result of the moderate LD 
between these two SNPs and rs11130605. However, it is also possible that 
polymorphism tagged by the rs11720285 and rs9809315 SNPs influences FLNB 
mRNA expression and hence BMD independently of the rs11130605 LD block 
through regulatory elements that were not identified n the above analysis. This 
theory is supported by the results from the haplotye analysis, which identified a 
strong positive influence on femoral neck BMD Z-score f the CTT haplotype which 
could indicate independent contributions from each of the three alleles.  
 
In conclusion, polymorphism at the SNPs rs11720285, rs11130605 and rs9809315, 
all of which are located in either the 5’ region or intron 1 of the FLNB gene, is 
significantly associated with BMD in Caucasian women. Therefore, the hypothesis 
has been supported by the data. The associations observed are almost certainly due to 
regulatory effects on the expression of the gene. Future studies could investigate 
exactly how these polymorphisms regulate expression of the FLNB gene (discussed 
in Chapter 7). 
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Chapter 6 – ARHGEF3 transcript profiling and effects of ARHGEF3 and 
RHOA gene knockdown on osteoblast-like and osteoclast-like cells in vitro   
6.1 Introduction 
Rho proteins are thought to be involved in multiple biological processes in numerous 
tissue types, some of which include: gene transcription, vesicle trafficking, 
microtubule dynamics, establishment of cell polarity, ntegrin signalling, cell cycle 
progression and actin cytoskeletal reorganisation (Etienne-Manneville and Hall, 
2002). Activation of the RHOA protein can occur in response to extracellular stimuli 
from a number of cytokines, growth factors, hormones, integrins and adhesion 
molecules. Most of these activate RHOA through G-protein coupled receptors 
(GPCRs), a large family of transmembrane receptors hat transfer extracellular 
signals into the interior of a cell. The GPCRs use various guanine nucleotide binding 
proteins (G-proteins) for signal transduction, some of which activate RHOA though 
regulation of the RhoGEFs (Siehler, 2009, Meyer et al., 2008). RHOA can also be 
activated by the ephrin A receptors through the neuronal GEF (NGEF) (Shamah et 
al., 2001), the insulin-like growth factor 1 receptor hrough forming a complex with 
ARHGEF12 (Becknell et al., 2003), and by the transmembrane receptor kinectin 1 
(Santama et al., 2004). Once activated, RHOA has been shown to interact with a 
wide variety of downstream effectors, potentially initiating a vast array of signalling 
cascades.  
 
Much evidence has been presented as to the mechanisms by which activated RHOA 
influences the actin cytoskeleton. Watanabe et al. identified diaphanous homolog 1 
(DIAPH1) as a downstream effector of RHOA (Watanabe et al., 1997). DIAPH1 is a 
member of the formin group of proteins that are involved in producing long, straight 
actin filaments by catalysing actin nucleation and polymerisation (Goode and Eck, 
2007). DIAPH1 was also found to bind profilin (Watanabe et al., 1997), a protein 
that promotes the polymerisation of actin (Cao et al., 1992, Pantaloni and Carlier, 
1993). RHOA, DIAPH1 and profilin were found to co-lcalise in the membrane 
ruffles of rapidly spreading cells, suggesting that DIAPH1 acts as a molecular link 
between RHOA and profilin in a cytoskeletal mechanism that appears to be involved 
with cell motility (Watanabe et al., 1997). A later study by Peck et al. identified and 
characterised a ubiquitously expressed RHOA-binding protein designated Rhophilin-
2 (Peck et al., 2002). Through studies in the HeLa cervical cancer cell line, the 
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authors produced evidence to suggest that Rhophilin-2 acts as a scaffold protein that 
increases filamentous actin turnover or limits stress fibre formation in the absence of 
high levels of RHOA activity (Peck et al., 2002). 
 
One of the main downstream effectors of RHOA is the Rho-associated coiled-coil 
containing kinase (ROCK), which controls a number of different signalling pathways 
involved with cytoskeletal reorganisation. ROCK is a serine/threonine kinase that 
phosphorylates various substrates (Riento and Ridley, 2003). One of these substrates 
is the myosin-binding subunit of myosin phosphatase, which is deactivated upon 
phosphorylation by ROCK (Kimura et al., 1996, Uehata e  al., 1997). When this is 
coupled with the ROCK-induced phosphorylation of myosin light chain (Amano et 
al., 1996), actin cross-linking by myosin is stimulated which enhances actomyosin 
contractility (Narumiya et al., 2009). ROCK has also been found to stabilise existing 
actin filaments by phosphorylating LIM-kinase, whic subsequently phosphorylates 
and deactivates cofilin (Maekawa et al., 1999), a sm ll protein that stimulates actin 
filament disassembly (Lappalainen and Drubin, 1997). A study by Hirakawa et al. in 
human umbilical vein endothelial cells has also highlighted a possible role for 
RHOA – ROCK signalling in actin cytoskeletal reorganisation mediated through 
tyrosine phosphorylation of focal adhesion kinase and paxillin (Hirakawa et al., 
2004). Figure 6.1 presents an overview of the RhoGEF/RHOA signalling pathways 
discussed in this section.  
 
As mentioned in previous chapters, the RHOA gene has been shown to have a role in 
both osteoblasts (McBeath et al., 2004, Meyers et al., 2005) and osteoclasts 
(Chellaiah et al., 2000). Given the results in thisesis showing association between 
polymorphism in the ARHGEF3 and RHOA genes and BMD in postmenopausal 
women, the role of the products of these genes in osteoblasts and osteoclasts was 
investigated. The first aim of the work presented in this chapter was to analyse 
expression of the NM_001128616 transcript variant of the ARHGEF3 gene, which 
carries the SNP rs7646054 (see Chapter 3), in osteoblast-like and osteoclast-like 
cells using quantitative real-time PCR. The second aim was to identify genes, from a 
list of candidates, whose expression was influenced by knockdown of the ARHGEF3 
and RHOA genes in osteoblast-like and osteoclast-like cells using microarray.  




Figure 6.1. Schematic diagram of proposed mechanisms by which the RhoGEF/RHOA signalling pathways control cytoskeletal actin 
dynamics. 
146 
microarray findings, since this technique is considere  to be an appropriate method 
of confirming microarray-generated data (Provenzano d Mocellin, 2007). The third 
aim of this chapter was to determine whether knockdwn of the ARHGEF3 and 
RHOA genes influences the resorptive capabilities of osteoclast-like cells.   
 
6.1.1 Hypotheses 
The NM_001128616 transcript variant of the ARHGEF3 gene is expressed in bone 
cells. 
 
Knockdown of the ARHGEF3 and RHOA genes in osteoblast-like and osteoclast-like 
cells results in significant changes to the expression of genes involved with bone cell 
function or the RHOA signalling pathway. 
 
Knockdown of the ARHGEF3 and RHOA genes in osteoclast-like cells results in 
significant changes to their bone-resorptive capabilities. 
 
6.2 Materials and methods 
6.2.1 Cell culture 
The human osteoblast-like cell lines Saos-2 (derived from osteosarcoma tissue), 
hFOB 1.19 (immortalised foetal osteoblasts) and MG-63 (derived from osteosarcoma 
tissue) were used for the gene knockdown work. These cell lines were cultured in 
DMEM (Sigma-Aldrich) pH 7.4 supplemented with 4.77 g/L HEPES, 3.7 g/L 
NaHCO3, 10 % FBS and 1 % penicillin/streptomycin (100 units penicillin and 100 
µg streptomycin per mL of media). The human BE(2)-M17 cell line (derived from 
neuroblastoma tissue) was cultured in Opti-MEM (Invitrogen) pH 7.4 supplemented 
with 2.4 g/L NaHCO3, 5 % foetal bovine serum (FBS) and 1 % 
penicillin/streptomycin. Peripheral blood mononuclear cells/osteoclast-like cells 
(described below) were cultured in α-MEM (Invitrogen) pH 7.4 supplemented with 
2.2 g/L NaHCO3, 10 % FBS and 1 % penicillin/streptomycin. All cell culture media 
was sterilised prior to addition of FBS by filtration through a 0.8 µm filter. All cells 
were cultured at 37 ºC with 5 % CO2 and the medium was changed every 2 – 3 days. 
Total RNA was harvested from each culture using the RNeasy Mini Kit (QIAGEN) 
and reverse transcription of the RNA was performed using the QuantiTect Reverse 
Transcription Kit (QIAGEN) (see Chapter 2 for a full description of these 
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techniques). Quantitation of total RNA was performed using an ND-1000 
spectrophotometer (NanoDrop Technologies).  
 
6.2.2 Isolation of peripheral blood mononuclear cells and osteoclastogenesis 
Osteoclast-like cells were differentiated from periheral blood mononuclear cells 
isolated from 4 donors: a 47 year old Caucasian male (donor 1), a 28 year old 
Caucasian male (donor 2), a 56 year old Caucasian male (donor 3) and a 62 year old 
Caucasian male (donor 4). Each batch of cells was isolated from 30 mL whole blood 
collected in 10 mL K2EDTA Vacutainer tubes (Becton, Dickinson and Company). 
Anti-coagulated whole blood samples were centrifuged at 2,200 rpm for 10 min at 
room temperature before buffy coats were collected an  diluted to a total volume of 
4 mL with 1X PBS (phosphate buffered saline, Appendix I). The cell suspension was 
then gently layered over 3 mL of Ficoll-Paque (Pharmacia) before being centrifuged 
again at 1,600 rpm for 40 min at room temperature. Th  top layer of plasma was then 
removed before the lymphocyte layer was collected and transferred to a clean tube. 
These cells were gently re-suspended in 6 mL 1X PBSand centrifuged at 800 rpm 
for 10 min at room temperature. The supernatant was then removed and this wash 
step was repeated. The washed cells were re-suspended in 5 mL medium 
supplemented with 10 ng/mL macrophage colony stimulating factor (M-CSF) and 
seeded directly into either a 24-well tissue culture plate or 25 cm2 tissue culture flask. 
After two days, the medium was replaced with medium supplemented with 10 ng/mL 
M-CSF and 100 ng/mL RANKL. The cells were then grown using this medium 
formulation for 17 days while osteoclastogenesis occurred (Figure 6.2). 
 
6.2.3 siRNA knockdown  
Transfection of cells with siRNA sequences was used to knockdown expression of 
each of the ARHGEF3 and RHOA genes. Two different siRNA sequences were used 
in tandem to knockdown expression of each gene. There is evidence to suggest that 
the RHOA protein has a half-life of up to 31 hours (Backlund, 1997), therefore a 
minimum gene knockdown period of 48 hours was used to ensure that the reduction 
in expression of the RHOA gene was sufficiently prolonged so as to have an effect at 
the protein level. Negative controls treated with AllStars Negative Control siRNA 
(QIAGEN) were included in each experiment. This negative control siRNA is a 
tested and validated non-silencing siRNA that has no homology to any known 
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Figure 6.2. Peripheral blood mononuclear cells undergoing osteoclastogenesis as 
viewed under a phase contrast microscope (100X magnification). These cells 
were cultured for 16 days. Note the presence of multiple nuclei in some of the cells.
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mammalian genes and has minimal off target effects as confirmed with Affymetrix 
GeneChip arrays (QIAGEN, 2010). All knockdown experiments were performed in 
triplicate. 
 
6.2.3.i Osteoblast-like cells  
siRNA knockdown experiments were performed in 24-well tissue culture plates with 
each well containing 500 µL of the aforementioned DMEM-based culture medium. 
For the Saos-2, hFOB 1.19 and MG-63 osteoblast-like cell lines, each well was 
seeded with 5 x 104 cells. Cells were grown for 24 hours before fresh medium was 
added to each culture and transfections were performed using a final siRNA 
concentration of 30 nM for transfection. The mix used had the following composition 
and was prepared at room temperature: 
 
Component Volume (per well) 
10 µM siRNA 1.82 µL of each of the 2 
siRNA sequences 
FBS-free DMEM 96.36 µL 
HiPerFect Transfection Reagent (QIAGEN) 6 µL 
Total volume 106 µL 
 
The above transfection mix was left at room temperature for 10 min to allow 
formation of transfection complexes before 106 µL was added dropwise to each well. 
Cells in each well were incubated with the transfection mix for 48 hours at 37 ºC 
prior to washing with 1X PBS (at room temperature) and subsequent extraction of 
total RNA. 
 
6.2.3.ii Peripheral blood mononuclear cells/osteoclast-like cells  
500 µL of freshly isolated peripheral blood mononuclear cells were aliquotted into 
each of 9 wells in a 24-well tissue culture plate. After osteoclastogenesis had 
occurred, as observed microscopically and confirmed biochemically (discussed 
later), siRNA knockdown experiments were performed using a final siRNA 
concentration of 100 nM for transfection. The mixture used had the following 
composition and was prepared at room temperature: 
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Component Volume (per well) 
10 µM siRNA  6.07 µL of each of the 2 
siRNA sequences 
FBS-free α-MEM 87.86 µL 
HiPerFect Transfection Reagent (QIAGEN) 6 µL 
Total volume 106 µL 
 
The above transfection mix was left at room temperature for 10 min before 106 µL 
was added dropwise to each well. Cells in each well re incubated with the 
transfection mix for 48 hours at 37 ºC prior to washing with 1X PBS (at room 
temperature) and subsequent extraction of total RNA.  
 
6.2.4 Microarray 
A microarray analysis was performed on the RNA samples extracted from the Saos-2 
cells and osteoclast-like cells from donor 1 that hd been treated with ARHGEF3, 
RHOA and negative control siRNA. This was performed to identify genes that are 
differentially expressed as a direct result of knockdown of ARHGEF3 and RHOA. 
Microarray analysis was performed using the HumanHT-12 v3 Expression BeadChip 
Kit (Illumina Inc.) and the TotalPrep RNA Amplification Kit (Applied Biosystems). 
The HumanHT-12 BeadChip profiles the expression of m re than 25,000 annotated 
genes derived from NCBI RefSeq (Build 36.2) (Illumina, 2008). An outline of the 
approach used is given below: 
 
Nine RNA samples extracted from Saos-2 cell cultures and 9 RNA samples extracted 
from osteoclast-like cell cultures (donor 1) were analysed by microarray. Each set of 
9 samples was comprised of: 3 cultures treated with siRNA specific for ARHGEF3; 3 
cultures treated with siRNA specific for RHOA; and 3 cultures treated with negative 
control siRNA. The quality and quantity of all RNA samples was checked prior to 
microarray analysis using a 2100 Bioanalyzer (Agilent Technologies). 10 µL of each 
RNA sample was subsequently processed for amplification and analysis by 
microarray. These analyses were performed by staff located in the Molecular 
Biology department at PathWest Laboratory Medicine WA.  
 
6.2.5 Gene selection 
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While data were generated for most of the 25,000 genes included on the microarray, 
only 264 candidate genes were selected for statistical analysis in order to limit the 
potential for false positives. These candidate genes w re selected on the basis of 
belonging to any of the following categories: genes thought to have a role in 
osteoblast function (45), genes thought to have a role in osteoclast function (62) or 
genes thought to be a part of the RHOA signalling pathway (157). Appendix III has a 
full list of the candidate genes analysed. 
 
6.2.6 Real-time PCR 
Quantitative real-time PCR was used to check for expr ssion of the NM_001128616 
transcript variant of the ARHGEF3 gene, determine gene knockdown levels achieved 
and to validate microarray results for selected targets (see Chapter 2 for a full 
description of the technique). This was performed on cDNA template using SYBR 
Green technology. cDNA samples were diluted in 1X TE buffer (Tris-EDTA buffer, 
Appendix I) before analysis. QuantiTect Primer Assay  (QIAGEN) were used to 
amplify most gene transcript sequences. Bioinformatics analysis revealed that the 
QuantiTect Primer Assay for the ACTA2 gene only amplifies one of the two 
transcript variants for this gene. Therefore, custom primer pairs were designed for 
this gene and the NM_001128616 transcript from the ARHGEF3 gene using the web-
based Primer3 software package (Rozen and Skaletsky, 2000) (see Appendix II for 
primer sequences). The human 18S ribosomal RNA gene(RRN18S), which has been 
validated as a suitable internal reference (housekeeping gene) for quantitative real-
time PCR in a variety of human tissues (Aerts et al., 2004, Banda et al., 2008, 
Catalan et al., 2007), was selected as an internal reference for this work. The purpose 
of the internal reference is to allow for normalisation of the data for variations in the 
quantity of cDNA added to each reaction. The reaction efficiency of each primer pair 
was calculated by amplifying a 10-fold dilution series of target sequence across 5 
orders of magnitude. This was performed to confirm that the reaction efficiency of 
each gene of interest is no more than 10 % from that of the internal reference as 
recommended by Schmittgen and Livak (Schmittgen and Livak, 2008). The log 
template dilution (x-axis) was plotted against the cycle threshold (CT) value obtained 
for each dilution (y-axis) with the slope of the line put into the equation m = - (1 / log 
E), where m is the slope of the line and E is the reaction efficiency. A reaction 
efficiency of 2.0 equates to a perfect doubling of amplicon product during each PCR 
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cycle. All reactions were performed in triplicate with the mean CT value used in the 
statistical analysis. The reaction efficiencies derived from these experiments are 
shown in Table 6.1. Melting-curve analysis was performed on all real-time PCR 
products to confirm amplification of a single sequenc  (see Chapter 2 for a full 
description of this technique). A random selection f PCR products were also 
subjected to agarose gel electrophoresis for additional confirmation of the specificity 
of amplification.  
 
6.2.7 Bone resorption assays 
Essentially, this involved incubation of osteoclast-like cells on bone slices and 
monitoring of the subsequent resorption pit formation. Osteoclast-like cells from 
donor 1 were grown on bovine bone slices to determine whether knockdown of the 
ARHGEF3 or RHOA genes affects their resorption capabilities. Peripheral blood 
mononuclear cells were isolated from 30 mL whole blood and seeded into a 25 cm2 
tissue culture flask. Osteoclastogenesis was induced for 10 – 14 days (as described 
previously), by which time the cells had differentiated into small multinucleated 
osteoclasts. At this point, the cells were detached from the tissue culture flask using 
Cell Dissociation Solution (Sigma-Aldrich), since if left to differentiate for longer 
they become very difficult to detach. Processing of the cells for resorption studies 
was then performed according to the standard protocols established by Prof Jiake Xu 
and colleagues (Centre for Orthopaedic Research, The University of Western 
Australia). The detached osteoclasts were pelleted by centrifugation at 1,500 rpm for 
5 min and resuspended in fresh medium supplemented with 10 ng/mL M-CSF and 
100 ng/mL RANKL. 100 µL of the cell suspension was then seeded into each of 18 
wells containing a slice of bovine bone in a 96-well tissue culture plate. The cells 
were left for 2 hours to attach to the bone slices b fore the medium was removed and 
replaced with 50 µL of fresh medium. Transfection was then performed using a final 
siRNA concentration of 100 nM. The mix used had the following composition and 
was prepared at room temperature:  
 
Component Volume (per well) 
10 µM siRNA 1 µL of each of the 2 
siRNA sequences 
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FBS-free α-MEM 47 µL 
HiPerFect Transfection Reagent (QIAGEN) 1 µL 
Total volume 50 µL 
 
The above transfection mix was left at room temperature for 10 min before 50 µL 
was added dropwise to each well. Cells in each well re incubated with the 
transfection mix for 96 hours at 37 ºC. Each bone slic  was then removed and either 
stained for the osteoclast marker, tartrate resistant acid phosphatase (TRAP), or 
gently scrubbed to remove the osteoclast-like cells and analysed for resorption pit 
formation. The resorption pit analyses were performed on 2 bone chips for each 
treatment. Light microscopy was used to confirm the pr sence of resorption pits on 
each bone chip (Figure 6.3) and a NewView 6300 3D Optical Profilometer (Zygo 
Corp.) was used in conjunction with the MetroPro v8.2.0 (Zygo Corp.) software 
package to quantitate the volume of each resorption pit (Figure 6.4). The volume of 
each resorption pit was measured 3 times with the mean of these 3 readings used in 
the statistical analysis. 
 
6.2.8 TRAP staining 
Osteoclast-like cells were TRAP stained (using a chromogenic TRAP enzyme 
substrate) to confirm production of the TRAP enzyme as an indicator of the 
osteoclast phenotype. This involved washing the cells with 1X PBS, fixation with 4 
% paraformaldehyde for 15 min, washing 3 times with 1X PBS before incubation 
with filtered TRAP stain solution (Appendix I) at 37 °C for 25 min. The stained cells 
were then washed 3 times with 1X PBS prior to visual ation using light microscopy 
(Figure 6.5).  
 
6.2.9 Statistical analysis 
6.2.9.i Microarray  
Differential expression analysis of the microarray data using the Illumina custom 
error model was performed using the BeadStudio v3.4.0 (Illumina Inc.) software 
package. Samples treated with the negative control siRNA were specified as the 
reference group. The raw microarray gene expression data were normalised using the 
quantile normalisation algorithm (Bolstad et al., 2003), which adjusts the sample 
signals to minimise the influence of variation arising from non-biological factors (eg. 
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Table 6.1. Quantitative real-time PCR primer pair reaction efficiencies. 











A reaction efficiency of 2.0 is equivalent to a perfect doubling of target sequence 
during each PCR cycle. 
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Figure 6.3. Image of an osteoclast resorption pit as viewed under a light 
microscope using 200X magnification. The location of the resorption pit is 
indicated by the arrow. 
156 
 
Figure 6.4. Image of an osteoclast resorption pit as viewed using a NewView 
6300 3D Optical Profilometer. The depth of the pit is delineated by colour, blue 
being the deepest, and orange/yellow being the shallowest. 
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Figure 6.5. Image of TRAP stained osteoclast-like cells attached to a bovine 
bone slice as viewed under a light microscope (250X magnification). The location 
of a TRAP stained osteoclast-like cell is indicated by the arrow. 
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pipetting variation) (Illumina, 2007). Background subtraction was performed on the 
data to minimise the variation in background noise between arrays and to remove 
signal resulting from non-specific hybridisation (Dunning et al., 2008). Once 
background subtraction has been performed on the data, the expected signal for 
unexpressed targets is zero. The data were corrected for multiple testing using the 
Benjamini-Hochberg False Discovery Rate algorithm (Benjamini and Hochberg, 
1995).  
 
6.2.9.ii Real-time PCR  
Gene expression ratios were calculated using the comparative CT method as 
described by Schmittgen and Livak (Schmittgen and Livak, 2008). Briefly, the ∆CT 
(CT of the test gene - CT of the internal reference) was calculated for each gene of 
interest in each sample in the test and control groups. This figure was then entered 
into the equation 2-∆CT with the mean ± standard deviation calculated for each of the 
test and control groups. The mean of the test group was then divided by the mean of 
the control group to generate the expression ratio. An unpaired t-test was performed 
comparing the 2-∆CT data from the test group with the control group to determine 
whether differences in expression observed were statistic lly significant.  
 
6.2.9.iii Bone resorption assays  
The volume of each resorption pit recorded for each of the knockdown groups was 
compared with the negative control group using an unpaired t-test. Throughout, two-
tailed P-values are reported, with P ≤ 0.05 considered significant.  
 
6.3 Results 
6.3.1 NM_001128616 transcript profiling in bone cells 
As mentioned in Chapter 3, the ARHGEF3 SNP rs7646054 that was found to be 
significantly associated with BMD is located within the 5’ UTR of a recently 
described transcript variant of the gene designated NM_001128616 (Totoki et al., 
2007). To determine whether this transcript variant is expressed in osteoblast-like 
cells, cDNA from the Saos-2 cell line was subjected to real-time PCR using 2 primer 
pairs: one designed to amplify all ARHGEF3 transcript variants and one designed to 
amplify a sequence that is specific for the 5’ UTR of the NM_001128616 transcript. 
While expression of the ARHGEF3 gene was confirmed in this cell type, no 
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NM_001128616-specific amplification was detected. Since the NM_001128616 
transcript variant was originally discovered in brain tissue (Totoki et al., 2007), 
cDNA from the neuroblastoma cell line BE(2)-M17 was checked for presence of the 
transcript as this cell line more closely resembles the cell type found in brain tissue. 
Again, expression of the ARHGEF3 gene was confirmed in this cell type but no 
NM_001128616-specific amplification was detected. Finally, cDNA from each of 
the 4 batches of osteoclast-like cells (obtained from 4 different donors) and the hFOB 
1.19 and MG-63 osteoblast-like cell lines were also checked for presence of the 
transcript. All 6 of these cell types were found to express the ARHGEF3 gene. 
Neither of the hFOB 1.19 or MG-63 osteoblast-like cell lines were found to express 
NM_001128616, however all 4 batches of osteoclast-like cells were found to express 
the transcript. Therefore, the osteoclast-like cells were the only cell type found to 
express the NM_001128616 transcript variant of the ARHGEF3 gene. 
 
6.3.2 Microarray and real-time PCR in osteoblast-like cells 
6.3.2.i Microarray results 
Knockdown of the ARHGEF3 and RHOA genes was confirmed by quantitative real-
time PCR prior to microarray analysis. For the ARHGEF3 and RHOA genes, a mean 
knockdown of 81 % and 79 % was achieved respectively in the Saos-2 cells (Table 
6.2a and 6.2b). Out of the 202 candidate genes examined in the osteoblast-like cells, 
ARHGEF3 and RHOA knockdown resulted in significant changes in expression of 8 
and 2 genes respectively after adjustment for multiple testing (Table 6.3 and Table 
6.4). For the ARHGEF3 knockdown cultures, the genes that were found to be 
influenced by knockdown include: TNFRSF11B, SP7, ALPL, ANGPTL2, GNA11, 
MYO9B, GNAI2 and PFN1. For the RHOA knockdown cultures, the genes that were 
found to be influenced by knockdown include: PTH1R and ACTA2. 
 
6.3.2.ii Confirmation of microarray results by real-time PCR 
Two of the differentially regulated genes from each of the ARHGEF3 and RHOA 
knockdown groups were selected for confirmation andreplication analysis. These 
genes were selected based on a number of factors includi g their potential relevance 
in bone metabolism (Table 6.5), their level of expression in the cell type and the size 
and statistical significance of the regulatory effect. The 2 genes selected from the 
ARHGEF3 knockdown experiments were TNFRSF11B and ALPL; those selected 
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Table 6.2a. Quantitative real-time PCR validation of ARHGEF3 gene knockdown in each cell type. 
Cell type 2-∆CT test group 2-∆CT control group Expression ratio P 
Saos-2 (first batch) 7.8 x 10-6 ± 7.8 x 10-7 4.1 x 10-5 ± 5.2 x 10-6 0.19 < 0.001 
Saos-2 (second batch) 6.6 x 10-6 ± 7.9 x 10-7 2.6 x 10-5 ± 2.1 x 10-6 0.25 < 0.001 
hFOB 1.19 5.9 x 10-6 ± 7.8 x 10-7 2.4 x 10-5 ± 2.1 x 10-6 0.25 < 0.001 
MG-63 3.1 x 10-6 ± 2.6 x 10-7 1.9 x 10-5 ± 1.4 x 10-6 0.16 < 0.001 
Osteoclast-like (donor 1) 8.9 x 10-5 ± 8.5 x 10-6 2.4 x 10-4 ±5.8 x 10-6 0.37 < 0.001 
Osteoclast-like (donor 2) 5.5 x 10-4 ± 9.9 x 10-5 9.2 x 10-4 ± 2.8 x 10-5 0.59 0.003 
Osteoclast-like (donor 3) 3.2 x 10-4 ± 9.1 x 10-5 6.8 x 10-4 ± 1.1 x 10-4 0.48 0.01 
Osteoclast-like (donor 4) 6.7 x 10-4 ± 5.7 x 10-5 8.8 x 10-4 ± 2.1 x 10-4 0.75 0.15 
2-∆CT values are given as mean ± SD. 
Expression ratios are given as expression of the gen in the knockdown cultures relative to the negative control cultures. 
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Table 6.2b. Quantitative real-time PCR validation of RHOA gene knockdown in each cell type. 
Cell type 2-∆CT test group 2-∆CT control group Expression ratio P 
Saos-2 (first batch) 1.4 x 10-3 ± 1.1 x 10-4 6.5 x 10-3 ± 4.4 x 10-4 0.21 < 0.001 
Saos-2 (second batch) 1.5 x 10-3 ± 2.3 x 10-4 4.7 x 10-3 ± 2.5 x 10-4 0.32 < 0.001 
hFOB 1.19 1.1 x 10-3 ± 1.8 x 10-4 4.9 x 10-3 ± 4.1 x 10-4 0.23 < 0.001 
MG-63 6.4 x 10-4 ± 2.6 x 10-4 3.8 x 10-3 ± 2.9 x 10-4 0.17 < 0.001 
Osteoclast-like (donor 1) 8.4 x 10-4 ± 6.7 x 10-5 5.4 x 10-3 ± 2.0 x 10-4 0.16 < 0.001 
Osteoclast-like (donor 2) 4.2 x 10-3 ± 3.6 x 10-4 6.6 x 10-3 ± 2.8 x 10-4 0.64 < 0.001 
Osteoclast-like (donor 3) 2.4 x 10-3 ± 2.7 x 10-4 4.4 x 10-3 ± 3.2 x 10-4 0.55 0.001 
Osteoclast-like (donor 4) 3.5 x 10-3 ± 3.6 x 10-4 5.2 x 10-3 ± 3.4 x 10-4 0.68 0.004 
2-∆CT values are given as mean ± SD. 
Expression ratios are given as expression of the gen in the knockdown cultures relative to the negative control cultures. 
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Table 6.3. List of genes significantly influenced by ARHGEF3 knockdown in Saos-2 osteoblast-like cells as determined by microarray 
analysis. 
Gene Gene product Mean signal – knockdown 
(fluorescence units) 





TNFRSF11B Osteoprotegerin 235 308 0.76  < 0.001  
SP7 Osterix 434 381 1.14 0.007 
ALPL Alkaline phosphatase 19262 17173 1.12  0.03  
ANGPTL2 Angiopoietin-like 2 81 50 1.64 < 0.001 
GNA11 Guanine nucleotide binding protein alpha 11 352 469 0.75 0.002 
MYO9B Myosin IXB 165 212 0.78 0.005 
GNAI2 Guanine nucleotide binding protein alpha 
inhibiting activity polypeptide 2 
1106 1330 0.83 0.006 
PFN1 Profilin 1 7458 8220 0.91 0.02 
Expression ratios are given as expression of the gen in the knockdown cultures relative to the negative control cultures. 
P values have been adjusted for multiple testing. 
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Table 6.4. List of genes significantly influenced by RHOA knockdown in Saos-2 osteoblast-like cells as determined by microarray 
analysis. 
Gene Gene product Mean signal – knockdown 
(fluorescence units) 





PTH1R Parathyroid hormone 1 receptor 1166 492 2.37  0.002  
ACTA2 Alpha 2 actin, smooth muscle 3059 7812 0.39  < 0.001  
Expression ratios are given as expression of the gen in the knockdown cultures relative to the negative control cultures. 
P values have been adjusted for multiple testing. 
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Table 6.5. Genes selected for confirmation and replication analysis in the osteoblast-like cells. 
Gene Potential relevance of gene product in bone metabolism 
TNFRSF11B OPG is an osteoblast-produced decoy receptor for RANKL that primarily works to inhibit osteoclastogenesis (Hofbauer and 
Schoppet, 2004). OPG has also been shown to have a rol in suppressing osteoclast survival (Akatsu et al., 1998), activity 
(Hakeda et al., 1998) and attachment to bone surfaces (O'Brien et al., 2000). Polymorphism within the TNFRSF11B gene has 
been identified as significantly associated with BMD in multiple studies (Richards et al., 2009, Richards et al., 2008, 
Rivadeneira et al., 2009, Styrkarsdottir et al., 2008). Refer to Chapter 1, section 1.4.2.ii  for more information. 
ALPL Alkaline phosphatase is a membrane-bound enzyme that is expressed at high levels in osteoblasts and is thought to play a role 
in tissue mineralisation (Rodan, 1992). Increased circulating levels of the enzyme are often seen in bo e disorders such as 
Paget’s disease (Golob et al., 1996) and osteomalacia (softening of the bones due to defective bone mineralisation) (Rendina et 
al., 2009). 
PTH1R A receptor for PTH and PTH-related protein that is expressed on the surface of osteoblasts and is responsible for mediating 
some of the effects of PTH on bone (discussed in Chapter 1). Mutations in the PTH1R gene have been implicated in Ollier 
disease (Rendina et al., 2009), which is characterised by the presence of multiple enchondromas (cartilaginous tumours) in the 
bone marrow (Silve and Juppner, 2006). 
ACTA2 A cytoskeletal protein that appears to be a part of the RHOA signalling pathway (Mack et al., 2001, Zhao et al., 2007), 
expression of which has been found to be reduced during osteochondrogenesis of smooth muscle cells (Speer et al., 2010, 
Zebboudj et al., 2003). 
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from the RHOA knockdown experiments were PTH1R and ACTA2. Quantitative real-
time PCR data confirmed the microarray findings in these samples except for the 
increased expression of the ALPL gene in the ARHGEF3 knockdown Saos-2 cells, 
which could not be confirmed as statistically significant (Table 6.6).  
 
A second set of ARHGEF3 and RHOA knockdown experiments was performed in 
Saos-2 cells in an effort to validate the quantitative real-time PCR results. Mean 
knockdown levels of 75 % and 68 % were achieved for the ARHGEF3 and RHOA 
genes respectively as determined by quantitative real-time PCR (Table 6.2a and 
6.2b). Out of the 4 genes selected for confirmation and replication analysis (2 from 
the ARHGEF3 and 2 from the RHOA knockdown groups), the significant findings for 
the TNFRSF11B, PTH1R and ACTA2 genes were replicated (Table 6.6). The ALPL 
gene, which was found to be significantly up-regulated in response to ARHGEF3 
knockdown in the microarray analysis, was found to be significantly down-regulated 
by ARHGEF3 knockdown in the second batch of Saos-2 cells (Table 6.6).  
 
Two additional osteoblast-like cell lines, hFOB 1.19 and MG-63, were also used for 
further replication analyses. In the hFOB 1.19 cellline, a mean knockdown of 75 % 
and 77 % was achieved for the ARHGEF3 and RHOA genes respectively (Table 6.2a 
and 6.2b). In the MG-63 cell line, a mean knockdown of 84 % and 83 % was 
achieved for the ARHGEF3 and RHOA genes respectively (Table 6.2a and 6.2b). Out 
of the 4 genes selected for confirmation and replication analysis, the down-regulation 
of the TNFRSF11B gene in response to ARHGEF3 knockdown was replicated in the 
hFOB 1.19 cells and the down-regulation of the ACTA2 gene in response to RHOA 
knockdown was replicated in both the hFOB 1.19 and MG-63 cells (Table 6.6). The 
up-regulation of the ALPL gene in response to ARHGEF3 knockdown in the batch of 
Saos-2 cells analysed by microarray was replicated in the MG-63 cells (Table 6.6). 
Expression of the PTH1R gene was not detected in the hFOB 1.19 or MG-63 cell 
lines, therefore possible regulatory effects could not be studied. Overall, the down-
regulation of the ACTA2 gene in response to RHOA knockdown was the most 
consistent result observed. 
 
6.3.3 Microarray and real-time PCR in osteoclast-like cells 




Table 6.6. Quantitative real-time PCR validation of gene regulation in osteoblast-like cells in response to ARHGEF3 and RHOA gene 
knockdown. 
Cell type Knockdown Gene amplified 2-∆CT test group 2-∆CT control group Expression ratio P 
Saos-2 (first batch) ARHGEF3 TNFRSF11B 5.9 x 10-4 ± 5.0 x 10-5 7.7 x 10-4 ± 6.1 x 10-5 0.76 0.02 
  ALPL 2.9 x 10-2 ± 1.0 x 10-3 2.7 x 10-2 ± 2.7 x 10-3 1.09 0.21 
 RHOA PTHR1 3.9 x 10-4 ± 6.0 x 10-5 2.0 x 10-4 ± 1.7 x 10-5 1.98 0.006 
  ACTA2 5.3 x 10-4 ± 5.4 x 10-5 1.7 x 10-3 ± 8.7 x 10-5 0.32 < 0.001 
Saos-2 (second batch) ARHGEF3 TNFRSF11B 4.4 x 10-4 ± 3.2 x 10-5 5.9 x 10-4 ± 4.0 x 10-5 0.73 0.006 
  ALPL 1.6 x 10-2 ± 1.1 x 10-3 2.2 x 10-2 ± 1.4 x 10-3 0.75 0.007 
 RHOA PTHR1 2.3 x 10-4 ± 2.6 x 10-5 1.4 x 10-4 ± 3.6 x 10-5 1.60 0.03 
  ACTA2 7.8 x 10-4 ± 4.6 x 10-5 2.2 x 10-3 ± 1.8 x 10-5 0.35 < 0.001 
hFOB 1.19 ARHGEF3 TNFRSF11B 2.6 x 10-4 ± 1.0 x 10-5 3.7 x 10-4 ± 2.6 x 10-5 0.72 0.003 
  ALPL 5.7 x 10-5 ± 1.8 x 10-6 6.2 x 10-5 ± 6.9 x 10-6 0.92 0.29 
 RHOA PTHR1 - - - - 
  ACTA2 2.1 x 10-4 ± 1.2 x 10-5 4.2 x 10-4 ± 4.0 x 10-5 0.50 < 0.001 
MG-63 ARHGEF3 TNFRSF11B 8.2 x 10-3 ± 1.2 x 10-3 8.0 x 10-3 ± 7.4 x 10-4 1.02 0.83 
  ALPL 4.3 x 10-5 ± 2.7 x 10-6 3.7 x 10-5 ± 2.3 x 10-6 1.16 0.04 
 RHOA PTHR1 - - - - 
  ACTA2 4.2 x 10-5 ± 1.3 x 10-5 1.3 x 10-4 ± 8.5 x 10-6 0.34 < 0.001 
2-∆CT values are given as mean ± SD. 
Expression ratios are given as expression of the gen in the knockdown cultures relative to the negative control cultures. 
The second batch of Saos-2 cells was used to validate the results obtained from the first before proceeding with the additional cell lines. 
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In the osteoclast-like cells, knockdown of the ARHGEF3 and RHOA genes was 
confirmed by quantitative real-time PCR prior to microarray analysis. For the 
ARHGEF3 and RHOA genes, a mean knockdown of 63 % and 84 % was achieved 
respectively in the osteoclast-like cells from donor 1 (Table 6.2a and 6.2b). 
Expression of the genes encoding the osteoclastic bio hemical markers TRAP 
(ACP5), cathepsin K (CTSK) and calcitonin receptor (CALCR) was confirmed from 
the microarray output. The ACP5 and CTSK genes were found to be expressed at 
particularly high levels in this cell type (mean microarray signal > 14,000 
fluorescence units). Out of the 219 candidate genes xamined in the osteoclast-like 
cells, ARHGEF3 and RHOA knockdown resulted in significant changes in expression 
of 12 and 9 genes respectively after adjustment for multiple testing (Table 6.7 and 
Table 6.8). For the ARHGEF3 knockdown cultures, the genes that were found to be 
influenced by knockdown include: CCL5, HLA-C, SNCA, TNF, OSCAR, CD44, 
BIRC3, ITGB7, ITGAE, ITGAL, ITGA3 and ITGAM. For the RHOA knockdown 
cultures, the genes that were found to be influenced by knockdown include: TNF, 
THBS2, CCL5, ITGB7, ARHGDIA, IGF1, ACTA2, MYL9 and ITGAE. Of these, the 
influence of RHOA knockdown on expression of the ACTA2 gene was also observed 
in the osteoblast-like cells. 
 
6.3.3.ii Confirmation of microarray results by real-time PCR 
Two of the differentially regulated genes from each of the ARHGEF3 and RHOA 
knockdown experiments were selected for confirmation and replication analysis. 
These genes were selected based on a number of factrs including their potential 
relevance in bone metabolism (Table 6.9), their level of expression in the cell type 
and the size and statistical significance of the regulatory effect. The 2 genes selected 
from the ARHGEF3 knockdown experiments were CCL5 and OSCAR; those selected 
from the RHOA knockdown experiments were ARHGDIA and ACTA2. Quantitative 
real-time PCR was able to confirm the microarray findings in these samples (Table 
6.10). 
 
Replication of the regulatory effects observed in response to ARHGEF3 and RHOA 
knockdown in the osteoclast-like cells from donor 1 was attempted in osteoclast-like 
cells from 3 additional donors. In the cells obtained from donor 2, a mean 
knockdown of 41 % and 36 % was achieved for the ARHGEF3 and RHOA genes 
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Table 6.7. List of genes significantly influenced by ARHGEF3 knockdown in osteoclast-like cells as determined by microarray analysis. 
Gene Gene product Mean signal – knockdown 
(fluorescence units) 





CCL5 Chemokine ligand 5 4402 588 7.48  < 0.001  
HLA-C Major histocompatibility complex, class I, C 235 87 2.71 < 0.001 
SNCA Synuclein, alpha 129 260 0.49 < 0.001 
TNF Tumour necrosis factor alpha 420 156 2.69 < 0.001 
OSCAR Osteoclast associated immunoglobulin-like receptor 1950 1244 1.57  0.01  
CD44 CD44 molecule 2279 3360 0.68 0.03 
BIRC3 Baculoviral IAP repeat-containing 3 496 321 1.55 0.04 
ITGB7 Integrin, beta 7 588 106 5.54 < 0.001 
ITGAE Integrin, alpha E 256 483 0.53 < 0.001 
ITGAL Integrin, alpha L 145 79 1.85 0.003 
ITGA3 Integrin, alpha 3 107 221 0.48 0.003 
ITGAM Integrin, alpha M 1033 1699 0.61 0.004 
Expression ratios are given as expression of the gen in the knockdown cultures relative to the negative control cultures. 
P values have been adjusted for multiple testing. 
Osteoclast-like cells derived from donor 1. 
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Table 6.8. List of genes significantly influenced by RHOA knockdown in osteoclast-like cells as determined by microarray analysis. 
Gene Gene product Mean signal – knockdown 
(fluorescence units) 





TNF Tumour necrosis factor alpha 345 156 2.21 < 0.001 
THBS2 Thrombospondin 2 89 43 2.05 < 0.001 
CCL5 Chemokine ligand 5 891 588 1.52 0.006 
ITGB7 Integrin, beta 7 246 106 2.32 < 0.001 
ARHGDIA Rho GDP dissociation inhibitor alpha 579 998 0.58  < 0.001 
IGF1 Insulin-like growth factor 1 121 42 2.86 < 0.001 
ACTA2 Alpha 2 actin, smooth muscle 545 965 0.56  0.001  
MYL9 Myosin, light chain 9, regulatory 22 49 0.46 0.04 
ITGAE Integrin, alpha E 342 483 0.71 0.04 
Expression ratios are given as expression of the gen in the knockdown cultures relative to the negative control cultures. 
P values have been adjusted for multiple testing. 
Osteoclast-like cells derived from donor 1. 
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Table 6.9. Genes selected for confirmation and replication analysis in the osteoclast-like cells. 
Gene Potential relevance of gene product in bone metabolism 
CCL5 The product of the CCL5 gene is a chemoattractant cytokine (Schall et al., 1990) that has been implicated in rheumatoid 
arthritis, osteoarthritis (Lisignoli et al., 2002, Volin et al., 1998) and osteomyelitis (infection of the bone) (Wright and 
Friedland, 2002). Expression of CCL5 has been shown to be induced during osteoclast differentiation (Day et al., 2004) and 
there is evidence to suggest that CCL5 produced by osteoclasts induces osteoblast chemotaxis (Yano et al., 2005).  
OSCAR An osteoclast-associated receptor that is expressed in preosteoclasts and mature osteoclasts and may play a critical role in 
osteoclast differentiation (Kim et al., 2002). OSCAR expression has been found to be up-regulated in circulating monocytes 
obtained from rheumatoid arthritis patients and expr ssion of the receptor seems to be related to the inflammatory activity of 
the disease (Herman et al., 2008).  
ARHGDIA The product of the ARHGDIA gene is a Rho GDP dissociation inhibitor that inhibits RHOA activation (DerMardirossian and 
Bokoch, 2005), effectively working in an opposite manner to ARHGEF3. A recent study has suggested that expression of 
ARHGDIA is significantly up-regulated in rat osteoblasts trea ed with PTH in vivo and in vitro (Sun et al., 2009). 
ACTA2 See Table 6.5. 
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Table 6.10. Quantitative real-time PCR validation of gene regulation in osteoclast-like cells in response to ARHGEF3 and RHOA gene 
knockdown. 
Cell source Knockdown Gene amplified 2-∆CT test group 2-∆CT control group Expression ratio P 
Donor 1 ARHGEF3 CCL5 4.1 x 10-3 ± 1.3 x 10-3 5.5 x 10-4 ± 1.2 x 10-4 7.49 0.008 
  OSCAR 1.1 x 10-3 ± 3.9 x 10-5 8.9 x 10-4 ± 8.4 x 10-5 1.27 0.01 
 RHOA ARHGDIA 1.0 x 10-3 ± 1.2 x 10-4 1.8 x 10-3 ± 1.4 x 10-4 0.57 0.002 
  ACTA2 1.1 x 10-4 ± 9.0 x 10-6 1.9 x 10-4 ± 1.8 x 10-5 0.62 0.003 
Donor 2 ARHGEF3 CCL5 1.6 x 10-3 ± 2.6 x 10-4 2.3 x 10-3 ± 1.1 x 10-4 0.67 0.009 
  OSCAR 1.8 x 10-4 ± 2.6 x 10-5 2.2 x 10-4 ± 1.7 x 10-5 0.84 0.13 
 RHOA ARHGDIA 1.2 x 10-3 ± 9.4 x 10-5 1.7 x 10-3 ± 8.2 x 10-5 0.74 0.004 
  ACTA2 7.7 x 10-4 ± 1.1 x 10-4 7.8 x 10-4 ± 4.7 x 10-5 0.98 0.86 
Donor 3 ARHGEF3 CCL5 1.9 x 10-3 ± 3.8 x 10-4 5.3 x 10-3 ± 8.9 x 10-4 0.36 0.004 
  OSCAR 4.0 x 10-4 ± 6.2 x 10-5 5.0 x 10-4 ± 1.2 x 10-4 0.81 0.30 
 RHOA ARHGDIA 8.6 x 10-4 ± 1.4 x 10-4 1.1 x 10-3 ± 1.2 x 10-4 0.81 0.14 
  ACTA2 5.8 x 10-4 ± 1.1 x 10-5 7.1 x 10-4 ± 1.3 x 10-5 0.82 < 0.001 
Donor 4 ARHGEF3 CCL5 2.2 x 10-3 ± 7.4 x 10-4 3.0 x 10-3 ± 5.9 x 10-4 0.72 0.19 
  OSCAR 2.9 x 10-4 ± 3.7 x 10-5 3.1 x 10-4 ± 3.1 x 10-5 0.96 0.66 
 RHOA ARHGDIA 8.8 x 10-4 ± 8.3 x 10-5 1.0 x 10-3 ± 1.0 x 10-4 0.85 0.11 
  ACTA2 8.7 x 10-4 ± 6.1 x 10-5 1.0 x 10-3 ± 7.5 x 10-5 0.88 0.09 
2-∆CT values are given as mean ± SD. 
Expression ratios are given as expression of the gen in the knockdown cultures relative to the negative control cultures. 
172 
respectively (Table 6.2a and 6.2b). In the cells obtained from donor 3, a mean 
knockdown of 52 % and 45 % was achieved for the ARHGEF3 and RHOA genes 
respectively (Table 6.2a and 6.2b). In the cells obtained from donor 4, a mean 
knockdown of 25 % and 32 % was achieved for the ARHGEF3 and RHOA genes 
respectively (Table 6.2a and 6.2b). Consistent replication of the findings from the 
microarray analysis proved difficult in this cell type. However, the down-regulation 
of the ARHGDIA and ACTA2 genes observed in response to RHOA knockdown was 
replicated in the cells obtained from donor 2 and donor 3 respectively (Table 6.10). 
The CCL5 gene, which was found to be significantly up-regulated in response to 
ARHGEF3 knockdown in the cells obtained from donor 1, was found to be 
significantly down-regulated in the cells obtained from donors 2 and 3 (Table 6.10). 
 
6.3.4 Bone resorption assays 
The mean resorption pit volume observed ± standard eviation was 54,441 µm3 ± 
36,693 µm3, 34,593 µm3 ± 22,194 µm3 and 45,282 µm3 ± 33,416 µm3 for the 
ARHGEF3 knockdown, RHOA knockdown and negative control cultures 
respectively. No significant differences were observed between either of the 
treatment groups and the negative control group (P = 0.47 and 0.33 for the 
ARHGEF3 and RHOA knockdown groups respectively; Figure 6.6).  
 
6.4 Discussion 
The main objectives of the work described in this chapter were to determine whether 
the NM_001128616 transcript variant of ARHGEF3 is expressed in bone cells, 
examine the influence of ARHGEF3 and RHOA knockdown on expression of genes 
relevant to bone metabolism and the RHOA signalling pathway in osteoblast-like and 
osteoclast-like cells, and to determine whether knoc d wn of ARHGEF3 and RHOA 
influences the bone resorptive capabilities of osteclast-like cells. 
 
Concerning the first objective, expression of the ARHGEF3 gene was detected in all 
cell types examined, but was substantially higher in osteoclast-like cells than in 
osteoblast-like cells (~19 fold higher in the osteoclast-like cells based on the 
microarray output). However, expression of the NM_001128616 transcript variant of 
the ARHGEF3 gene was detected only in the osteoclast-like cells. It is possible that 




Figure 6.6. Bone resorption pit formation of osteoclasts treated with ARHGEF3, RHOA and negative control siRNA. Neither the 
ARHGEF3 nor RHOA siRNA groups are significantly different from the n gative control siRNA group. Values are given as mean ± SEM. n = 
number of pits analysed. 
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its expression was below detectable levels, but it is also possible that osteoblasts do 
not express this particular transcript. In any case, if polymorphism at rs76546054 
influences BMD through effects on the NM_001128616 transcript variant, it seems 
more likely that this effect is mediated through the osteoclast than the osteoblast, 
although an influence through the osteoblast cannot be totally excluded. Further 
studies could focus on allele-specific expression analysis of the NM_001128616 
transcript in cells obtained from individuals that are heterozygous for polymorphism 
at rs7646054 (discussed in Chapter 7).  
 
Due to the associations identified in this thesis between polymorphism in the 
ARHGEF3 and RHOA genes and bone density in women, the effects of knckdown 
of these two genes on expression of selected candidte genes in bone cells was 
investigated. Greater gene knockdown levels were achieved in the osteoblast-like 
cells than in the osteoclast-like cells (78.7 % versus 45.2 % mean knockdown for the 
ARHGEF3 gene; and 76.7 % versus 49.3 % mean knockdown for the RHOA gene, as 
determined by quantitative real-time PCR). Concerning the studies performed in the 
osteoblast-like cells, expression of the ACTA2 gene was found to be significantly 
down-regulated by RHOA knockdown in all three osteoblast-like cell lines examined 
(Saos-2, hFOB 1.19 and MG-63), with an average expression ratio of 0.38 seen in 
knockdown cell cultures relative to control cell cultures by quantitative real-time 
PCR. The ACTA2 gene encodes an alpha actin cytoskeletal protein, and w s found to 
be expressed at high levels in the Saos-2 cell line as determined by microarray and 
quantitative real-time PCR analysis. This supports expressed sequence tag (EST) 
profile data for the gene from the NCBI database which suggest that ACTA2 mRNA 
is expressed in human bone and bone marrow. There hav  been very few studies on 
the role of the ACTA2 gene product in bone metabolism, with most studies having 
been carried out in smooth muscle cells. It is a major component of the smooth 
muscle cell contractile apparatus, accounting for ar und 40 % of the total protein and 
around 70 % of the total actin in smooth muscle cells (Fatigati and Murphy, 1984, 
Owens, 1995). There is evidence in the literature to suggest that the ACTA2 gene is 
regulated by RHOA signalling, this is discussed furthe  in Chapter 7. 
 
Knockdown of the ARHGEF3 gene in both batches of Saos-2 cells resulted in 
consistent and significant down-regulation of the levels of TNFRSF11B (OPG) 
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mRNA. This effect was replicated in the hFOB 1.19 cells, but not in the MG-63 cell 
line. It is not clear why this effect was not seen in the MG-63 cells, it may be an 
effect particular to the cell line. In addition to hese findings, knockdown of the 
RHOA gene in both batches of Saos-2 cells resulted in sig ificant up-regulation of 
PTH1R (parathyroid hormone 1 receptor) mRNA levels, although expression of this 
gene was not detected in the hFOB 1.19 or MG-63 cell lin s. These genes both have 
a major role in the mechanism by which osteoblasts stimulate osteoclastogenesis 
upon exposure to PTH, suggesting that the ARHGEF3 and RHOA genes may be 
involved in this process. Supporting evidence for this theory comes from a recent 
publication by Wang and Stern, who found that the oste clastogenic activity of 
UMR-106 rat osteoblast-like cells was inhibited when the cells were transfected with 
constitutively active Rhoa (Wang and Stern, 2010). This is discussed further in 
Chapter 7. 
 
Caution is advised in drawing any conclusions from the gene expression data in the 
osteoclast-like cells, since consistently high gene k ockdown (> 60 %) was not 
achieved in the cells obtained from donors 2, 3 and 4. Nevertheless, some interesting 
results were obtained. Expression of the ARHGDIA gene was found to be 
significantly reduced in response to RHOA gene knockdown in the osteoclast-like 
cells obtained from donors 1 and 2. The product of he ARHGDIA gene is a Rho 
GDP dissociation inhibitor (GDI) that is a negative r gulator of several of the 
RhoGTPases (DerMardirossian and Bokoch, 2005). RhoGDIs keep the Rho proteins 
in their inactive GDP-bound state by inhibiting the exchange of GDP for GTP 
(Fukumoto et al., 1990) and sequestering them in the cytosol (Olofsson, 1999). The 
down-regulation of ARHGDIA expression seen in the RHOA knockdown osteoclast-
like cells in this study could be a compensatory mechanism for the reduced 
expression of the RHOA gene. Expression of the ACTA2 gene was found to be 
significantly down-regulated in response to RHOA knockdown in the osteoclast-like 
cells obtained from donors 1 and 3. This adds further support to the earlier 
suggestion that expression of this gene is regulated by the RHOA signalling pathway. 
The inconsistent nature of the results described here for the ARHGDIA and ACTA2 
genes is probably due to the variable gene knockdown that was achieved in this cell 
type. However, it does appear that there is a trend towards down-regulation of these 
genes in response to RHOA knockdown. 
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Finally, some preliminary studies were conducted on the influence of ARHGEF3 and 
RHOA gene knockdown on osteoclast activity, as measured by resorption pit 
formation on bone slices. The osteoclast-like cells were generated in vitro from 
peripheral blood mononuclear cells and demonstrated he multi-nucleated 
morphology that is characteristic of the osteoclast cell type with production of 
TRAP. That the cells could also form resorption pits was further verification that the 
differentiation of osteoclast-like cells had been successful. However, there were no 
significant differences observed between the bone resorptive capabilities of the 
osteoclast-like cells treated with ARHGEF3 or RHOA siRNA and those treated with 
negative control siRNA. There are several possible explanations for this, one of 
which is the large amount of variation observed within each treatment group during 
the resorption pit volume analysis. Another possible explanation is the disappointing 
level of gene knockdown achieved in this cell type, as alluded to previously. As such, 
one cannot come to any firm conclusion from this negative finding. Alternative 
techniques that could be employed in future studies to achieve greater gene 
knockdown in osteoclast-like cells are discussed in Chapter 7. 
 
In conclusion, the total expression of all ARHGEF3 transcript variants appears to be 
much higher in the osteoclast-like cells examined than in the osteoblast-like cell 
lines. Expression of the NM_001128616 transcript of ARHGEF3 was detected in the 
osteoclast-like cells, therefore the hypothesis that t is transcript variant is expressed 
in bone cells has been supported by the data. The fact that this transcript only 
appeared to be expressed by the osteoclast-like cells indicates that if variation at the 
rs7646054 SNP site is directly responsible for the associations observed with BMD 
via this transcript, the effect is likely to be mediated through the osteoclast. 
Knockdown of the ARHGEF3 and RHOA genes in the three osteoblast-like cell lines 
revealed important regulatory changes, including significant down-regulation of the 
ACTA2 gene in response to RHOA knockdown in all three cell lines, significant 
down-regulation of the TNFRSF11B gene in response to ARHGEF3 knockdown in 
the Saos-2 and hFOB 1.19 cell lines, and significant up-regulation of the PTH1R 
gene in response to RHOA knockdown in the Saos-2 cell line. These results suggest 
that the RHOA gene product may regulate the expression of the ACTA2 gene, and 
that the ARHGEF3 and RHOA genes may have a role in PTH-mediated signalling in 
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the osteoblast, which could have downstream effects on osteoclastogenesis. In the 
osteoclast-like cells, greater than 60 % gene knockd wn was achieved only in the 
cells obtained from one of the donors (donor 1). Some interesting regulatory effects 
were observed in these cells, including down-regulation of both the ARHGDIA and 
ACTA2 genes in response to RHOA knockdown. The hypothesis that knockdown of 
the ARHGEF3 and RHOA genes in osteoblast-like and osteoclast-like cells 
influences the expression of genes involved with bone cell function has been 
supported to some degree (for example, the influence of RHOA knockdown on 
ACTA2 expression in the osteoblast-like cells), although clearly additional validation 
is required for a number of the genes examined, especially in the osteoclast-like cells.  
No significant effects on the bone-resorptive capabilities of the osteoclast-like cells 
were observed as a result of ARHGEF3 or RHOA knockdown, therefore the 
hypothesis that knockdown of these genes would influe ce their bone resorptive 
capabilities has not been supported by the data. However, this could be due to 
insufficient gene knockdown. Future studies could attempt replication of some of the 
other significant gene regulatory findings from themicroarray analysis. 
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Chapter 7 – General discussion and conclusion 
7.1 Role of the ARHGEF3, RHOA and FLNB genes in BMD regulation 
The studies presented in this thesis provide evidence to suggest that common 
polymorphism within the ARHGEF3, RHOA and FLNB genes may have a role in 
BMD regulation. These three genes are all located within the 3p14-p22 chromosomal 
region, which has been identified by multiple genome-wide linkage (GWL) studies 
as a potential quantitative trait locus for BMD (Duncan et al., 1999, Lee et al., 2006, 
Wilson et al., 2003, Wynne et al., 2003, Xiao et al., 2006). Interestingly, all three of 
these genes appear to have a role in cytoskeletal dyn mics and actin polymerisation 
(Stossel et al., 2001, Arthur et al., 2002, Etienne-Manneville and Hall, 2002). There 
is evidence in the literature to suggest that RHOA and the filamin proteins do in fact 
interact and are involved in the same intracellular signalling pathways (Bellanger et 
al., 2000, Bourguignon et al., 2006, Leung et al., 2010), which suggests that the 
associations observed between these genes and BMD are mediated through common 
mechanisms or pathways. 
 
Variants in multiple genes within biochemical pathways such as the Wnt signalling 
and RANK-RANKL-OPG pathways have been shown to play a role in susceptibility 
to osteoporosis (Richards et al., 2008, Rivadeneira et l., 2009, Styrkarsdottir et al., 
2008). The evidence presented here suggests that the ARHGEF3-RHOA-FLNB 
pathway also has multiple genetic variants that mayinfluence an individual’s risk of 
developing the disease. This would not be the first time that multiple genes involved 
with a particular function or pathway have been identified in the same chromosomal 
region. Prokaryotes possess characteristic gene clusters that are known as operons, 
where multiple genes that function together in the same biochemical pathway are 
located close together in the genome and their expression is co-regulated (Osbourn 
and Field, 2009). Functional gene clusters have also been identified in eukaryotes, 
including humans, and this phenomenon has been sugge ted to have evolutionary 
benefits (Hurst et al., 2004). For example, the major histocompatibility complex, 
which is a cluster of genes that are essential to the immune system, has been 
localised to the 6p21 region of the human genome (1999). Another example would 
be the close proximity of the gene encoding glutamine phosphoribosyl 
pyrophosphate amidotransferase, which is involved in the initial step in de novo 
purine synthesis, and that encoding phosphoribosylamidoimidazole-
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succinocarboxamide synthase, which is involved in the same pathway (Brayton et al., 
1994). It is possible that the 3p14-p22 region of the human genome contains a non-
random clustering of genes involved with cytoskeletal dynamics and actin 
polymerisation, with subsequent effects on bone density regulation. However, it is 
debatable whether the ARHGEF3, RHOA and FLNB genes are in close enough 
proximity to constitute a gene cluster. More evidence is required to give this theory 
credibility.  
 
As discussed in previous chapters, cytoskeletal dynamics have a well documented 
role in both the differentiation of osteoblasts (McBeath et al., 2004, Meyers et al., 
2005) and the bone resorption function of osteoclasts (Chellaiah et al., 2000). It is 
therefore plausible that common variation within the ARHGEF3, RHOA and FLNB 
genes could result in small changes to the cytoskeleton with subsequent effects on 
the lineage commitment of mesenchymal stem cells and the bone resorptive 
capabilities of osteoclasts. These subtle effects could result in miniscule changes to 
the bone resorptive cycle that accumulate over the course of an individual’s lifetime 
and result in a detrimental effect on BMD. 
 
7.2 Relevance of the ARHGEF3, RHOA and FLNB genes to the linkage observed 
between the 3p14-p22 chromosomal region and BMD 
That the ARHGEF3, RHOA and FLNB genes are collectively responsible for the 
linkage observed between the 3p14-p22 chromosomal region and BMD could 
explain why a single gene from this region with a large influence on BMD has not 
previously been identified, an outcome that perhaps would have been anticipated 
based on the strength of the linkage observed (Wilson et al., 2003, Xiao et al., 2006). 
Indeed, this phenomenon could hold true for other regions of the genome linked with 
BMD in which no single gene with a large influence on BMD has been identified, a 
plausible theory considering the large number of genes thought to have a minor 
influence on the BMD phenotype. Analysis of the LD between the three SNPs 
located in the ARHGEF3, RHOA and FLNB genes that demonstrated the most 
significant associations with BMD parameters (rs7646054, rs17595772 and 
rs9809315 respectively) using JLIN (Carter et al., 2006) suggests that the LD 
between these three polymorphisms is very low (D’ and r2 < 0.2) (Figure 7.1). This 
would strongly suggest that the associations reportd in this thesis between variation 
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Figure 7.1. LD analysis of rs17595772 (RHOA), rs7646054 (ARHGEF3) and 
rs9809315 (FLNB) in the discovery cohort. 
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in each of these genes and BMD phenotypes are indepe nt. In addition to this, 
Rivadeneira et al. identified significant associations between variation in the 
CTNNB1 gene (Rivadeneira et al., 2009), which encodes an integral component of 
the Wnt signalling pathway (beta-catenin) (Wagner et al., 2010), and BMD in a 
large-scale meta-analysis of five genome-wide associati n studies (discussed in 
Chapter 1). This gene is located within the support intervals defined for the 3p14-
p22 chromosomal region by Wilson et al. as linked with BMD, which is flanked by 
the markers D3S1298 and D3S1285, so therefore may also contribute to the linkage 
observed (Wilson et al., 2003).  
 
7.2.1 Other instances of multiple genes contributing o a single linkage peak 
If the ARHGEF3, RHOA and FLNB genes are collectively responsible for the linkage 
seen between the 3p14-p22 chromosomal region and BMD, it would not be the first 
instance of multiple genes contributing to a single linkage peak. Jamieson et al. 
genotyped 16 microsatellites located across the 17q genomic region in 92 multi-case 
tuberculosis families (627 individuals) from Brazil (Jamieson et al., 2004). The 
authors decided to examine this region for linkage with tuberculosis susceptibility 
after a region on mouse chromosome 11, which is syntenic with 17q in humans, was 
found to carry susceptibility genes to cutaneous lei hmaniasis (a type of skin 
infection caused by a single-celled parasite) (Mock et al., 1993, Roberts et al., 1993). 
A single linkage peak for tuberculosis susceptibiliy ocated in the chromosomal 
region 17q12 was observed (Jamieson et al., 2004). The authors then genotyped 49 
SNPs with a minor allele frequency ≥ 0.1 located in various candidate genes 
throughout the region, identifying significant associations between polymorphism in 
4 genes and susceptibility to tuberculosis (Jamieson et al., 2004). Subsequent 
stepwise conditional logistic regression analysis of the data suggested that the 4 
genes contribute separate main effects, prompting the authors to speculate that the 4 
genes may collectively account for the linkage seen at 17q12 (Jamieson et al., 2004).  
 
A more recent publication by Chang et al. describes a GWL study aimed at 
identifying regions of the human genome linked with essential-hypertension 
(chronically elevated blood-pressure with no identifiable cause) (Chang et al., 2007). 
Five sets of microsatellite markers with an average int rmarker distance of 9.2 cM 
were genotyped in 1,010 European American (EA) and 816 African American (AA) 
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subjects from 592 families (Chang et al., 2007). The authors observed strong linkage 
of diastolic blood pressure with chromosome 1q in the EA subset, a genomic region 
that had been previously linked with blood pressure-related phenotypes (Hunt et al., 
2002, James et al., 2003, Perola et al., 2000). Sixteen additional microsatellite 
markers were then genotyped within this chromosomal region, with the original 
linkage peak being resolved into two distinct peaks, located at 175.6 cM and 218.5 
cM (Chang et al., 2007). The authors selected 9 candid te genes from this region for 
further analysis, with 58 SNPs located in or around these 9 genes genotyped in both 
the EA and AA subsets (Chang et al., 2007). Variation within two of these candidate 
genes was found to be significantly associated withbot  systolic and diastolic blood 
pressure in both subsets, while variation in a third gene was found to be associated 
with systolic blood pressure in the AA subset (Chang et al., 2007). Variation within 
each of these three genes was then analysed in two replication populations, with 
significant associations observed between each geneand blood pressure phenotypes 
in at least one of the replication groups (Chang et al., 2007). For each SNP that was 
significantly associated with blood pressure in more than one cohort, the same allele 
was associated with higher blood pressure in each cohort (Chang et al., 2007). 
Analysis of the pairwise linkage disequilibrium betw en the SNPs located in the 
three genes that demonstrated associations with blood pressure phenotypes suggested 
that each gene is independently associated with blood pressure (all pairwise r2 values 
< 0.02) (Chang et al., 2007). The authors suggested that since the susceptibility 
alleles for most complex diseases have modest affects, the linkage signals uncovered 
by most GWL studies are likely to arise from multiple genes located in the same 
region that have a combined effect (Chang et al., 2007). They also speculated that the 
clustering of multiple genes that influence a specific phenotype may be 
evolutionarily advantageous (Chang et al., 2007). 
 
7.3 Expression of the ACTA2 gene may be regulated by RHOA signalling in 
bone cells 
The most consistent regulatory effect seen in the gene knockdown work described in 
Chapter 6 was the down-regulation of ACTA2 mRNA expression seen in all three 
osteoblast-like cell lines (Saos-2, hFOB 1.19 and MG-63) in response to RHOA 
knockdown. The effect was also seen in the osteoclast-like cells obtained from 
donors 1 and 3. There is evidence in the literature o suggest that expression of the 
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ACTA2 gene is influenced by RHOA activity. Mack et al. found that expression of 
constitutively active Rhoa in rat smooth muscle cell u tures significantly increased 
the activity of the Acta2 promoter, whereas inhibition of Rhoa decreased the activity 
of the promoter (Mack et al., 2001). They also found that stimulation of actin 
polymerisation in these smooth muscle cells by treatm nt with jasplakinolide, a 
cyclic peptide isolated from marine sponge that hasbeen shown to bind to and 
stabilise filamentous actin in vivo (Bubb et al., 1994), increased the activity of the 
Acta2 promoter by 13-fold (Mack et al., 2001). Zhao et al. published evidence 
suggesting that static tensile forces applied to rat fibroblasts stimulates the promoter 
activity of the Acta2 gene through the Rho signalling pathway (Zhao et al., 2007). 
Collectively, these data suggest that expression of the ACTA2 gene may be regulated 
through the RHOA signalling pathway, and the results presented in this thesis 
support this. 
 
7.4 A possible role for ARHGEF3 and RHOA in PTH-induced signalling in the 
osteoblast with subsequent effects on osteoclastogenesis 
The cell culture work described in Chapter 6 found that knockdown of the 
ARHGEF3 gene in two of the three osteoblast-like cell lines studied resulted in the 
down-regulation of TNFRSF11B mRNA (encoding OPG), and that knockdown of the 
RHOA gene stimulated up-regulation of PTH1R mRNA (encoding parathyroid 
hormone 1 receptor) in the Saos-2 cell line. These genes are both central to the 
mechanism by which PTH stimulates osteoclast differentiation through the 
osteoblast. As discussed in Chapter 1, treatment of osteoblasts with PTH, which 
binds to the receptor encoded by the PTH1R gene, has been shown to stimulate 
osteoclastogenesis through increasing the production of RANKL (by promoting 
expression of the TNFSF11 gene) and decreasing the production of OPG (by 
inhibiting expression of the TNFRSF11B gene) (Lee and Lorenzo, 1999, Huang et 
al., 2004). There is a large amount of evidence in the literature to suggest that RHOA 
is a signalling intermediate for PTH in osteoblasts. Radeff et al. found that treatment 
of UMR-106 rat osteoblast-like cells with Clostridium difficile toxin B (Radeff et al., 
2004), which specifically inhibits the Rho proteins (including RHOA) through 
glucosylation of the nucleotide binding site (Wilkins and Lyerly, 1996), reduced 
PTH-induced expression of the Il6 gene, the product of which has been shown to 
promote osteoclastogenesis (Lowik et al., 1989). The authors concluded that the Rho 
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proteins are an important component of PTH signallig in osteoblasts and may have 
a role in the activation of the intracellular messeng r protein kinase C alpha (Radeff 
et al., 2004). A recent study published by Wang and Stern stably transfected UMR-
106 rat osteoblast-like cells with either constitutively active Rhoa (caRhoa) or 
dominant negative Rhoa (dnRhoa) and co-cultured them with RAW 264.7 mouse 
monocyte/macrophage-like cells to examine the effects on hormone-stimulated 
osteoclastogenesis (Wang and Stern, 2010). They found that when the cells 
transfected with dnRhoa were treated with PTH and/or calcitriol, the production of 
TNFSF11 mRNA (encoding RANKL) increased and production of TNFRSF11B 
mRNA (encoding OPG) decreased, stimulating osteoclastogenesis of the RAW 264.7 
cells (Wang and Stern, 2010). However, when the cells transfected with caRhoa were 
treated with PTH and/or calcitriol, the levels of TNFSF11 and TNFRSF11B mRNA 
did not change significantly and osteoclastogenesis of the RAW 264.7 cells failed to 
occur (Wang and Stern, 2010). When the UMR-106 cells transfected with caRhoa 
were treated with the ROCK inhibitor Y27632, the ability of the cells to stimulate 
osteoclastogenesis of the RAW 264.7 cells was restor d (Wang and Stern, 2010). 
These results led the authors to suggest that RHOA signalling can inhibit hormone-
stimulated osteoclastogenesis through effects on RANKL and OPG expression in 
osteoblasts (Wang and Stern, 2010). The results present d in this thesis add to the 
body of evidence that exists in the literature suggesting a role for RHOA in PTH-
induced signalling in the osteoblast. 
 
7.5 Limitations of these studies 
7.5.1 Gene knockdown levels in osteoclast-like cells  
A significant limitation to the ARHGEF3 and RHOA gene knockdown work 
performed was the poor levels of gene knockdown achieved in the osteoclast-like 
cells. The failure to obtain maximal gene knockdown co founds the interpretation of 
results obtained from experiments performed in these cells, particularly where the 
results are negative. Several strategies could be employed to increase the level of 
gene knockdown achieved. siRNA knockdown could be carried out at an earlier 
stage of osteoclast differentiation when the cells are smaller and have a higher ratio 
of surface area to cell volume. Additional methods f delivering siRNA to the cells 
could also be explored, such as electroporation techniques (Stroh et al., 2010) or the 
use of a viral vector (Chen et al., 2005). Viral vectors can also be used in the nuclear 
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delivery of gene expression cassettes that express short hairpin RNA (shRNA), 
which act as endogenous interfering RNA and have the potential to achieve stable 
gene knockdown (Sliva and Schnierle, 2010). An additional siRNA delivery method 
is the magnetofection technique, which involves the targeting of siRNA associated 
with magnetic nanoparticles to the cell surface through application of a gradient 
magnetic field (Mykhaylyk et al., 2008). Magnetofection has been found to yield 
high transfection efficiencies with low cytotoxic effects (Ensenauer et al., 2010). 
Alternatively, experiments could be conducted on oste clasts obtained from mice in 
which the gene of interest has been knocked out through either introduction of a 
targeted mutation or transfection with a dominant-negative construct. These latter 
techniques have the potential to yield cells that are completely deficient in functional 
gene product, as opposed to gene knockdown techniques in which some of the 
functional gene product remains. However, the major limitation here is that the cells 
are not from human origin. 
 
7.5.2 Bone resorption assays 
There were two major limitations to the bone resorpti n assays performed in this 
thesis. Firstly, the level of gene knockdown achieved was poor, as already alluded to. 
Secondly, there was a large amount of variation see in the resorption pit volumes 
observed within each treatment group. The latter result d in large standard deviations 
within each treatment group and made it difficult to interpret the data. The problem 
could be due to inaccuracies in the three-dimensional quantification of the osteoclast 
resorption pits. This process is made difficult by the unevenness of the bone slice 
surface (caused by the cutting of the bone) and the erroneous contribution to the 
resorption pit volumes made by pre-existing exposed osteocyte lacunae and blood 
vessel spaces. To avoid this problem, an alternative method of assessing the bone 
resorptive capabilities of osteoclasts could be employed. Foged et al. developed an 
enzyme-linked immunosorbent assay (ELISA) for quantit ting the bone resorption of 
osteoclasts cultured in vitro by quantifying the amount of type 1 collagen released 
into the culture medium during the resorptive process (Foged et al., 1996). This 
technique has the advantage of not relying on volumetric resorption pit 




7.6 Future studies 
7.6.1 Polymorphism at rs7646054 and expression of NM_001128616 
Since rs7646054 is located within the 5’ UTR of the NM_001128616 transcript 
variant of ARHGEF3, the allele present at rs7646054 is carried on the
NM_001128616 mRNA. A real-time PCR approach could therefore be used to 
quantitate the amount of NM_001128616 mRNA transcript carrying each allele to 
examine the influence of polymorphism at rs7646054 on expression of this 
transcript. This technique was considered for use in this project when the 
associations between variation at rs7646054 and BMD phenotypes were first 
identified and an in silico bioinformatics analysis suggested that polymorphism at 
this SNP site alters the folding and stability of the 5’ UTR of this transcript 
(discussed in Chapter 3). However, at that stage of the project the NM_001128616 
transcript variant had only been recently described an  real-time PCR could not 
detect this transcript in either the Saos-2 osteoblast-like cell line or the BE(2)-M17 
neuroblastoma cell line, hence its existence could not be confirmed. It was not until 
much later in the project that this transcript was detected using real-time PCR in the 
osteoclast-like cells (discussed in Chapter 6).  
 
To perform this technique, blood samples would first need to be collected from a 
number of individuals that are heterozygous at the rs7646054 SNP site. Since they 
are heterozygous at this polymorphic site, these individuals will express one copy of 
the NM_001128616 transcript variant carrying each allele for rs7646054. The 
peripheral blood mononuclear cells (PBMCs) can be isolated from the whole blood 
using the Ficoll-Paque centrifugal separation technique described in Chapter 6. The 
PBMCs can then be cultured for 4 days with phytohaemagglutinin (PHA), which is a 
lectin that has been shown to stimulate proliferation as well as mRNA and protein 
expression in lymphocytes (Jagus-Smith and Kay, 1976). This PHA treatment is 
important as it will up-regulate the expression of the NM_001128616 mRNA 
transcript variant, allowing greater quantities to be available for subsequent analysis. 
Alternatively, the PBMCs could be stimulated to differentiate into osteoclast-like 
cells as described in Chapter 6, since expression of the transcript has been confirmed 
in this cell type. After culture, total RNA can be extracted from the cells and reverse 
transcribed. The resulting cDNA could then be subjected to quantitative real-time 
PCR utilising two allele-specific TaqMan probes forthe rs7646054 SNP site. If the 
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expression of one allele is higher than the other, it will be reflected in the quantity of 
template carrying each allele that is detected by the real-time PCR assay. These 
results can be compared against results obtained using the same real-time PCR assay 
on genomic DNA samples obtained from individuals that are heterozygous at 
rs7646054, as these samples would be expected to have a 50/50 ratio of each allele. 
A standard curve can also be created using serial dilutions of two DNA samples, one 
homozygous for the A allele at rs7646054 and one homozygous for the G allele, 
mixed together in different proportions. This can be used to accurately calculate the 
expression ratio of each allele. Differences in the quantity of transcript carrying one 
allele compared to the other could indicate differences in the transcription rate of the 
two alleles or, as previously suggested, differences in the mRNA stability of the two 
transcripts. 
 
7.6.2 Polymorphism at rs17595772 and rs17080528 and expression of the RHOA 
gene 
A similar principal to that described above could be used to investigate whether 
polymorphism at rs17595772 or rs17080528, which are both located in the RHOA 
gene and were found to be significantly associated with BMD parameters in this 
thesis (see Chapter 4), influences expression of RHOA mRNA. Blood samples would 
first be collected from a number of individuals that are homozygous for the major 
and minor alleles at these polymorphic sites. PBMCs can then be isolated from these 
samples and cultured with PHA before total RNA is extracted and reverse 
transcribed. Gene expression ratios representing the ratio of expression of the RHOA 
gene relative to an internal reference (such as the 18S ribosomal RNA gene) can then 
be calculated for each sample using quantitative real-time PCR in conjunction with 
the comparative CT statistical method described by Schmittgen and Livak (discussed 
in Chapter 6) (Schmittgen and Livak, 2008). An unpaired t-test can then be used to 
determine whether there is a significant difference between the gene expression 
ratios from each homozygote group.  
 
7.6.3 Investigation of how polymorphism at rs11720285, rs11130605 and rs9809315 
regulates expression of the FLNB gene 
The three FLNB SNPs rs11720285, rs11130605 and rs9809315 have been identified 
as significantly associated with FLNB mRNA expression (Wilson et al., 2009) and 
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BMD parameters in women (see Chapter 5). The exact mechanism by which these 
SNPs regulate expression of the FLNB gene remains to be determined. It is possible 
that polymorphism tagged by one or more of these SNPs influences the binding of 
transcription factors to regulatory sequences predict  to lie within a 650 bp region 
surrounding the 5’ UTR and first exon of the FLNB gene (discussed in Chapter 5). It 
would be interesting to sequence this 650 bp region plus the 2 Kb of sequence 
immediately 5’ of the FLNB transcription start site for polymorphisms in strong 
linkage disequilibrium with the rs11720285, rs11130605 and rs9809315 SNPs. If 
such polymorphisms were discovered, any potential ch nges to transcription factor 
binding sites (TFBS) could be analysed in silico using the bioinformatics software 
packages F-SNP (Lee and Shatkay, 2008) and PROMO (Messeguer et al., 2002). 
Any potential changes to TFBS identified by this analysis could then be verified in 
vitro using an electrophoretic mobility shift assay (EMSA). This is performed by 
generating oligonucleotide probes containing the prdicted TFBS sequence with 
either the wild-type or polymorphic allele present. These probes are then incubated 
with nuclear extract from a human cell line known to express the FLNB gene. The 
reaction mixtures are electrophoresed on either an ag rose or polyacrylamide gel and 
the banding patterns examined to determine whether transcription factor binding has 
occurred. An oligonucleotide probe that has bound to a transcription factor will 
migrate through the gel more slowly than unbound probe. 
 
7.6.4 Further investigation into the role of the ARHGEF3 and RHOA genes in the 
osteoblast 
The findings published by Wang and Stern (Wang and Stern, 2010), coupled with the 
evidence presented in this thesis, suggests that the ARHGEF3 and RHOA genes may 
have a role in regulating the osteoclastogenic capabilities of the osteoblast. 
Therefore, the influence of knockdown of the ARHGEF3 and RHOA genes on 
expression of RANKL and OPG in human osteoblast-like cells in response to 
treatment with PTH could be examined. Out of the three osteoblast-like cell lines 
used in this thesis, the Saos-2 was the only one that was found to express the PTH1R 
receptor. Hence, this cell line would be a good candidate for use in this work. It 
would also be interesting to examine the effects of FLNB gene knockdown in the 
Saos-2 cells under these conditions, as this could provide clues as to whether the 
FLNB gene is also involved in this mechanism.  
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7.6.5 Investigation of the effects of ARHGEF3, RHOA and FLNB gene knockdown 
on the osteoclast cytoskeleton 
It would be interesting to attempt one of the alternative knockdown techniques 
described above (section 7.5.1) in actively resorbing osteoclast-like cells 
differentiated from human PBMCs. The effects of thegene knockdown on the 
intracellular actin structures of the cells could then be analysed by staining with 
fluorescent phalloidin (Wulf et al., 1979) followed by visualisation using confocal 
microscopy (Small et al., 1999). Phalloidin, a membr of the phallotoxin family of 
poisonous bicyclic heptapeptides derived from the poisonous mushroom Amanita 
phalloides (Wieland and Faulstich, 1978), binds tightly to filamentous actin (Estes et 
al., 1981) and is commonly used to visualise actin filaments in both living and fixed 
cells (Small et al., 1999). This technique could reveal whether the actin cytoskeleton 
of resorbing human osteoclast-like cells is significantly disrupted by knockdown of 
the ARHGEF3, RHOA and FLNB genes. 
 
7.7 Conclusion 
This thesis has identified common variation within theARHGEF3 and RHOA genes 
as significantly associated with BMD in Caucasian women. Polymorphism within 
these genes has not been previously implicated in BMD regulation or osteoporosis. 
In addition to these results, this thesis has produce  supporting evidence for a 
previous publication that reported significant associations between polymorphism in 
the FLNB gene and BMD in Caucasian women (Wilson et al., 2009). Out of five 
SNPs previously identified as associated with FLNB mRNA levels, three were found 
to be significantly associated with BMD in Caucasian women in this thesis. The 
ARHGEF3, RHOA and FLNB genes are all thought to have a role in cytoskeletal 
reorganisation (Arthur et al., 2002, Hall, 1998, Stossel et al., 2001), a mechanism that 
has been implicated in osteoblast differentiation (McBeath et al., 2004, Meyers et al., 
2005) and osteoclast function (Chellaiah et al., 2000). These three genes are all 
located within the 3p14-p22 region of the human genome, a region that has been 
linked with BMD in multiple studies (Duncan et al., 1999, Wilson et al., 2003, 
Wynne et al., 2003, Xiao et al., 2006, Lee et al., 2006). Therefore, the unifying 
hypothesis that one or more genes in the human genomic 3p14-p22 region are 
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significantly associated with bone mineral density in Caucasian women has been 
supported by the data.  
 
One of the polymorphisms found to influence BMD in this thesis, rs7646054, is 
located within the 5’ UTR of a transcript variant of the ARHGEF3 gene termed 
NM_001128616. In the functional studies performed in this thesis, expression of this 
transcript variant was detected in osteoclast-like cells but not osteoblast-like cells. 
This suggests that if polymorphism at rs76546054 influe ces BMD through effects 
on the NM_001128616 transcript variant, it seems likely that this effect is mediated 
through the osteoclast. Expression of mRNA encoding alpha 2 actin, smooth muscle 
(ACTA2) was found to be consistently down-regulated by RHOA gene knockdown 
in osteoblast-like cells, supporting evidence in the literature suggesting that 
expression of the ACTA2 gene is regulated by the RHOA signalling pathway. 
Expression of OPG mRNA was found to be significantly down-regulated by 
knockdown of the ARHGEF3 gene in two out of three osteoblast-like cell lines 
examined, whereas parathyroid hormone 1 receptor mRNA was found to be 
significantly up-regulated by RHOA gene knockdown in Saos-2 osteoblast-like cells. 
These results could suggest a role for the ARHGEF3 and RHOA genes in PTH-
mediated signalling in the osteoblast. Successful knoc down of the ARHGEF3 and 
RHOA genes was found to be difficult in osteoclast-like cells, although there was 
some evidence to suggest that knockdown of RHOA reduces the expression of Rho 
GDP dissociation inhibitor alpha and ACTA2. Knockdown of the ARHGEF3 and 
RHOA genes was not found to significantly influence the bone-resorptive capabilities 
of osteoclast-like cells. However, the lack of effect could be due to insufficient gene 
knockdown in this cell type. 
 
7.8 Significance of findings 
The findings presented in this thesis are significant because while ARHGEF3 and 
RHOA were considered to be candidate genes for bone density regulation, this is the 
first demonstration that variation within these genes is significantly associated with 
BMD in Caucasian women and therefore may have a role in osteoporosis. 
Cytoskeletal dynamics has a well established role in osteoblast differentiation and 
osteoclast function, however it had not been previously considered a major factor in 
the development of osteoporosis. This thesis also provides supporting evidence of a 
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role for another gene involved with the cytoskeleton, FLNB, and BMD regulation. 
These results not only contribute to the medical and scientific community’s 
understanding of osteoporosis and the genetic architecture behind the heritable 
component of the disease, but they also provide the basis for further studies in the 
area. They could also assist in the future development of a panel of genetic marker 
tests to identify individuals at increased risk of developing osteoporosis. This panel 
could take the form of a diagnostic array which includes other genetic loci that have 
been identified as contributing to variance in BMD. Once individuals have been 
identified as susceptible to osteoporosis due to their genetic makeup, early 
intervention strategies can be applied to reduce their risk of developing the disease. 
The cell culture work performed in this thesis is the first to examine the effects of 
ARHGEF3 and RHOA gene knockdown in bone cells using siRNA. The findings 
from this work highlight the NM_001128616 transcript variant of ARHGEF3, the 
influence of RHOA signalling on expression of the ACTA2 gene, and the PTH-
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1X Tris EDTA (TE) buffer 
Item Quantity 
1M Tris-HCl (pH 8.0) 10 ml 
0.25 M EDTA 400 µl 
Distilled-deionised water 990 ml 
Sterilise by autoclaving 
 
1X phosphate buffered saline (PBS) 
Item Quantity 
Sodium Chloride (NaCl) 8 g 
Potassium Chloride (KCl) 0.2 g 
Sodium Phosphate Dibasic (Na2HPO4) 1.44 g 
Potassium Phosphate (KH2PO4) 0.24 g 
Distilled-deionised water Make up to 1 L 
Adjust pH to 7.4 
Sterilise by autoclaving 
 
TRAP stain buffer (500 ml) 
Item Quantity 
Sodium Acetate 6.8 g 
Sodium Tartrate Dihydrate 5.8 g 
Glacial Acetic Acid 1.1 ml 
Distilled-deionised water Make up to 500 ml 
Adjust pH to 5.0 
 
TRAP stain solution (500 ml) 
Item Quantity 
Naphthol AS-MX Phosphate Disodium Salt 50 mg 
2-Ethoxyethanol 2.5 ml 
Fast Red Violet LB Salt 300 mg 
TRAP Stain Buffer Make up to 500 ml 




Oligonucleotide primer sequences used in MALDI-ToF mass spectrometry SNP 
genotyping 
SNP Primer sequences 
rs7646054 Forward: 5’-GCCAGAAACGATTCCATGAT-3’ 
 Reverse: 5’-GCATTGTCACCTGAAGCAGA-3’ 
 Genotyping: 5’-TGAATCTCCCAAGATGA-3’ 
rs1566487 Forward: 5’-GCCTCATGCCACTCTGAAAT-3’ 
 Reverse: 5’-GGTACAGATGCTTGGCCACT-3’ 
 Genotyping: 5’-TTTGGGGCCCATAACTCAGGAAA-3’ 
rs6803697 Forward: 5’-TGGCTCAATGACCATAACCA-3’ 
 Reverse: 5’-CCTCGGGCTGTACTTCTTGA-3’ 
 Genotyping: 5’-AAATTACAGGATTCTAACT-3’ 
rs12632941 Forward: 5’-TCCTTTCCCAGCCAGTAGAA-3’ 
 Reverse: 5’-CCACTCCAGTCTGAGCAACA-3’ 
 Genotyping: 5’-AGAGAGACTGTGTCACA-3’ 
rs4681928 Forward: 5’-TGATGGCTAACAAGCAGCAG-3’ 
 Reverse: 5’-ATTTGGCAGCCCTCTATCCT-3’ 
 Genotyping: 5’-ACTCTGTCATTCAACAAAC-3’ 
rs1344142 Forward: 5’-TCCATCTTGTCATGGTCCAG-3’ 
 Reverse: 5’-CTTGATTCTGGGAGCCAGTC-3’ 
 Genotyping: 5’-TTGTCATGGTCCAGCCAGGCA-3’ 
rs17080528 Forward: 5’-GGGAGACAGGTTGGAGTGAG-3’ 
 Reverse: 5’-GCCACACTCTCTGGTTAGGC-3’ 
 Genotyping: 5’-TTCTCCAGCCAGGATCAGG-3’ 
rs17595772 Forward: 5’-GGGCCCTGTGTCCATATAAA-3’ 
 Reverse: 5’-GAGCCACGATGATTGCTCTT-3’ 
 Genotyping: 5’-CAGAGGGTGTTAATTCAGCCT-3’ 
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Custom designed oligonucleotide primer sequences usd in quantitative real-time 
PCR 
Target Primer sequences 
NM_001128616 Forward: 5’-CGTGAATTTGGAATCCTGCT-3’ 
 Reverse: 5’-AATGCTGGAAAGCTTGGAGA-3’ 
ACTA2 Forward: 5’-GCAACACGAAGCTCATTGTAGA-3’ 





Microarray candidate gene lists 
Osteoblast-specific Osteoclast-specific 
AHSG ACP5 PRMT3 
ALPL ADORA1 RAC2 
AMBN AKAP5 RELB 
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BGLAP ATP5C1 RPS20 
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MSX1 FMNL3  
PDGFRB FUBP1  
PHEX GABPA  
PTHLH GBF1  
PTHR1 GSR  
RUNX2 HLA-C  
SOST IL5  
SOX9 ILF3  
SP7 KCNA2  
SPP1 LHX1  
STATH LTA  
TFIP11 MEFV  
TNFRSF11B MMP9  
TNFSF11 MYL6  
TP53 NFATC1  
TUFT1 OAZ1  
TWIST1 OSCAR  




RHOA signalling pathway 
ACTA1 GNA12 MYH14 PKN1 
ACTA2 GNAI1 MYH2 PLD1 
ACTB GNAI2 MYH3 PPAP2B 
ACTC1 GNAI3 MYH4 PPP1R12A 
ACTG1 IGF1 MYH6 PPP1R12B 
ACTG2 IGF1R MYH7 PTK2 
ACTR2 IGF2 MYH7B PTK2B 
ACTR3 ITGA1 MYH8 RDX 
ANGPTL2 ITGA10 MYH9 RHOA 
ARHGAP1 ITGA11 MYL1 RHOB 
ARHGAP22 ITGA2 MYL2 RHPN1 
ARHGAP4 ITGA2B MYL3 RHPN2 
ARHGAP5 ITGA3 MYL4 ROCK1 
ARHGDIA ITGA4 MYL5 ROCK2 
ARHGDIB ITGA5 MYL7 RTKN 
ARHGEF1 ITGA6 MYL9 SLC9A1 
ARHGEF10 ITGA7 MYLK TLN1 
ARHGEF11 ITGA8 MYO10 VIL2 
ARHGEF12 ITGA9 MYO15A WASF1 
ARHGEF15 ITGAD MYO18B  
ARHGEF16 ITGAE MYO1A  
ARHGEF2 ITGAL MYO1B  
ARHGEF3 ITGAM MYO1C  
ARHGEF4 ITGAV MYO1D  
ARHGEF5 ITGAX MYO1E  
ARHGEF6 ITGB1 MYO1F  
ARHGEF7 ITGB2 MYO3A  
ARHGEF9 ITGB3 MYO5A  
ARPC2 ITGB4 MYO5B  
ARPC3 ITGB5 MYO5C  
BAIAP2 ITGB6 MYO6  
CDC42EP1 ITGB7 MYO7A  
CDC42EP2 ITGB8 MYO7B  
CDC42EP3 KTN1 MYO9A  
CDC42EP4 LIMK1 MYO9B  
CDC42EP5 LIMK2 NET1  
CFL1 LPAR1 NGEF  
CFL2 MCF2L PFN1  
CHN1 MGRN1 PFN2  
CHN2 MRLC2 PIP4K2B  
CIT MSN PIP4K2C  
EDG4 MYBPH PIP5K1A  
EDG7 MYH1 PIP5K1B  
EPHA1 MYH10 PIP5K1C  
GDI1 MYH11 PIP5K2A  
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